(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 2 091 965 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 21, 40, 53, 55, 105

(48) Corrigendum issued on:
25.09.2013 Bulletin 2013/39

(45) Date of publication and mention of the grant of the patent:
15.05.2013 Bulletin 2013/20

(21) Application number: **07827901.5**

(22) Date of filing: **16.10.2007**

(51) Int Cl.:
C07K 14/435 *(2006.01)* ***A61K 38/00*** *(2006.01)*
A61K 39/00 *(2006.01)* ***A61P 35/00*** *(2006.01)*
C07K 7/00 *(2006.01)* ***C12N 15/09*** *(2006.01)*

(86) International application number:
PCT/JP2007/001122

(87) International publication number:
WO 2008/047473 (24.04.2008 Gazette 2008/17)

(54) PEPTIDE VACCINES FOR CANCERS EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES

PEPTIDIMPFSTOFFE GEGEN KREBSARTEN, BEI DENEN MPHOSPH1- ODER DEPDC1-POLYPEPTIDE EXPRIMIERT WERDEN

VACCINS PEPTIDIQUES POUR DES CANCERS EXPRIMANT LES POLYPEPTIDES MPHOSPH1 OU DEPDC1

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: **17.10.2006 US 852575 P**

(43) Date of publication of application:
26.08.2009 Bulletin 2009/35

(60) Divisional application:
12155444.8 / 2 476 697
12155446.3 / 2 476 698
12155448.9 / 2 476 699

(73) Proprietor: **Oncotherapy Science, Inc.**
Kawasaki-shi
Kanagawa 213-0012 (JP)

(72) Inventors:
- **FUJIOKA, Tomoaki**
  Morioka-shi
  Iwate 020-8505 (JP)
- **NAKAMURA, Yusuke**
  Bunkyo-ku
  Tokyo 113-8654 (JP)
- **TSUNODA, Takuya**
  Bunkyo-ku
  Tokyo 113-8654 (JP)
- **OSAWA, Ryuji**
  Kawasaki-shi
  Kanagawa 213-0012 (JP)
- **SHIDA, Midori**
  Kawasaki-shi
  Kanagawa 213-0012 (JP)

(74) Representative: **Vossius & Partner**
Siebertstrasse 4
81675 München (DE)

(56) References cited:
WO-A2-03/040165 **WO-A2-2006/085684**

- **FERRIES ESTELLE ET AL: "Identification of p53 peptides recognized by CD8+ T lymphocytes from patients with bladder cancer", HUMAN IMMUNOLOGY, vol. 62, no. 8, August 2001 (2001-08), pages 791-798, XP002615255, ISSN: 0198-8859**

Printed by Jouve, 75001 PARIS (FR)

(Cont. next page)

- ITO KEIICHI ET AL: "Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer.", INTERNATIONAL JOURNAL OF CANCER, vol. 108, no. 5, 20 February 2004 (2004-02-20), pages 712-724, XP002615256, ISSN: 0020-7136
- KOMORI HIROYUKI ET AL.: 'Identification of HLA-A2- or HLA-A24-restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma' CLIN. CANCER RES. vol. 12, no. 9, 01 May 2006, pages 2689 - 2697, XP003020537
- UCHIDA N. ET AL.: 'Ring Finger Protein 43 as a New Target for Cancer Immunotherapy' CLIN. CANCER RES. vol. 10, 2004, pages 8577 - 8586, XP001544092
- ABAZA AOUATER ET AL.: 'M phage Phosphoprotein 1 Is a Human Plus-end-directed Kinesin-related Protein Required for Cytokinesis' J. BIOL. CHEM. vol. 278, no. 30, 2003, pages 27844 - 27852, XP008109739

Description

Technical Field

[0001] The present disclosure relates to the field of biological science, more specifically to the field of cancer therapy. In particular, the present disclosure relates to novel peptides that serve as extremely effective cancer vaccines, and drugs for treating and preventing tumors containing such peptides.

Background Art

[0002] It has been demonstrated that CD8+ cytotoxic T lymphocytes (CTLs) recognize epitope peptides derived from tumor- associated antigens (TAAs) presented on MHC class I molecules, and lyse the tumor cells. Since the discovery of the MAGE family as the first example of TAAs, many other TAAs have been discovered using immunological approaches (Boon T. (1993) Int J Cancer 54: 177- 80.; Boon T. et al., (1996) J Exp Med 183: 725- 9.; van der Bruggen P et al., (1991) Science 254: 1643- 7.; Brichard V et al., (1993) J Exp Med 178: 489- 95.; Kawakami Y et al., (1994) J Exp Med 180: 347- 52.) . Some of them are now in clinical development as targets of immunotherapy. TAAs discovered so far include MAGE (van der Bruggen P et al., (1991) Science 254: 1643- 7.), gp100 (Kawakami Y et al., (1994) J Exp Med 180: 347- 52.), SART (Shichijo S et al., (1998) J Exp Med 187: 277- 88.), and NY- ESO- 1 (Chen Y.T. et al., (1997) Proc. Natl. Acd. Sci. USA, 94: 1914- 8.) . On the other hand, certain gene products demonstrated to be somewhat specifically over- expressed in tumor cells have been shown to be recognized as targets for inducing cellular immune responses. Such gene products include p53 (Umano Y et al., (2001) Br J Cancer, 84: 1052- 7.), HER2/neu (Tanaka H et al., (2001) Br J Cancer, 84: 94- 9.), CEA (Nukaya I et al., (1999) Int. J. Cancer 80, 92- 7.) and the like.

[0003] Despite significant progress in basic and clinical research concerning TAAs (Rosenberg SA et al., (1998) Nature Med, 4: 321-7.; Mukherji B. et al., (1995) Proc Natl Acad Sci USA, 92: 8078-82.: Hu X et al., (1996) Cancer Res, 56: 2479-83.), only a very limited number of candidate TAAs suitable for treatment of cancers are presently available. TAAs that are abundantly expressed in cancer cells, and whose expression is restricted to cancer cells, would be promising candidates as immunotherapeutic targets.

[0004] Both HLA-A24 and HLA-A0201 are common HLA alleles in the Japanese and Caucasian populations (Date Y et al., (1996) Tissue Antigens 47: 93-101.; Kondo A et al., (1995) J Immunol 155: 4307-12.; Kubo RT et al., (1994) J Immunol 152: 3913-24.; Imanishi et al., Proceeding of the eleventh International Histocompatibility Workshop and Conference Oxford University Press, Oxford. 1065 (1992); Williams F et al., (1997) Tissue Antigen 49: 129-33.). Thus, antigenic peptides of cancers presented by these HLA alleles may find particular utility in the treatment of cancers among Japanese and Caucasian patients. Further, it is known that the induction of low-affinity CTL in vitro usually results from exposure to high concentrations of peptide, generating a high level of specific peptide/MHC complexes on antigen-presenting cells (APCs), which can effectively activate these CTL (Alexander-Miller et al., (1996) Proc Natl Acad Sci USA 93: 4102-7.).

[0005] Recent developments in cDNA microarray technologies have enabled the construction of comprehensive profiles of gene expression of malignant cells as compared to normal cells (Okabe, H. et al., (2001) Cancer Res., 61, 2129-37.; Lin YM. et al., (2002) Oncogene, 21;4120-8.; Hasegawa S. et al., (2002) Cancer Res 62:7012-7.). This approach enables an understanding of the complex nature of cancer cells and the mechanisms of carcinogenesis and facilitates the identification of genes whose expression is deregulated in tumors (Bienz M. et al., (2000) Cell 103, 311-20.). Among the transcripts identified as up-regulated in cancers, MPHOSPH1 (M-phase phosphoprotein 1; GenBank Accession No. NM_016195; SEQ ID Nos.1, 2), and DEPDC1 (DEP domain containing 1; GenBank Accession No. BM683578) have been recently discovered. See WO 2004/031413, WO 2006/085684 and WO 2007/013,665, the entire contents of which are incorporated by reference herein. DEPDC1 has been described in the context of two different transcriptional variants - DEPDC1 V1 (SEQ ID Nos.3, 4) and DEPDC1 V2 (SEQ ID Nos: 5, 6). These genes have been shown to be specifically up-regulated in tumor cells of the various cancer tissues of the cases analyzed (see below); however, Northern blot analyses demonstrate that these gene products are not found in normal vital organs (see PCT/JP2006/302684). In that immunogenic peptides derived from MPHOSPH1, and DEPDC1 may find utility in killing tumor cells expressing those antigens, these genes are of particular interest to the present inventors.

[0006] Since cytotoxic drugs, such as M- VAC, often cause severe adverse reactions, it is clear that thoughtful selection of novel target molecules on the basis of well- characterized mechanisms of action is important in the development of effective anticancer drugs having a minimized risk of negative side effects. Toward this goal, the inventors previously performed expression profile analysis on various cancers and normal human tissue, and discovered multiple genes that are specifically over- expressed in cancer (Lin YM, et al., Oncogene. 2002 Jun 13; 21: 4120- 8.; Kitahara O, et al., Cancer Res. 2001 May 1; 61: 3544- 9.; Suzuki C, et al., Cancer Res. 2003 Nov 1; 63: 7038- 41.; Ashida S, Cancer Res. 2004 Sep 1; 64: 5963- 72.; Ochi K, et al., Int J Oncol. 2004 Mar; 24 (3) : 647- 55.; Kaneta Y, et al., Int J Oncol. 2003 Sep; 23: 681- 91.; Obama K, Hepatology. 2005 Jun; 41: 1339- 48.; Kato T, et al., Cancer Res. 2005 Jul 1; 65: 5638-

46.; Kitahara O, et al., Neoplasia. 2002 Jul- Aug; 4: 295- 303.; Saito- Hisaminato A et al., DNA Res 2002, 9: 35- 45.) . Of these, MPHOSPH1 (in house No. C2093) and DEPDC1 (in house No. B5860N) were identified genes over- expressed in various cancers. In particular, MPHOSPH1 was identified as over- expressed in bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, soft tissue tumor. Similarly, DEPDC1 was identified as over- expressed in bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, NSCLC, lymphoma, osteosarcoma, prostate cancer, SCLC, soft tissue tumor

[0007] MPHOSPH1 was previously identified as one of the proteins specifically phosphorylated at the G2/M transition and characterized as a plus-end-directed kinesin related protein (Abaza A et al., J Biol Chem 2003, 278: 27844-52.). More particularly, MPHOSPH1 has been previously documented to be a plus-end-directed molecular motor that plays a crucial role in cytokinesis, and accumulates in the midzone of the spindle during anaphase to telophase in HeLa cells (Abaza A et al., J Biol Chem 2003, 278: 27844-52; Kamimoto T et al., J Biol Chem 2001, 276: 37520-8). The MPHOSPH1 cDNA encodes a 1780-amino acid protein that is composed of three domains: an NH2-kinasin motor domain, a central coiled coil-stalk domain, and a C-globular tail domain. Together, this data suggests that MPHOSPH1 is an NH2-type kinesin-related protein.

[0008] As for DEPDC1, its function remains unclear. The DEP domain contained in this protein is also found in Dishevelled, Egl-10, and Pleckstrin. The DEP domain in Drosophila dishevelled plays an essential role in rescue planar polarity defects and induces JNK signaling; nevertheless, its function in Humans has not yet been clarified. However, as disclosed in PCT/JP2006/302684, DEPDC1 siRNAs can suppress the growth of cancer cells. These results demonstrate that DEPDC1 plays an important role in growth of most cancer cells.

Summary of the Invention

[0009] The invention relates to the embodiments as defined in the claims.

As noted above, MPHOSPH1 (M-phase phosphoprotein 1), and DEPDC1 (DEP domain containing 1) have been identified as up-regulated in various cancers. More particularly, the genes were identified using gene expression profiling with a genome-wide cDNA microarray. As discussed above, expression of MPHOSPH1 and DEPDC1 has been shown to be specifically up-regulated in various tumor cells, including lung cancer and bladder cancer. As described in Table 1, MPHOSPH1 expression was shown to be validly elevated in 30 out of 31 bladder cancers, 8 out of 36 breast cancers, 18 out of 18 cervical cancers, 5 out of 17 cholangincellular carcinomas, 25 out of 31 CMLs, 6 out of 11 colorectal cancers, 6 out of 14 gastric cancers, 5 out of 5 NSCLCs, 7 out of 7 lymphomas, 6 out of 10 osteosarcomas, 7 out of 22 prostate cancers, 10 out of 18 renal carcinomas and 15 out of 21soft tissue tumors. At the same time, DEPDC1 expression was shown to be validly elevated in 23 out of 25 bladder cancers, 6 out of 13 breast cancers, 12 out of 12 cervical cancers, 6 out of 6 cholangincellular carcinomas, 3 out of 4 CMLs 2 out of 4 colorectal cancers, 6 out of 6 NSCLCs, 7 out of 7 lymphomas, 10 out of 14 osteosarcomas, 11 out of 24 prostate cancers, 14 out of 14 SCLCs and 22 out of 31 soft tissue tumors as described in Table 1.

[0010] The present disclosure is based, at least in part, on the identification of specific epitope peptides of the gene products of these genes (MPHOSPH1 and DEPDC1) which possess the ability to induce cytotoxic T lymphocytes (CTLs) specific to the corresponding molecules. As discussed in detail below, Peripheral Blood Mononuclear Cells (PBMC) of healthy donor were stimulated using HLA-A*2402 and HLA-A*0201 binding candidate peptides derived from MPHOSPH1 or DEPDC1. CTL clones and/or lines were then established with specific cytotoxicity against the HLA-A24 or HLA-A2 positive target cells pulsed with each of the candidate peptides. These results demonstrate that these peptides are HLA-A24 or HLA-A2 restricted epitope peptides that can induce potent and specific immune responses against cells expressing MPHOSPH1 or DEPDC1.

[0011] Accordingly, the present disclosure provides methods for treating or preventing a disease associated with the over- expression of MPHOSPH1 and/or DEPDC1, e.g. cancer. Such methods involves the step of administering to a subject in need thereof a MPHOSPH1 and/or DEPDC1 polypeptide of the disclosure. Administration of such peptide (s) results in the induction of anti- tumor immunity. Thus, the present disclosure provides methods for inducing anti- tumor immunity in a subject, such methods involving the step of administering to the subject a MPHOSPH1 and/or DEPDC1 polypeptide, as well as pharmaceutical compositions for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g cancer, that include the MPHOSPH1 and/or DEPDC1 polypeptides. Exemplary cancers include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, and soft tissue tumor.

[0012] That is, the present disclosure includes following embodiments, and any combinations thereof.

[1] An isolated peptide having cytotoxic T cell inducibility, wherein said peptide derived from amino acid sequence of SEQ ID NO: 2, 4, or 6.

[2] An isolated peptide of less than about 15 amino acids selected from the group consisting of peptides comprising the amino acid sequences of SEQ ID NO: 7, 8 and 12, or a peptide having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 8 and 12, wherein 1, 2, or several amino acids are substituted, deleted, or added.

[3] The peptide having cytotoxic T cell inducibility of [2], wherein the second amino acid from the N-terminus is phenylalanine, tyrosine, methionine, or tryptophan.

[4] The peptide having cytotoxic T cell inducibility of [2], wherein the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.

[5] An isolated peptide of less than about 15 amino acids selected from the group consisting of peptides comprising the amino acid sequences of SEQ ID NO: 9, 10, 11, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 253, 254 and 255, or a peptide having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9, 10, 11, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 253, 254 and 255, wherein 1, 2, or several amino acids are substituted, deleted, or added.

[6] The peptide having cytotoxic T cell inducibility of [5], wherein the second amino acid from the N-terminus is leucine or methionine.

[7] The peptide having cytotoxic T cell inducibility of [5], wherein the C-terminal amino acid is valine or leucine.

[8] A vector in which the DNA encodes peptides of any one of [1] to [7].

[9] A pharmaceutical composition for treating or preventing a disease associated with over-expression of the genes of SEQ ID NO: 1, 3 and/or 5, said composition comprising one or more peptides of any one of [1] to [7].

[10] The pharmaceutical composition of [9], wherein the disease is cancer.

[11] The pharmaceutical composition of [10], wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC and soft tissue tumor.

[12] An exosome that presents on its surface a complex comprising a peptide of any one of [1] to[7] and an HLA antigen.

[13] The exosome of [12], wherein the HLA antigen is HLA-A24.

[14] The exosome of [13], wherein the HLA antigen is HLA-A2402.

[15] The exosome of [12], wherein the HLA antigen is HLA-A2.

[16] The exosome of [13], wherein the HLA antigen is HLA-A0201.

[17] A method of inducing antigen-presenting cells having a high cytotoxic T cell inducibility comprising the step of contacting an antigen-presenting cell with a peptide of any one of [1] to [7].

[18] A method of inducing cytotoxic T cells by contacting a T cell with a peptide of any one of [1] to [7].

[19] A method of inducing antigen-presenting cells having high cytotoxic T cell inducibility, said method comprising the step of transferring a gene comprising a polynucleotide encoding a peptide of any one of [1] to [7] to an antigen-presenting cell.

[20] An isolated cytotoxic T cell, which is induced by contacting a T cell with a peptide of any one of claims 1 to 7 or which is transduced with the nucleic acids encoding the TCR subunits polypeptides binding with a peptide of any one claims 1 to 7 in the context of HLA-A24 or HLA-A2.

[21] An antigen-presenting cell, which comprises a complex formed between an HLA antigen and a peptide of any one of [1] to [7].

[22] The antigen-presenting cell of [21], induced by the method of [17].

[23] A vaccine for inhibiting proliferation of cells expressing genes of SEQ ID NO: 1, 3 and/or 5, wherein the vaccine comprises a peptide of any one of [1] to [7] as the active ingredient.

[24] The vaccine of [23], wherein the cell is a cancer cell.

[25] The vaccine of [24], wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC and soft tissue tumor.

[26] The vaccine of [23], formulated for administration to a subject whose HLA antigen is HLA-A24 or HLA-A2.

[27] A method of treating or preventing a disease associated with the over-expression of the genes of SEQ ID NO: 1, 3 and/or 5 in a subject comprising administering to said subject a vaccine comprising one or more peptide of any one of [1] to [7], an immunologically active fragment thereof, or a polynucleotide encoding said peptide or immunologically active fragment.

[28] The method of [27], wherein the disease is cancer.

[29] The method of [28], wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC and soft tissue tumor.

[0013] Alternatively, the present disclosure also relates to a method of inducing cytotoxic T cells comprising the step of contacting a T- cell with the antigen- presenting cell produced by the method of [19] .

[0014] These and other objects and features of the disclosure will become more fully apparent when the following detailed description is read in conjunction with the accompanying figures and examples. However, it is to be understood that both the foregoing summary and the following detailed description are of preferred embodiments, and not restrictive of the disclosure or other alternate embodiments of the disclosure.

Brief Description of the Drawings

[0015]

[fig. 1] Figure 1A depicts the results of an IFN- gamma ELISPOT assay for the screening of epitope peptides which, in turn, demonstrate that MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7) is a potent producer of IFN- gamma. CTLs for those peptides derived from MPHOSHP1 were generated according to the protocols described in "Materials and Methods" section of the examples below. Resulting CTLs having detectable specific CTL activity are shown. In particular, the cells in the well number #4 stimulated with MPHOSPH1- A24- 9- 278 showed potent IFN- gamma production to recognize peptide pulsed target cells, as compared to the control. Figure 1B depicts the results of the IFN- gamma ELISPOT assay for the screening of CTL clones after limiting dilution (MPHOSPH1- A24- 9- 278 CTL clone) . The cells in the positive well were expanded and limiting dilution was performed. As the depicted results demonstrate, CTL clones having higher specific CTL activities against the peptide- pulsed target as compared to the activities against target without peptide pulse were established.

[fig. 2] Figure 2A depicts the results of an IFN- gamma ELISPOT assay for the screening of epitope peptides cytotoxicity, which, in turn, demonstrate that MPHOSPH1- A24- 10- 278 (SEQ ID NO: 8) is a potent producer of IFN- gamma . CTLs for those peptides derived from MPHOSHP1 were generated according to the protocols described in "Materials and Methods" section of the examples below. Resulting CTLs having detectable specific CTL activity are shown. In particular, the cells in the well number #8 stimulated with MPHOSPH1- A24- 10- 278 showed potent IFN- gamma production as compared to the control. Figure 2B depicts the results of an IFN- gamma ELISPOT assay for the screening of CTL clones after limiting dilution (MPHOSPH1- A24- 10- 278 CTL clone) . The cells in the positive well were expanded and limiting dilution was performed. As the depicted results demonstrate, CTL clones having higher specific CTL activities against the MPHOSPH1- A24- 10- 278- pulsed target as compared to the activities against target without peptide pulse as shown where established.

[fig. 3] Figure 3A depicts the establishment of CTL clones stimulated with MPHOSPH1- A24- 9- 278. (SEQ ID NO: 7) . This CTL clone demonstrated high specific CTL activity against target cells (A24LCL) pulsed with MPHOSPH1- A24- 9- 278, but did not show significant CTL activity against the same target cells (A24LCL) pulsed with no peptides. Figure 3B depicts the establishment of CTL clones stimulated with MPHOSPH1- A24- 10- 278 (SEQ ID NO: 8) . This CTL clone demonstrated high specific CTL activity against target cells (A24LCL) pulsed with MPHOSPH1- A24- 10- 278, whereas it did not show significant CTL activity against the same target cells (A24LCL) pulsed with no peptides. R means Responder: CTL clone. S means Stimulator: peptide- pulsed A24- LCL ($1x10^4$/ well) .

[fig. 4] Figure 4 depicts the expression of MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7) on the target cell surface with HLA- A24. Specific CTL activity against COS7 transfected both with the full length MPHOSPH1 gene and the HLA- A*2402 molecule was assayed using as effector cells the CTL clone raised by MPHOSPH1- A24- 9- 278. COS7 transfected with full length MPHOSPH1 but not HLA- A*2402 and COS7 transfected with HLA- A*2402 but not full length MPHOSPH1 were prepared as controls. The CTL clone demonstrated high specific CTL activity against COS7 transfected with both MPHOSPH1 and HLA- A24. However, it did not show significant specific CTL activity against COS7 transfected neither MPHOSPH1 nor HLA- A24. R means Responder: CTL clone. S means Stimulator: COS7 transfectant ($1x10^4$ / well) .

[fig. 5] Figure 5 depicts the CTL activity against bladder cancer cell lines endogenously expressing MPHOSPH1. The established CTL clone induced with MPHOSPH1- A24- 9- 278 peptide recognized tumor cells endogenously expressing MPHOSPH1. HT1376, RT- 4 and J82 cells expressed MPHOSPH1 endogenously, respectively. CTL clone showed IFN- gamma production against HT 1376 which have HLA- A*2402 genotype, but no showing response against RT- 4 and J82, does not have HLA- A*2402 genotype.

[fig. 6] Figure 6 depicts in vivo immunogenicity analysis using MPHOSPH1- A24- 9- 278 peptide. IFA- conjugated peptide was injected subcutaneously into BALB/c mice on days 0 and 7. On day 14, splenocytes of vaccinated mice were harvested and used as responder cells, and $1x10^4$ RLmalel cells pulsed MPHOSPH1- A24- 9- 278 peptide were used as stimulator cells for IFN- gamma ELISPOT assay. Spot forming counts (SFC) were indicated in cases of each mice; five mice (Anil~Ani5) were vaccinated epitope peptide and three mice (negal~nega3) were injected Mock IFA emulsion as a negative control.

[fig. 7] Figure 7 depicts the results of an IFN- gamma ELISPOT assay for the screening of epitope peptides, which, in turn, demonstrate that MPHOSPH1- A2- 9- 282 (SEQ ID NO: 9), MPHOSPH1- A2- 9- 638 (SEQ ID NO: 10) and MPHOSPH1- A2- 10- 1714 (SEQ ID NO: 11) possess potent IFN- gamma production activity. CTLs for those peptides

derived from MPHOSHP1 were generated according to the protocols described in "Materials and Methods" section of the examples set forth below. Resulting CTLs having detectable specific CTL activity are shown. In particular, Figure 7A demonstrates that the cells in the well number #1 and #5, stimulated with MPHOSPH1- A2- 9- 282, showed potent IFN- gamma production sufficient to recognize peptide pulsed target cells, as compared to the control. Figure 7B demonstrates that the cells in the well number #8 stimulated with MPHOSPH1- A2- 9- 638 showed potent IFN- gamma production sufficient to recognize peptide pulsed target cells, as compared to the control. Figure 7C demonstrates that the cells in the well number #4 stimulated with MPHOSPH1- A2- 10- 1714 showed potent IFN- gamma production to recognize peptide pulsed target cells, as compared to the control.

[fig. 8] Figure 8 depicts the establishment for CTL lines stimulated with MPHOSPH1- A02- 9- 282, (SEQ ID NO: 9) MPHOSPH1- A02- 9- 638 (SEQ ID NO: 10) and MPHOSPH1- AU2- 10- 1714 (SEQ ID NO: 11) . The cells in the positive well were expanded, and, as the depicted results demonstrate, CTL lines having higher specific CTL activities against the MPHOSPH1- A02- 9- 282- pulsed target (A), MPHOSPH1- A02- 9- 638- pulsed target (B) or MPHOSPH1- A02- 10- 1714- pulsed target (C) compared to the activities against target without peptide pulse were established.R means Responder: CTL lines. S means Stimulator: peptide- pulsed T2 ($1x10^4$/ well) .

[fig. 9] Figure 9A depicts the results of an IFN- gamma ELISPOT assay for the screening of CTL clones after limiting dilution (MPHOSPH1- A2- 9- 282 CTL clone) . The cells in the positive well were expanded and limiting dilution was performed. As the depicted results demonstrate CTL clones having higher specific CTL activities against the MPHOSPH1- A2- 9- 282 (SEQ ID NO: 9) pulsed target as compared to the activities against target without peptide pulse were established. Figure 9B depicts the establishment of CTL clones stimulated with MPHOSPH1- A02- 9- 282. The CTL clone demonstrated high specific CTL activity against target cells (T2) pulsed with MPHOSPH1- A2- 9- 282, but did not possess significant CTL activity against the same target cells (T2) pulsed with no peptides. R means Responder: CTL clone. S means Stimulator: peptide- pulsed T2 ($1x10^4$/ well) .

[fig. 10] Figure 10A depicts the results of an IFN- gamma ELISPOT assay for the screening of epitope peptides, which, in turn, demonstrate that DEPDC1- A24- 9- 294 (SEQ ID NO: 12) is a potent producer of IFN- gamma. CTLs for those peptides derived from DEPDC1 were generated according to the protocols described in "Materials and Methods" section of the examples set forth below. Resulting CTLs showing detectable specific CTL activity are shown. The cells in the well number #10 stimulated with DEPDC1- A24- 9- 294 showed potent IFN- gamma production to recognize peptide pulsed target cells, compared with the control. Figure 10B depicts the results of an IFN- gamma ELISPOT assay for the screening of CTL clones after limiting dilution (DEPDC1- A24- 9- 294 CTL clone) . The cells in the positive well were expanded and limiting dilution performed. As the depicted results demonstrate, CTL clones having higher specific CTL activities against the DEPDC1- A24- 9- 294- pulsed target compared to the activities against target without peptide pulse were established.

[fig. 11] Figure 11 depicts the establishment for CTL clones stimulated with DEPDC1- A24- 9- 294 (SEQ ID NO: 12) . The CTL clone showed high specific CTL activity against target cells (A24LCL) pulsed with DEPDC1- A24- 9- 294, whereas it did not show significant CTL activity against the same target cells (A24LCL) pulsed with no peptides. R means Responder: DEPDC- A24- 9- 294 CTL clone. S means Simulator: peptide- pulsed A24- LCL ($1x10^4$/ well) .

[fig. 12] Figure 12 depicts the expression of DEPDC1- A24- 9- 294 (SEQ ID NO: 12) on the target cell surface with HLA- A24. Specific CTL activity against COS7 transfected with both the full length DEPDC1 gene and the HLA- A*2402 molecule was assayed using as effector cells the CTL clone raised by DEPDC1- A24- 9- 294. COS7 transfected with full length DEPDC1 but not HLA- A*2402 and COS7 transfected HLA- A*2402 but not full length DEPDC1 were prepared as controls. The CTL clone established demonstrated high specific CTL activity against COS7 transfected with both DEPDC1 and HLA- A24. However, it did not show significant specific CTL activity against COS7 transfected with neither DEPDC1 nor HLA- A24. R means Responder: DEPA24- 9- 294 CTL clone. S means Stimulator: COS7 transfectant ($1x10^4$/ well) .

[fig. 13] Figure 13 depicts the CTL activity against bladder cancer cell lines endogenously expressing DEPDC 1. The established CTL clone induced with DEPDC1- A24- 9- 294 peptide recognized tumor cells endogenously expressing DEPDC 1. HT 1376, RT- 4 and J82 cells expressed DEPDC1 endogenously, respectively. CTL clone showed IFN- gamma production against HT1376 which have HLA- A*2402 genotype, but no showing response against RT- 4 and J82, does not have HLA- A*2402 genotype.

[fig. 14] Figure 14 depicts the in vivo immunogenicity analysis using DEPDC1- A24- 9- 294 peptide. IFA- conjugated peptide was injected subcutaneously into BALB/c mice on days 0 and 7. On day 14, splenocytes of vaccinated mice were harvested and used as responder cells, and $1x10^4$ RLmale1 cells pulsed DEPDC1- A24- 9- 294 peptide were used as stimulator cells for IFN- gamma ELISPOT assay. Spot forming counts (SFC) were indicated in cases of each mice; five mice (Ani1~Ani5) were vaccinated epitope peptide and two mice (nega1 and nega2) were injected Mock IFA emulsion as a negative control.

[fig. 15] Figure 15 depicts potent IFN- gamma production of DEPDC1- A02- 10- 644, -10- 575, -10- 506, -10- 765, -10- 395, -10- 224, -9- 297, -10- 296 and- 10- 302 by IFN- gamma ELISPOT assay for the screening of epitope peptides. CTLs for those peptides derived from DEPDC1 were generated in the way described in "Materials and

Methods". The cells in the well number #4 and #7 stimulated with DEPDC1- A02- 10- 644, #2 with DEPDC1- A02- 10- 575, #7 with DEPDC1- A02- 10- 506, #1 with DEPDC1- A02- 10- 765 and #1 with DEPDC1- A02- 10- 395, #1 and #2 with DEPDC1- A02- 10- 224, #4 with DEPDC1- A02- 9- 297, #3 and #4 with DEPDC1- A02- 10- 296 and #2, #3, #5 and #7 with DEPDC1- A02- 10- 302 showed potent IFN- gamma production compared with the control.

[fig. 16] Figure 16 depicts IFN- gamma production of CTL line generated with DEPDC1- A02- 10- 296 peptide. The established CTL lines raised by DEPDC1- A02- 10- 296 peptide have potent IFN- gamma production activity. It was shown IFN- gamma production against peptide- pulsed target cells, but not shown that against target cells without peptide pulse. Target cells were used T2 cells, expressed HLA- A2 molecule at cell surface.

[fig.l7] Figure 17 depicts CTL activity against targets endogenously expressing DEPDC1 and HLA- A2 molecule. It was shown in upper panel that the established CTL line generated with DEPDC1- A02- 10- 296 peptide possessed IFN- gamma production activity against target cells which endogenously expressed DEPDC1V2 and HLA- A2. The case of using DEPDC1- A02- 10- 296 peptide was shown in lower panel. The target cells expressing only DEPDC1V2 and expressing only HLA- A2 with treatment of DEPDC1V1- 9- 674 or DEP- 9- 462 peptide pulse were prepared as the negative control. The target cells were prepared from HEK293 transfectant which stable expressed HLA- A2 or mock.

[fig.18]Figure 18 depicts antigen expression in Case 2. In Case 2, both MPHOSPH1 and DEPDC1 were expressed strongly. Therefore, two kinds of epitope peptides derived from MPHOSPH1 and DEPDC1 have been vaccinated.

[fig.19]Figure 19 depicts the clinical evaluation for local recurrence of bladder cancer in Case 2. Case 2 were evaluated SD in accordance with RECIST criteria.

[fig.20]Figure 20 depicts antigen expression in Case 3. In Case 3, DEPDC1 was expressed strongly. Therefore, we have vaccinated the epitope peptide derived from DEPDC1 alone.

[fig.21]Figure 21 depicts clinical evaluation for right lobe of metastatic lung in Case 3. The progression rate was decreased after vaccination. Especially, the size of the tumor was decreased after 3rd courses.

[fig.22]Figure 22 depicts clinical evaluation for left lobe of metastatic lung in Case 3. The progression rate was decreased after vaccination. Especially, the size of the tumor was decreased after 3rd courses.

[fig.23]Figure 23 depicts the Anti-tumor effect in Case 3. The progression rate of metastatic tumor was decreased after vaccination.

[fig.24]Figure 24 depicts specific CTL response in Case 3. Specific CTL response was strongly shown after vaccination.

[fig.25]Figure 25 depicts antigen expression in Case 4. In Case 4, MPHOSPH1 and DEPDC1 were expressed. Therefore, two kinds of epitope peptides derived from MPHOSPH1 and DEPDC1 have been vaccinated.

[fig.26]Figure 26 depicts the clinical evaluation for local recurrence of bladder cancer in Case 4. The size of the tumor was reduced 20% in accordance with RECIST criteria after 1st course vaccination.

Detailed Description of the Invention

[0016] The words "a", "an", and "the" as used herein mean "at least one" unless otherwise specifically indicated.

[0017] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0018] Identification of new TAAs, particularly those that induce potent and specific anti-tumor immune responses, warrants further development of the clinical application of the peptide vaccination strategy in various types of cancer (Boon T et al., (1996) J Exp Med 183: 725-9.; van der Bruggen P et al., (1991) Science 254: 1643-7.; Brichard V et al., (1993) J Exp Med 178: 489-95.; Kawakami Y et al., (1994) J Exp Med 180: 347-52.; Shichijo S et al., (1998) J Exp Med 187:277-88.; Chen YT et al., (1997) Proc.Natl.Acd. Sci.USA, 94: 1914-8.; Harris CC, (1996) J Natl Cancer Inst 88: 1442-55.; Butterfield LH et al., (1999) Cancer Res 59:3134-42.; Vissers JL et al., (1999) Cancer Res 59: 5554-9.; van der Burg SH et al., (1996) J. Immunol 156:3308-14.; Tanaka F et al., (1997) Cancer Res 57:4465-8.; Fujie T et al., (1999) Int J Cancer 80:169-72.; Kikuchi M et al., (1999) Int J Cancer 81 : 459-66.; Oiso M et al., (1999) Int J Cancer 81:387-94.). As noted above, MPHOSPH1 (M-phase phosphoprotein 1; GenBank Accession No. NM_016195; SEQ ID Nos.1, 2) and DEPDC1 (DEP domain containing 1; GenBank Accession No. BM683578), more particularly its two variants, DEPDC1V1 (SEQ ID Nos.3, 4) and DEPDC1V2 (SEQ ID No. 5, 6), were previously identified using cDNA microarray technologies as over-expressed in various cancers. MPHOSPH1 was previously identified as one of the proteins specifically phosphorylated at the G2/M transition, and characterized as a plus-end-directed kinesin related protein (Abaza A et al., J Biol Chem 2003, 278: 27844-52.). More particularly, MPHOSPH1 was previously documented to be plus-end-directed molecular motor that plays a crucial role in cytokinesis, and accumulates in the midzone of the spindle during anaphase to telophase in HeLa cells (Abaza A et al., J Biol Chem 2003, 278: 27844-52; Kamimoto T et al., J Biol Chem 2001, 276: 37520-8.).The MPHOSPH1 DNA encodes a 1780-amino acid protein that is composed of three domains: an NH2-kinasin motor domain, a central coiled coil-stalk domain, and a C-globular tail domain. These data suggest that MPHOSPH1 is an NH2-type kinesin-related protein.

[0019] The function of DEPDC1 protein remains unclear. The DEP domain included this protein is found in Dishevelled, Egl-10, and Pleckstrin. In particular, the DEP domain in Drosophila dishevelled is essential to rescue planar polarity defects and induces JNK signaling; nevertheless, its function in Human has not yet been clarified. However, as disclosed in PCT/JP2006/302684, DEPDC1 (in house No. B5860N) has two different transcriptional variants consisting of 12 and 11 exons, corresponding to DEPDC1 V1 and V2, respectively. Alternative variations in exon 8 of V1 were noted, and the other remaining exons were found to be common to both variants. V2 variant has no exon 8 of the V1, but generates the same stop codon within last exon. The full-length cDNA sequences of the B5860NV1 and B5860NV2 variants consist of 5318 and 4466 nucleotides, respectively. The ORF of these variants start at within each exon 1. Eventually, V1 and V2 transcripts encode 811 and 527 amino acids, respectively. siRNAs suppressed the growth of cancer cells. These results demonstrate that DEPDC1 plays important roles in growth of most cancer cells.

[0020] As disclosed in PCT/JP2006/302684, MPHOSPH1 and DEPDC1 are over-expressed in bladder cancer but show minimal expression in normal tissues. In addition, these genes were found to have a significant function related to cell proliferation.

[0021] In the present disclosure, peptides derived from MPHOSPH1 or DEPDC1 are shown to be TAA epitopes restricted by HLA- A24 and HLA- A2, an HLA allele commonly found in the Japanese and Caucasian populations. Specifically, using their binding affinities to HLA- A24 and HLA- A2, candidates of HLA- A24 and HLA- A2 binding peptides derived from MPHOSPH1 or DEPDC1 were identified. After the in vitro stimulation of T- cells by dendritic cells (DCs) loaded with these peptides, CTLs were successfully established using MPHOSPH1- A24- 9- 278 (IYNEYIYDL (SEQ ID NO: 7)), MPHOSPH 1- A24- 10- 278 (IYNEYIYDLF (SEQ ID NO: 8)), MPHOSPH1- A2- 9- 282 (YIYDLFVPV (SEQ ID NO: 9)), MPHOSPH1- A2- 9- 638 (RLAIFKDLV (SEQ ID NO: 10)), MPHOSPH1- A2- 10- 1714 (TMSSSKLSNV (SEQ ID NO: 11)), DEPDC1- A24- 9- 294 (EYYELFVNI (SEQ ID NO: 12)), DEPDC1- A02- 10- 644 (SLMIHTFSRC (SEQ ID NO: 240)), DEPDC1- A02- 10- 575 (SLLPASSMLT (SEQ ID NO: 241)), DEPDC1- A02- 10- 506 (QLCRSQSLLL (SEQ ID NO: 243)), DEPDC1- A02- 10- 765 (KQFQKEYPLI (SEQ ID NO: 244)), DEPDC1- A02- 10- 395 (IMGGSCHNLI (SEQ ID NO: 249), DEPDC1- A02- 10- 224 (NMANTSKRGV (SEQ ID NO: 253)), DEPDC1- A02- 9- 297 (ELFVNILGL (SEQ ID NO: 226)), DEPDC1- A02- 10- 296 (YELFVNILGL (SEQ ID NO: 254)) . DEPDC1- A02- 10- 301 (NILGLLQPHL (SEQ ID NO: 255)), DEPDC1- A2- 9- 589 (LLQPHLERV (SEQ ID NO: 192)), DEPDC1- A2- 9- 619 (LLMRMISRM (SEQ ID NO: 195)), DEPDC 1- A2- 9- 290 (LLTFEYYEL (SEQ ID NO: 197)), DEPDC1- A2- 9- 563 (RLCKSTIEL (SEQ ID NO: 209)), DEPDC1- A2- 9- 653 (CVLCCAEEV (SEQ ID NO: 225)), DEPDC1- A2- 10- 674 (FLMDHHQEIL (SEQ ID NO: 228)) and DEPDC1- A2- 10- 302 (ILVVCGYITV (SEQ ID NO: 230)) . These CTLs demonstrated potent cytotoxic activity against the peptide- pulsed A24LCL and T2 cells. Furthermore, CTL clones derived from these cells also demonstrated specific cytotoxicity against HLA- A24 or HLA- A2 positive cells expressing MPHOSPH1 or DEPDC1, respectively.. However, these CTL clones did not express cytotoxic activity against cells having expression of only one of peptides, including HLA- A24, HLA- A2, MPHOSPH1 and DEPDC 1. Together these results suggest the utility of MPHOSPH I and DEPDC1 as TAAs for cancer cells and that MPHOSPH1- A24- 9- 278 (IYNEYIYDL (SEQ ID NO: 7)), MPHOSPH1- A24- 10- 278 (IYNEYIYDLF (SEQ ID NO: 8)), MPHOSPH1- A2- 9- 282 (YIYDLFVPV (SEQ ID NO: 9)), MPHOSPH1- A2- 9- 638 (RLAIFKDLV (SEQ ID NO: 10)), MPHOSPH1- A2- 10- 1714 (TMSSSKLSNV (SEQ ID NO: 11)), DEPDC1- A24- 9- 294 (EYYELFVNI (SEQ ID NO: 12)), DEPDC1- A02- 10- 644 (SLMIHTFSRC (SEQ ID NO: 240)), DEPDC1- A02- 10- 575 (SLLPASSMLT (SEQ ID NO: 241)), DEPDC1- A02- 10- 506 (QLCRSQSLLL (SEQ ID NO: 243)), DEPDC1- A02- 10- 765 (KQFQKEYPLI (SEQ ID NO: 244)), DEPDC1- A02- 10- 395 (IMGGSCHNLI (SEQ ID NO: 249), DEPDC1- A02- 10- 224 (NMANTSKRGV (SEQ ID NO: 253)), DEPDC1- A02- 9- 297 (ELFVNILGL (SEQ ID NO: 226)), DEPDC1- A02- 10- 296 (YELFVNILGL (SEQ ID NO: 254)), DEPDC1- A02- 10- 301 (NILGLLQPHL (SEQ ID NO: 255)), DEPDC1- A2- 9- 589 (LLQPHLERV (SEQ ID NO: 192)), DEPDC1- A2- 9- 619 (LLMRMISRM (SEQ ID NO: 195)), DEPDC1- A2- 9- 290 (LLTFEYYEL (SEQ ID NO: 197)), DEPDC1- A2- 9- 563 (RLCKSTIEL (SEQ ID NO: 209)), DEPDC1- A2- 9- 653 (CVLCCAEEV (SEQ ID NO: 225)), DEPDC1- A2- 10- 674 (FLMDHHQEIL (SEQ ID NO: 228)) and DEPDC1- A2- 10- 302 (ILVVCGYITV (SEQ ID NO: 230)) are epitope peptides of each TAA restricted by HLA- A24 or HLA- A2. Since these antigens are over- expressed in most cancers and are associated with tumor cell proliferation, they find utility as immunotherapeutic targets against cancers. Exemplary cancers include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor.

[0022] Accordingly, the present disclosure further provides methods of treating or preventing a disease associated with the over- expression of MPHOSPH1 and/or DEPDC 1, e.g. cancers, in a subject, such methods including the steps of administering to a subject in need thereof an immunogenic peptide of less than about 40 amino acids, often less than about 20 amino acids, usually less than about 15 amino acids and having the amino acid sequence of SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255. Alternatively, the immunogenic peptide may be composed of a sequence of SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255 in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted or added, provided the resulting variant peptide retains the immunogenic activity (i.e., the ability to induce CTLs specific to cells expressing MPHOSPH1 and/or DEPDC1, e.g. cancers) . The number of residues to be substituted,

deleted, or added is generally 5 amino acids or less, preferably 4 amino acids or less, more preferably 3 amino acids or less, even more preferably one or two amino acids. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor.

[0023] Variant peptides (i.e., peptides having an amino acid sequence modified by substituting, deleting, or adding one, two or several amino acid residues to an original amino acid sequence) are known to retain the original biological activity (Mark DF et al., (1984) Proc Natl Acad Sci USA 81: 5662-6.; Zoller MJ and Smith M, (1982) Nucleic Acids Res 10:6487-500.; Dalbadie-McFarland G et al., (1982) Proc Natl Acad Sci USA 79: 6409-13.). In the context of the present disclosure, it is preferable that the amino acid modification results in conservation of the properties of the original amino acid side-chain (a process known as conservative amino acid substitution). Examples of properties of amino acid side chains include hydrophobic amino acids (A, I, L, M, F, P, W, Y, V), hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, T), and side chains having the following functional groups or characteristics in common: an aliphatic side-chain (G, A, V, L, I, P); a hydroxyl group containing side-chain (S, T, Y); a sulfur atom containing side-chain (C, M); a carboxylic acid and amide containing side-chain (D, N, E, Q); a base containing side-chain (R, K, H); and an aromatic containing side-chain (H, F, Y, W). Note, the parenthetic letters indicate the one-letter codes of amino acids.

[0024] In preferred embodiments, the immunogenic peptide is a nonapeptide (9-mer) or a decapeptide (10-mer).

[0025] The present disclosure further provides a method of inducing anti-tumor immunity for a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, in a subject, such a method including the steps of administering to a subject in need thereof an immunogenic peptide of the present disclosure, namely one having the amino acid sequence of S SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255 or a variant thereof (i.e., including 1, 2, or several amino acid substitutions, deletions, or additions). The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor.

[0026] In the context of the present disclosure, the subject is preferably a mammal. Exemplary mammals include, but are not limited to, e.g., a human, non-human primate, mouse, rat, dog, cat, horse, or cow.

[0027] In the present disclosure, the peptide can be administered to a subject via an in vivo or ex vivo protocol. Furthermore, the present disclosure also provides use of nonapeptide or decapeptide selected from peptides having the amino acid sequence of SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 and 255 (and variants thereof) for manufacturing an immunogenic composition for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinorna, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor.

[0028] Homology analyses of MPHOSPH1- A24- 9- 278 (IYNEYIYDL (SEQ ID NO: 7)), MPHOSPH1- A24- 10- 278 (IYNEYIYDLF (SEQ ID NO: 8)), MPHOSPH1- A2- 9- 282 (YIYDLFVPV (SEQ ID NO: 9)), MPHOSPH1- A2- 9- 638 (RLAIFKDLV (SEQ ID NO: 10)), MPHOSPH1- A2- 10- I714 (TMSSSKLSNV (SEQ ID NO: 11)), DEPDC1- A24- 9- 294 (EYYELFVNI (SEQ ID NO: 12)), DEPDC1- A2- 9- 589 (LLQPHLERV (SEQ ID NO: 192)), DEPDC1- A2- 9- 619 (LLMRMISRM (SEQ ID NO: 195)), DEPDC1- A2- 9- 290 (LLTFEYYEL (SEQ ID NO: 197)), DEPDC1- A2- 9- 563 (RLCKSTIEL (SEQ ID NO: 209)), DEPDC1- A2- 9- 653 (CVLCCAEEV (SEQ ID NO: 225)), DEPDC1- A2- 10- 674 (FLMDHHQEIL (SEQ ID NO: 228)), DEPDC1- A2- 10- 302 (ILVVCGYITV (SEQ ID NO: 230)) DEPDC1- A02- 10- 644 (SLMIhTFSRC (SEQ ID NO: 240)), DEPDC1- A02- 10- 575 (SLLPASSMLT (SEQ ID NO: 241)), DEPDC1- A02- 10- 506 (QLCRSQSLLL (SEQ ID NO: 243)), DEPDC1- A02- 10- 765 (KQFQKEYPLI (SEQ ID NO: 244)), DEPDC1- A02- 10- 395 (IMGGSCHNLI (SEQ ID NO: 249), DEPDC1- A02- 10- 224 (NMANTSKRGV (SEQ ID NO: 253)), DEPDC1- A02- 9- 297 (ELFVNILGL (SEQ ID NO: 226)), DEPDC1- A02- 10- 296 (YELFVNILGL (SEQ ID NO: 254)) and DEPDC1- A02- 10- 301 (NIL- GLLQPHL (SEQ ID NO: 255)) demonstrate that they do not have significant homology with the peptides derived from any known human gene products. Accordingly, the possibility of unknown or undesirable immune responses with immunotherapy against these molecules is significantly reduced.

[0029] Regarding HLA antigens, the data presented here demonstrate that the uses of A- 24 type or A- 2 type antigens (which are said to be highly expressed among the Japanese) are favorable for obtaining effective results. The uses of subtypes such as A- 2402 and A- 0201 are even more preferable. Typically, in the clinic, the type of HLA antigen of the patient requiring treatment is investigated in advance, which, in turn, enables the selection of appropriate peptides having high levels of binding affinity to the patient antigen, or having cytotoxic T cell (CTL) inducibility by antigen presentation. Furthermore, in order to obtain peptides having high binding affinity and CTL inducibility, substitution, deletion, or addition of 1, 2, or several amino acids may be performed based on the amino acid sequence of the naturally occurring MPHOSPH1 and DEPDC1 partial peptide. Herein, the term "several" means refers to 5 or less, more preferably 3 or less. Furthermore, in addition to peptides that are naturally displayed, since the regularity of the sequences of peptides displayed by binding to HLA antigens is already known (Kubo RT, et al., (1994) J. Immunol., 152, 3913- 24.; Rammensee HG, et al., (1995)

Immunogenetics. 41: 178- 228.; Kondo A, et al., (1995) J. Immunol. 155: 4307- 12.), modifications based on such regularity can be performed on the immunogenic peptides of the disclosure. For example, peptides possessing high HLA- 24 binding affinity in which the second amino acid from the N terminus substituted with phenylalanine, tyrosine, methionine, or tryptophan may be favorably used. Likewise, peptides whose C- terminal amino acid is substituted with phenylalanine, leucine, isoleucine, tryptophan, or methionine may also be used favorably. On the other hand, peptides possessing high HLA- A2 binding affinity having their second amino acid from the N terminus substituted with leucine or methionine, and peptides whose C- terminal amino acid is substituted with valine or leucine may be used favorably. Furthermore, 1 to 2 amino acids may be added to the N terminus and/or C terminus of the peptide.

[0030] However, when the peptide sequence is identical to a portion of the amino acid sequence of an endogenous or exogenous protein having a different function, side effects such as autoimmune disorders or allergic symptoms against specific substances may be induced. Therefore, it is preferable to avoid the situation wherein the immunogenic sequence matches the amino acid sequence of a known protein. This situation may be avoided by performing a homology search using available databases. If homology searches confirm that peptides in which 1, 2 or several different amino acids do not exist in nature, then the danger that modifications of the above- mentioned amino acid sequence that, for example, increase the binding affinity with HLA antigens, and/or increase the CTL inducibility can be avoided.

[0031] Although peptides having high binding affinity to the HLA antigens as described above are expected to be highly effective as cancer vaccines, the candidate peptides, which are selected according to the presence of high binding affinity as an indicator, must be examined for the actual presence of CTL inducibility. CTL inducibility may be routinely confirmed by inducing antigen- presenting cells carrying human MHC antigens (for example, B- lymphocytes, macrophages, and dendritic cells), or more specifically dendritic cells derived from human peripheral blood mononuclear leukocytes, and, after stimulation with the peptide of interest, mixing with CD8- positive cells and measuring the cytotoxic activity against the target cells. As the reaction system, transgenic animals produced to express a human HLA antigen (for example, those described in BenMohamed L, et al., (2000) Hum. Immunol.: 61 (8) : 764- 79 Related Articles, Books, Linkout.) may be used. For example, the target cells can be radiolabeled with ^{51}Cr and such, and cytotoxic activity can be calculated from radioactivity released from the target cells. Alternatively, it can be examined by measuring IFN-gamma produced and released by CTL in the presence of antigen- presenting cells that carry immobilized peptides, and visualizing the inhibition zone on the media using anti- IFN- gamma monoclonal antibodies.

[0032] As a result of examining the CTL inducibility of peptides as described above, it was discovered that those peptides having high binding affinity to an HLA antigen did not necessarily have high inducibility. However, nonapeptides or decapeptides selected from the group of peptides having the amino acid sequences indicated by IYNEYIYDL. (SEQ ID NO: 7), IYNEYIYDLF (SEQ ID NO: 8), YIYDLFVPV (SEQ ID NO: 9), RLAIFKDLV (SEQ ID NO: 10) . TMSSSKLSNV (SEQ ID NO: 11), EYYELFVNI (SEQ ID NO: 12), LLQPHLERV (SEQ ID NO: 192), LLMRMISRM (SEQ ID NO: 195) . LLTFEYYEL (SEQ ID NO: 197), RLCKSTIEL (SEQ ID NO: 209), CVLCCAEEV (SEQ ID NO: 225), FLMDHHQEIL (SEQ ID NO: 228), ILVVCGYITV (SEQ ID NO: 230) DEPDCI- A02- 10- 644 (SLMIHTFSRC (SEQ ID NO: 240)), DEPDC1- A02- 10- 575 (SLLPASSMLT (SEQ ID NO: 241)), DEPDC1- A02- 10- 506 (QLCRSQSLLL (SEQ ID NO: 243)), DEPDC1- A02- 10- 765 (KQFQKEYPLI (SEQ ID NO: 244)), DEPDC1- A02- 10- 395 (IMGGSCHNLI (SEQ ID NO: 249), DEPDC1- A02- 10- 224 (NMANTSKRGV (SEQ ID NO: 253)), DEPDC1- A02- 9- 297 (ELFVNILGL (SEQ ID NO: 226)), DEPDC1- A02- 10- 296 (YELFVNILGL (SEQ ID NO: 254)) and DEPDC1- A02- 10- 301 (NILGLLQPHL (SEQ ID NO: 255)) showed particularly high CTL inducibility.

[0033] As noted above, the present disclosure provides peptides having cytotoxic T cell indu- [0034] As noted above, the present disclosure provides peptides having cytotoxic T cell inducibility, namely those having the amino acid sequence of SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253. 254 or 255 or a variant thereof (i.e., those in which 1, 2, or several amino acids are substituted, deleted, or added) . It is preferable that the amino acid sequences composed of 9 or 10 amino acids indicated in SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255 or a variant thereof do not match an amino acid sequence associated with another endogenous protein. In particular, amino acid substitution to leucine or methionine at the second amino acid from the N terminus, amino acid substitution to valine or leucine at the C- terminal amino acid, and amino acid addition of 1 to 2 amino acids at the N terminus and/or C terminus are examples of preferred variants. One of skill in the art will recognize that in addition to amino acid substitutions and additions, immunologically active fragments of the peptides may also be used in the methods of the disclosure. Methods for determining active fragments are well known in the art. CTL clones obtained by stimulation by these modified peptides can recognize the original peptides and cause damage for cells expressing the original peptides.

[0034] Peptides of the present disclosure can be prepared using well known techniques. For example, the peptides can be prepared synthetically, using either recombinant DNA technology or chemical synthesis. Peptides of the present disclosure may be synthesized individually or as longer polypeptides comprising two or more peptides. The peptides of the present disclosure are preferably isolated, i.e., substantially free of other naturally occurring host cell proteins and fragments thereof.

[0035] The peptides of the present disclosure may contain modifications, such as glycosylation, side chain oxidation,

or phosphorylation; so long as the modifications do not destroy the biological activity of the peptides as described herein, namely the ability to binding to an HLA antigen and induce CTL. Other modifications include incorporation of D-amino acids or other amino acid mimetics that can be used, for example, to increase the serum half life of the peptides.

[0036] The peptides of this disclosure can be prepared as a combination, which includes two or more of peptides of the disclosure, for use as a vaccine for a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, such a vaccine inducing CTL in vivo. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor. The peptides may be in a cocktail or may be conjugated to each other using standard techniques. For example, the peptides can be expressed as a single polypeptide sequence. The peptides in the combination may be the same or different. By administering the peptides of this disclosure, the peptides are presented at a high density on the HLA antigens of antigen-presenting cells, which, in turn, induces CTLs that specifically react toward the complex formed between the displayed peptide and the HLA antigen. Alternatively, antigen-presenting cells having immobilized the peptides of this disclosure on their cell surface, obtained by removing dendritic cells from the subjects, may be stimulated by the peptides of this disclosure. Re-administration of these cells to the respective subjects induces CTL, and, as a result, aggressiveness towards the target cells can be increased.

[0037] More specifically, the present disclosure provides drugs for treating and/or preventing proliferation, metastasis, and such of a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, which include one or more of peptides of this disclosure. The peptides disclosed find particular utility in the treatment of a disease associating MPHOSPH1 and/or DEPDC1, e.g. cancers. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor.

[0038] The peptides disclosed can be administered to a subject directly, as a pharmaceutical composition that has been formulated by conventional formulation methods. In such cases, in addition to the peptides of this disclosure, carriers, excipients, and such that are ordinarily used for drugs can be included as appropriate, without particular limitations. The immunogenic compositions of this disclosure may be used for treatment and prevention of a disease associating MPHOSPH1 and/or DEPDC1, e.g. cancers. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor.

[0039] The immunogenic compositions for treatment and/or prevention of a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, which comprise as the active ingredient one or more peptides of the present disclosure, can further include an adjuvant so that cellular immunity will be established effectively. Alternatively, they may be administered with other active ingredients, such as anticancer agents. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor. Suitable formulations include granules. Suitable adjuvants are described in the literature (Johnson AG. (1994) Clin. Microbiol. Rev., 7:277-89.). Exemplary adjuvants include, but are not limited to, aluminum phosphate, aluminum hydroxide, and alum. Furthermore, liposome formulations, granular formulations in which the drug is bound to few-micrometer diameter beads, and formulations in which a lipid is bound to the peptide may be conveniently used. The method of administration may be oral, intradermal, subcutaneous, intravenous injection, or such, and may include systemic administration or local administration to the vicinity of the targeted tumor. The dose of the peptide(s) of this disclosure can be adjusted appropriately according to the disease to be treated, age of the patient; weight, method of administration, and such. Though the dosage is ordinarily 0.001 mg to 1000 mg, preferably 0.01 mg to 100 mg, more preferably 0.1 mg to 10 mg, preferably administered once in a few days to few months, one skilled in the art can readily select the appropriate dose and method of administration, as, the selection and optimization of these parameters is well within routine skill.

[0040] The present disclosure further provides intracellular vesicles called exosomes, which present complexes formed between the peptides of this invention and HLA antigens on their surface. Exosomes can be prepared, for example, by using the methods described in detail in Published Japanese Translation of International Publication Nos. Hei 11-510507 and 2000-512161, and are preferably prepared using antigen-presenting cells obtained from subjects who are targets of treatment and/or prevention. The exosomes of this disclosure can be inoculated as cancer vaccines, similarly to the peptides of this disclosure.

[0041] The type of HLA antigens used must match that of the subject requiring treatment and/or prevention. For example, in the Japanese population, HLA-A24 or HLA-A2, particularly HLA-A2402 or HLA-A0201, is often appropriate.

[0042] In some embodiments, the vaccine compositions of the present disclosure include a component which primes cytotoxic T lymphocytes. Lipids have been identified as agents capable of priming CTL in vivo against viral antigens. For example, palmitic acid residues can be attached to the epsilon- and alpha- amino groups of a lysine residue and then linked to an immunogenic peptide of the disclosure. The lipidated peptide can then be administered either directly, in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant. As another example of a lipid priming

of CTL responses, E. coli lipoproteins, such as tripalmitoyl- S- glycerylcysteinlyseryl- serine (P3CSS), can be used to prime CTL when covalently attached to an appropriate peptide (see, e.g., Deres K, et al., (1989) Nature 342: 561- 4.) .

[0043] The immunogenic compositions of the present disclosure may also include nucleic acids encoding one or more of the immunogenic peptides disclosed here. See, e.g., Wolff JA et al., (1990) Science 247: 1465- 8; U.S. Patent Nos. 5, 580, 859; 5, 589, 466; 5, 804, 566; 5, 739, 118; 5, 736, 524; 5, 679, 647; and WO 98/04720. Examples of DNA- based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide- mediated) delivery, cationic lipid complexes, and particle- mediated ("gene gun") or pressure- mediated delivery (see, e.g., U.S. Patent No. 5, 922, 687) .

[0044] The immunogenic peptides disclosed can also be expressed by viral or bacterial vectors. Examples of suitable expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e.g., as a vector to express nucleotide sequences that encode the peptide. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another suitable vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover CK, et al., (1991) Nature 351:456-60. A wide variety of other vectors useful for therapeutic administration or immunization e.g., adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, are known in the art. See, e.g., Shata MT, et al., (2000) Mol. Med. Today 6:66-71; Shedlock DJ and Weiner DB., et al., (2000) J. Leukoc. Biol. 68:793-806; and Hipp JD, et al., (2000) In Vivo 14:571-85.

[0045] The present disclosure also provides methods of inducing antigen-presenting cells using one or more peptides of this disclosure. The antigen-presenting cells can be induced by inducing dendritic cells from the peripheral blood monocytes and then contacting (stimulating) them with one or more peptides disclosed in vitro, ex vivo or in vivo. When peptides of the present disclosure are administered to the subjects, antigen-presenting cells that have the peptides of this disclosure immobilized to them are induced in the body of the subject. Alternatively, after immobilizing the peptides of this disclosure to the antigen-presenting cells, the cells can be administered to the subject as a vaccine. For example, the ex vivo administration may include the steps of:

a: collecting antigen-presenting cells from a subject, and
b: contacting the antigen-presenting cells of step a with a peptide of the present disclosure

[0046] The antigen-presenting cells obtained by step b can be administered to the subject as a vaccine.

[0047] This disclosure also provides a method for inducing antigen-presenting cells having a high level of cytotoxic T cell inducibility, in which the method includes the step of transferring genes composed of polynucleotide(s) encoding one or more peptides of this disclosure to antigen-presenting cells in vitro. The introduced genes may be in the form of DNAs or RNAs. For the method of introduction, without particular limitations, various methods conventionally performed in this field, such as lipofection, electro-poration, and calcium phosphate method may be suitably used. More specifically, transfection may be performed as described in Reeves ME, et al., (1996) Cancer Res., 56:5672-7.; Butterfield LH, et al., (1998) J. Immunol., 161:5607-13.; Boczkowski D, et al., (1996) J. Exp. Med., 184:465-72.; Published Japanese Translation of International Publication No. 2000-509281. By transferring the gene into antigen-presenting cells, the gene undergoes transcription, translation, and such in the cell, and then the obtained protein is processed by MHC Class I or Class II, and proceeds through a presentation pathway to present partial peptides.

[0048] The present disclosure further provides methods for inducing CTL using one or more peptides of this disclosure. When the peptides of this disclosure are administered to a subject, CTL are induced in the body of the subject, and the strength of the immune system targeting the cells expressing MPHOSPH1 and/or DEPDC1, e.g. cancer cells in the tumor tissues is thereby enhanced. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor. Alternatively, the peptides of the present disclosure may be used in the context of an ex vivo therapeutic method, in which subject-derived antigen-presenting cells and CD8-positive cells or peripheral blood mononuclear leukocytes are contacted (stimulated) with one or more peptides of this disclosure in vitro, and, after inducing CTL, the cells are returned to the subject. For example, the method may include the steps of:

a: collecting antigen-presenting cells from a subject,
b: contacting the antigen-presenting cells of step a with a peptide of the present invention,
c: mixing the antigen-presenting cells of step b with CD^{8+} T cells and co-culturing so as to induce cytotoxic T-cells:, and
d: collecting CD^{8+} T cells from the co-culture of step c.

The CD^{8+} T cells having cytotoxic activity obtained by step d can be administered to the subject as a vaccine.

[0049] The present disclosure further provides methods for producing activated cytotoxic T cell using the peptides of this disclosure. For example, the method may include the following steps of:

a: collecting T cells from a subject, and
b: contacting T cells with following peptides.

(1) An isolated peptide of less than about 15 amino acids selected from the group consisting of peptides having the amino acid sequences of SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 and 255.
(2) A peptide having cytotoxic T cell inducibility, wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 and 255, wherein 1, 2, or several amino acids are substituted, deleted, or added.

[0050] The present disclosure also provides method for producing APC having activated T-cell inducibility using the peptides of the present disclosure. For instance, the method may include the step of contacting antigen presenting cells with the peptides to produce antigen presenting cells presenting the peptide and HLA antigen on the surface.
In the context of the present disclosure, "activated cytotoxic T cell" induces IFN-gamma producing, IFN-gamma releasing, and death of tumor cells.

[0051] The present disclosure further provides isolated cytotoxic T cells induced using the peptides of this disclosure. The cytotoxic T cells, induced by stimulation with an antigen-presenting cell presenting one or more peptides of this disclosure, are preferably derived from subjects who are the target of treatment and/or prevention, and can be administered alone or in combination with other drugs, including one or more peptides of this disclosure or exosomes having anti-tumor activity. The obtained cytotoxic T cells act specifically against target cells presenting the peptides of this disclosure or preferably the same peptide(s) used for induction. The target cells may be cells that express MPHOSPH1 and/or DEPDC1 endogenously, or cells that are transfected with MPHOSPH1 and/or DEPDC1 genes. Cells that present the peptides of this disclosure on the cell surface, due to stimulation with these peptides, can also become targets of attack.

[0052] The present disclosure also provides antigen-presenting cells presenting complexes formed between HLA antigens and one or more peptides of this disclosure. The antigen-presenting cells, obtained through contact with the peptides of this disclosure or the nucleotides encoding such peptides, are preferably derived from subjects who are the target of treatment and/or prevention, and can be administered as vaccines, alone or in combination with other drugs, including the peptides, exosomes, or cytotoxic T cells of the present disclosure.

[0053] The present disclosure also provides a composition comprising nucleic acids encoding polypeptides that are capable of forming a subunit of a T cell receptor (TCR), and methods of using the same. The TCR subunits have the ability to form TCRs that confer specificity to T cells for tumor cells presenting MPHOSPH1 or DEPDC1. By using the known method in the art, the nucleic acids of alpha- and beta-chain as the TCR subunits of the CTL induced with one or more peptides of this disclosure may be identified (WO2007/032255) and Morgan et al., J Immunol, 171, 3288 (2003)). The derivative TCRs preferably bind target cells displaying the MPHOSPH1 or DEPDC1 peptide with high avidity, and optionally mediate efficient killing of target cells presenting the MPHOSPH1 or DEPDC1 peptide in vivo and in vitro.

[0054] The nucleic acids encoding the TCR subunits can be incorporated into suitable vectors e.g. retroviral vectors. These vectors are well known in the art. The nucleic acids or the vectors comprising them usefully can be transferred into a T cell, which T cell is preferably from a patient. Advantageously, the disclosure provides an off-the-shelf composition allowing rapid modification of a patient's own T cells (or those of another mammal) to rapidly and easily produce modified T cells having excellent cancer cell killing properties.

[0055] Also, the present disclosure provides CTLs which are prepared by transduction with the nucleic acids encoding the TCR subunits polypeptides binding with MPHOSPH1 or DEPDC1 peptide e.g. SEQ ID NOs: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255 in the context of HLA- A24 or HLA- A2. The transduced CTLs are capable of homing to cancer cells in vivo, and expanded by well known culturing method in vitro (e.g., Kawakami et al., J Immunol., 142, 3452- 3461 (1989)) . The T cells of the disclosure can be used to form an immunogenic composition useful in treating or preventing cancer in a patient in need of therapy or protection (WO2006/031221) .

[0056] In the context of the present disclosure, the term "vaccine" (also referred to as an immunogenic composition) refers to a substance that induces anti-tumor immunity or suppresses cancers upon inoculation into animals. According to the present disclosure, polypeptides having the amino acid sequence of SEQ ID NO: 7, 8 or 12 were suggested to be HLA-A24 restricted epitope peptides and those of SEQ ID NO: 9, 10, 11, 192, 195, 197, 209, 225, 226, 228 230, 240, 241, 243, 244, 249, 253, 254 or 255 were suggested to be HLA-A2 restricted epitope peptides that may induce potent and specific immune response against cells expressing MPHOSPH1 and/or DEPDC1, e.g. cancer cells expressing MPHOSPH 1 and/or DEPDC1. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor. Thus, the present invention also encompasses a method of inducing anti-tumor immunity using polypeptides having the amino acid sequence of SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255 or a variant thereof (i.e., including 1,

2, or several amino acid substitutions, deletions, or additions). In general, anti-tumor immunity includes immune responses such as follows:

- an induction of cytotoxic lymphocytes against tumors containing cells expressing MPHOSPH1 and/or DEPDC1,
- an induction of antibodies that recognize tumors containing cells expressing MPHOSPH1 and/or DEPDC1, and
- an induction of anti-tumor cytokine production.

[0057] Therefore, when a certain peptide induces any one of these immune responses upon inoculation into an animal, the peptide is decided to have anti- tumor immunity inducing effect. The induction of the anti- tumor immunity by a peptide can be detected by observing in vivo or in vitro the response of the immune system in the host against the peptide.

[0058] For example, a method for detecting the induction of cytotoxic T lymphocytes is well known. A foreign substance that enters the living body is presented to T cells and B cells by the action of antigen-presenting cells (APCs). T cells that respond to the antigen presented by APC in antigen specific manner differentiate into cytotoxic T cells (also referred to as cytotoxic T lymphocytes or CTLs) due to stimulation by the antigen, and then proliferate; this process is referred to herein as "activation" of T cells. Therefore, CTL induction by a certain peptide can be evaluated by presenting the peptide to a T cell by APC, and detecting the induction of CTL. Furthermore, APCs have the effect of activating CD4+ T cells, CD8+ T cells, macrophages, eosinophils and NK cells. Since CD4+ T cells are also important in anti-tumor immunity, the anti-tumor immunity inducing action of the peptide can be evaluated using the activation effect of these cells as indicators.

[0059] A method for evaluating the inducing action of CTL using dendritic cells (DCs) as APC is well known in the art. DC is a representative APC having the strongest CTL inducing action among APCs. In this method, the test polypeptide is initially contacted with DC and then this DC is contacted with T cells. Detection of T cells having cytotoxic effects against the cells of interest after the contact with DC shows that the test polypeptide has an activity of inducing the cytotoxic T cells. Activity of CTL against tumors can be detected, for example, using the lysis of ^{51}Cr-labeled tumor cells as the indicator. Alternatively, it is well known to evaluate the degree of tumor cell damage using ^{3}H-thymidine uptake activity or LDH (lactose dehydrogenase)-release as the indicator. Furthermore, it can be also examined by measuring IFN-gamma produced and released by CTL in the presence of antigen-presenting cells that carry immobilized peptides by visualizing using anti-IFN-gamma antibodies, such as an ELISPOT assay.

[0060] Apart from DC, peripheral blood mononuclear cells (PBMCs) may also be used as the APC. The induction of CTL is reported to be enhanced by culturing PBMC in the presence of GM-CSF and IL-4. Similarly, CTL has been shown to be induced by culturing PBMC in the presence of keyhole limpet hemocyanin (KLH) and IL-7.

[0061] The test polypeptides confirmed to possess CTL inducing activity by these methods are polypeptides having DC activation effect and subsequent CTL inducing activity. Therefore, polypeptides that induce CTL against tumor cells are useful as vaccines against diseases associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers. Furthermore, APC that have acquired the ability to induce CTL against a disease associating MPHOSPH1 and/or DEPDC1, e.g. cancers, by contacting with the polypeptides are useful as vaccines against the disease. Furthermore, CTL that have acquired cytotoxicity due to presentation of the polypeptide antigens by APC can be also used as vaccines against a disease associating MPHOSPH1 and/or DEPDC1, e.g. cancers. Such therapeutic methods for a disease associating MPHOSPH1 and/or DEPDC1, e.g. cancers, using anti-tumor immunity due to APC and CTL, are referred to as cellular immunotherapy. The cancers contemplated include, but are not limited to, bladder cancer, breast cancer, cervical cancer, cholangincellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC, soft tissue tumor.

[0062] Generally, when using a polypeptide for cellular immunotherapy, efficiency of the CTL- induction can be increased by combining a plurality of polypeptides having different structures and contacting them with DC. Therefore, when stimulating DC with protein fragments, it is advantageous to use a mixture of multiple types of fragments.

[0063] The induction of anti-tumor immunity by a polypeptide can be further confirmed by observing the induction of antibody production against tumors. For example, when antibodies against a polypeptide are induced in a laboratory animal immunized with the polypeptide, and when growth, proliferation and/or metastasis of tumor cells is suppressed by those antibodies, the polypeptide is determined to induce anti-tumor immunity.

[0064] Anti- tumor immunity can be induced by administering a vaccine of this disclosure, and the induction of anti-tumor immunity enables treatment and prevention of a disease associated with the over- expression of MPHOSPH1 and/or DEPDC1, e.g. cancers. Therapy against or prevention of the onset of a disease associated with the over- expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, may include inhibition of the growth of cells expressing MPHOSPH1 and/or DEPDC1, e.g. cancer cells, involution of these cells and suppression of occurrence of these cells, e.g. cancer cells. Decrease in mortality of individuals having a disease associating MPHOSPH1 and/or DEPDC1, e.g. cancers, decrease of the disease markers in the blood, alleviation of detectable symptoms accompanying the disease and such are also included in the therapy or prevention of the disease, e.g. cancers. Such therapeutic and preventive effects are preferably statistically significant, for example, observed at a significance level of 5% or less, wherein the

therapeutic or preventive effect of a vaccine against a disease associating MPHOSPH1 and/or DEPDC1, e.g. cancers, is compared to a control without vaccine administration. For example, Student's t- test, the Mann- Whitney U- test or ANOVA may be used for determining statistical significance.

[0065] In that the present disclosure provides a method for treating, or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, the therapeutic compounds or compositions may be administered prophylactically or therapeutically to subjects suffering from or at risk of (or susceptible to) developing the disease. Such subjects may be identified using standard clinical methods. In the context of the present disclosure, prophylactic administration occurs prior to the manifestation of overt clinical symptoms of disease, such that a disease or disorder is prevented or alternatively delayed in its progression. In the context of the field of medicine, the term "prevent" encompasses any activity which reduces the burden of mortality or morbidity from disease. Prevention can occur "t primary, secondary and tertiary prevention levels. While primary prevention avoids the development of a disease, secondary and tertiary levels of prevention encompass activities aimed at preventing the progression of a disease and the emergence of symptoms as well as reducing the negative impact of an already established disease by restoring function and reducing disease-related complications.

[0066] In the context of cancer treatment, the term "efficacious" refers to a treatment that leads to a decrease in size, prevalence or metastatic potential of cancer in a subject. When a treatment is applied prophylactically, "efficacious" means that the treatment retards or prevents occurrence of non cancer or alleviates a clinical symptom of cancer. The assessment of cancer can be made using standard clinical protocols. Furthermore, the efficaciousness of a treatment may be determined in association with any known method for diagnosing or treating cancer. For example, cancer can be diagnosed histopathologically or by identifying symptomatic anomalies.

[0067] The above-mentioned peptide, having immunological activity, or a polynucleotide or vector encoding such a peptide, may be combined with an adjuvant. An adjuvant refers to a compound that enhances the immune response against the peptide when administered together (or successively) with the peptide having immunological activity. Examples of suitable adjuvants include cholera toxin, salmonella toxin, alum and such, but are not limited thereto. Furthermore, a vaccine of this disclosure may be combined appropriately with a pharmaceutically acceptable carrier. Examples of such carriers are sterilized water, physiological saline, phosphate buffer, culture fluid and such. Furthermore, the vaccine may contain as necessary, stabilizers, suspensions, preservatives, surfactants and such. The vaccine is administered systemically or locally. Vaccine administration may be performed by single administration or boosted by multiple administrations.

[0068] When using APC or CTL as the vaccine of this disclosure , a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, can be treated or prevented, for example, by the ex vivo method. More specifically, PBMCs of the subject receiving treatment or prevention are collected, contacted ex vivo with a peptide of the present disclosure. Following the induction of APC or CTL, the cells may be administered to the subject. APC can be also induced by introducing a vector encoding the peptide into PBMCs ex vivo. APC or CTL induced in vitro can be cloned prior to administration. By cloning and growing cells having high activity of damaging target cells, cellular immunotherapy can be performed more effectively. Furthermore, APC and CTL isolated in this manner may be used for cellular immunotherapy not only against individuals from whom the cells are derived, but also against similar types of diseases in other individuals.

[0069] Aspects of the present disclosure are described in the following examples, which are presented only to illustrate the present disclosure and to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the disclosure.

[0070] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below.

EXAMPLES

[0071] Hereinafter, the present disclosure is exemplified, but not restricted, by the following Examples. However, materials, methods and such described herein only illustrate aspects of the disclosure and in no way are intended to limit the scope of the present disclosure . As such, materials, methods and such similar or equivalent to those described therein may be used in the practice or testing of the present disclosure.

EXAMPLE 1

MATERIALS AND METHODS

Cell lines

[0072] A24LCL cells (HLA- A24/24), human B- lymphoblastoid cell lines, T2 cell and COS7 were purchased from ATCC.

Candidate selection of peptide derived from MPHOSOH1 and DEPDC1

[0073] 9- mer and 10- mer peptides derived from MPHOSOH1 or DEPDC1 that bind to HLA- A*2402 and HLA- A*0201 molecule were predicted using binding prediction software "BIMAS" (bimas.dcrt.nih.gov/cgi- bin/ molbio/ken_ parker_ comboform) (Parker KC, et al., (1994) J Immunol.; 152 (1) : 163- 75.; Kuzushima K, et al., (2001) Blood., 98 (6) : 1872- 81.) . These peptides were synthesized by Sigma (Sapporo, Japan) according to the standard solid phase synthesis method and purified by reversed phase HPLC. The purity (>90%) and the identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Peptides were dissolved in dimethylsulfoxide (DMSO) at 20 mg/ml and stored at- 80 degrees C.

In vitro CTL Induction

[0074] Monocyte- derived dendritic cells (DCs) were used as antigen- presenting cells (APCs) to induce CTL responses against peptides presented on HLA. DCs were generated in vitro as described elsewhere (Nukaya I et al., (1999) Int. J. Cancer 80, 92- 7., Tsai V et al., (1997) J. Immunol 158: 1796- 802.) . Briefly, peripheral blood mononuclear cells (PBMCs) isolated from a normal volunteer (HLA- A*2402 and/or HLA- A*0201) by Ficoll- Paque (Pharmacia) solution were separated by adherence to a plastic tissue culture flask (Becton Dickinson) so as to enrich them for the monocyte fraction. The monocyte- enriched population was cultured in the presence of 1000 U/ml of GM- CSF (Genzyme) and 1000 U/ml of IL- 4 (Genzyme) in AIM- V (Invitrogen) containing 2% heat- inactivated autologous serum (AS) . After 7 days in the culture, the cytokine- generated DCs were pulsed with 20 mcg/ml of the synthesized peptides in the presence of 3 mcg/ml of beta 2- microglobulin for 4 hrs at 20 degrees C in AIM- V. These peptide- pulsed DCs were then inactivated by MMC (30 mcg/ml for 30 mins) and mixed at a 1: 20 ratio with autologous CD8+ T cells, obtained by positive selection with Dynabeads M- 450 CD8 (Dynal) and DETACHa BEAD™ (Dynal) . These cultures were set up in 48- well plates (Coming) ; each well contained $1.5x10^4$ peptide- pulsed DCs, $3x10^5$ CD^{8+} T cells and 10 ng/ml of IL- 7 (Genzyme) in 0.5 ml of AIM- V/ 2% AS. Three days later, these cultures were supplemented with IL- 2 (CHIRON) to a final concentration of 20 IU/ml. On day 7 and 14, the T cells were further restimulated with the autologous peptide- pulsed DCs. The DCs were prepared each time by the same way described above. CTL was tested against peptide- pulsed A24LCL cells or T2 cells after the 3rd round of peptide stimulation on day 21.

CTL Expansion Procedure

[0075] CTLs were expanded in culture using the method similar to that described by Riddell SR, et al., (Walter EA et al., (1995) N Engl J Med 333:1038-44.; Riddel SR, et al., (1996) Nature Med. 2:216-23.). A total $5x10^4$ of CTLs were resuspended in 25 ml of AIM-V/5% AS with 2 kinds of human B-lymphoblastoid cell lines, inactivated by MMC, in the presence of 40 ng/ml of anti-CD3 monoclonal antibody (Pharmingen). One day after initiating the cultures, 120 IU/ml of IL-2 were added to the cultures. The cultures were fed with fresh AIM-V/5% AS containing 30 IU/ml of IL-2 on days 5, 8 and 11.

Establishment of CTL clones

[0076] The dilutions were made to have 0.3, 1, and 3 CTLs/well in 96 round-bottomed micro titer plate (Nalge Nunc International). CTLs were cultured with $7x10^4$ cells/well of 2 kinds of human B-lymphoblastoid cell lines, 30ng/ml of anti-CD3 antibody, and 125 U/ml of IL-2 in total of 150 mcl/well of AIM-V containing 5%AS. 50 mcl /well of IL-2 was added to the medium 10 days later so that IL-2 became 125 U/ml in the final concentration. CTL activity of CTLs was tested on the 14th day, and CTL clones were expanded using the same method above.

Specific CTL activity

[0077] To examine the specific CTL activity, IFN- gamma ELISPOT assay and IFN- gamma ELISA were performed. Briefly, peptide- pulsed A24- LCL or T2 cell ($1x10^4$/ well) was prepared as a stimulator cell. Cultured Cells in 48 wells or CTL clones after limiting dilution were used as a responder cells. IFN- gamma ELISPOT assay and ELISA were performed under manufacture procedure.

Cell Culture and Transfection

[0078] HLA- A24 B- LCLs (A24LCL), Epstein Bar virus- transformed, was established. Jiyoye, EB- 3, COS7, HT 1376, RT- 4 and J82 were purchased from American Type Culture Collection (Rockville, MD) . A24LCL, Jiyoye and EB- 3 were maintained in RPMI1640 containing 10% fetal bovine serum (GEMINI Bio- Products) and 1% antibiotic solution (Sigma)

. COS7, HT1376, RT- 4 and J82 were maintained in appropriate medium and antibiotics. Transfection of COS7 and HEK were performed using FUGENE6 (Roche) . HEK- A2 cell, HLA- A*0201 molecule expressing stable clone, was established by transfection of pcDNA6.2- HLA- A2 plasmid and isolated by limiting dilution method in the presence of 5 mcg/ml Blastcidin S.

Immunogenicity of epitope peptides in BALB/c mice

[0079] For induction of the peptide-specific CTLs, immunization was given using 100 ml of vaccine mixture, which contains 50 mcl (100 mcg) of HLA-A24 restricted peptide and 50 mcl of IFA per mouse. The vaccine was subcutaneously injected in the right flank for the first immunization on day 0 and in the left flank for the second on the day 7. On day 14, splenocytes of the vaccinated mice, without any in vitro stimulation, were used responder cells, and RLmale1 cells pulsed with or without peptides were used as the stimulator cells for IFN-gamma ELISPOT assay.

RESULTS

Enhanced MPHOSPH1 and DEPDC1 expression in cancers

[0080] The global gene expression profile data obtained from various cancers using cDNA-microarray revealed that MPHOSPH1 (GenBank Accession No. NM_016195; SEQ ID No.1) and DEPDC1 (GenBank Accession No. BM683578) which had two variants; DEPDC1 V1 (SEQ ID Nos.3) and DEPDC1 V2 (SEQ ID No. 5) expression was elevated. MPHOSPH 1 expression was validly elevated in 30 out of 31 bladder cancers, 8 out of 36 breast cancers, 18 out of 18 cervical cancers, 5 out of 17 cholangincellular carcinomas, 25 out of 31 CMLs, 6 out of 11 colorectal cancers, 6 out of 14 gastric cancers, 5 out of 5 NSCLCs, 7 out of 7 lymphomas, 6 out of 10 osteosarcomas, 7 out of 22 prostate cancers, 10 out of 18 renal carcinomas and 15 out of 21 soft tissue tumors as compared with corresponding normal tissue. DEPDC 1 expression was validly elevated in 23 out of 25 bladder cancers, 6 out of 13 breast cancers, 12 out of 12 cervical cancers, 6 out of 6 cholangincellular carcinomas, 3 out of 4 CMLs, 2 out of 4 colorectal cancers, 6 out of 6 NSCLCs, 7 out of 7 lymphomas, 10 out of 14 osteosarcomas, 11 out of 24 prostate cancers, 14 out of 14 SCLCs and 22 out of 31 soft tissue tumors as compared with corresponding normal tissue (Table 1).

[0081]

[Table 1]

Ratio of cases observed up-regulation of *MPHOSPH1* or *DEPDC1* in cancerous tissue as compared with normal corresponding tissue							
	Bladder cancer	Breast cancer	Cervical cancer	Cholangiocellular Carcinoma	CML	Colorectal cancer	Gastric cancer
MPHOSPH1	30/31	8/36	18/18	5/17	25/31	6/11	6/14
DEPDC1	23/25	6/13	12/12	6/6	3/4	2/4	-
	NSCLC	Lymphoma	Osteosarcoma	Prostate cancer	Renal cancer	SCLC	Soft Tissue Tumor
MPHOSPH1	5/5	7/7	6/10	7/22	10/18	-	15/21
DEPDC1	6/6	7/7	10/14	11/24	-	14/14	22/31

Prediction of HLA-A24 andHLA-A2 binding peptides derived from MPHOSPH1 or DEPDC1

[0082] Table 2 sets forth the HLA-A*2402 binding peptides for MPHOSPH 1 in order of binding affinity. Table 2A sets forth 9-mer peptides derived from MPHOSPH1 and Table 2B sets forth 10-mer peptides derived from MPHOSPH 1. Table 3 sets forth the HLA-A*0201 binding peptides for MPHOSPH1 in order of binding affinity. Table 3A sets forth 9-mer peptides derived from MPHOSPH1 and Table 3B sets forth 10-mer peptides derived from MPHOSPH1.
Table 4 sets forth the HLA-A*2402 binding peptides for DEPDC1 V1 and V2 in order of binding affinity. Table 4A sets forth 9-mer peptides derived from DEPDC1 V1 and V2 and Table 4B sets forth 10-mer peptides derived from DEPDC1 V1.
Table 5 sets forth the HLA-A*0201 binding peptides for DEPDC1 V1 and V, Table 5A sets forth 9-mer peptides derived from DEPDC1 V1 and V2 and Table 5B sets forth 10-mer peptides derived from DEPDC1 V1 and V2.

[0083]

[Table 2A]

HLA-A*2402 binding 9-mer peptides derived from *MPHOSPH1*

Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score	Start = Position	Amino Acid Sequence	SEQ ID NO.	Binding Score
278	IYNEYTYDL	7	360	179	LFDSLQERL	29	24
1244	DYADLKEKL	13	316.8	268	KFSVWVSFF	30	20
1319	QYERACKDL	14	300	575	KLLDLIEDL	31	17.28
459	CYLAYDETL	15	300	1577	RFPKPELEI	32	16.5
462	AYDETLNVL	16	288	1414	KYNADRKKW	33	16.5
1054	GYKDENNRL	17	288	1230	RTQNLKADL	34	14.4
236	LYGSLTNSL	18	288	1421	KWLEEKMML	35	14.4
1446	KYAEDRERF	19	240	1617	KSNEMEEDL	36	14.4
899	NYDIAIAEL	20	220	1555	KIEDGSVVL	37	14.4
1118	CYKAKIKEL	21	220	1456	KQQNEMEIL	38	12
57	DYLQVCLRI	22	105	389	KTQNEGERL	39	12
676	KFNQIKAEL	23	92.4	1371	KWKEKCNDL	40	11.52
14	SYVFSADPI	24	75	1122	KIKELETIL	41	11.52
326	AYRLLKLGI	25	60	850	FLLTIENEL	42	11.088
255	DYEQANLNM	26	37.5	763	SSLIINNKL	43	11.088
29	NFDGIKLDL	27	28	1400	KLINLQDEL	44	10.56
286	LFVPVSSKF	28	27.72	133	IMQPVKDLL	45	10.08

Start position indicates the number of amino acid from N-terminal of MPHOSPH1. Binding score is derived from "BIMAS" described in Materials and Methods.

[0084]

[Table 2B]

HLA-A*2402 binding 10-mer peptides derived from *MPHOSPH1*

Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score	Start Position	Amino Acid Sequence	SEQ ID NO.	Binding
1414	KYNADRKKWL	46	600	1274	KLLRIKINEL	56	15.84
278	IYNEYIYDLF	8	252	1332	KIIEDMRMTL	57	14.4
1446	KYAEDRERFF	47	240	1299	RTIQQLKEQL	58	14.4
611	QYWAQREADF	48	100	1134	KVECSHSAKL	59	13.2
1740	LYTSEISSPI	49	70	859	KNEKEEKAEL	60	13.2
293	KFQKRKMLRL	50	60	586	KLINEKKEKL	61	13.2
849	AFLLTIENEL	51	55.44	943	KLMHTKIDEL	62	13.2
1667	TYSLRSQASI	52	50	838	RVLQENNEGL	63	12
1695	DFLQHSPSIL	53	30	369	RVIRVSELSL	64	12
174	RTLNVLFDSL	54	17.28	1159	RNLKEFQEHL	65	12

(continued)

HLA-A*2402 binding 10-mer peptides derived from *MPHOSPH1*

Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score	Start Position	Amino Acid Sequence	SEQ ID NO.	Binding
870	KOIVHFQQEL	55	15.84	281	EYIYDLFVPV	66	10.8

Start position indicates the number of amino acid from N-terminal of MPHOSPH1. Binding score is derived from "BIMAS" described in Materials and Methods.

[0085]

[Table 3A]

HLA-A*0201 binding 9-mer peptides derived from *MPHOSPH1*

Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score	Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score
575	KLLDLIEDL	31	1278.29	1184	KLKEEITQL	93	24.677
282	YIYDLFVPV	9	1096.62	888	TLSKEVQQI	94	23.995
298	KMLRLSQDV	67	650.504	280	NEYIYDLFV	95	23.802
218	ALLRQIKEV	68	591.888	552	LLDEDLDKT	96	23.415
850	FLLTIENEL	42	363.588	461	LAYDETLNV	97	21.546
1108	ALSELTQGV	69	285.163	980	NLPNTQLDL	98	21.362
331	KLGIKHOSV	70	243.432	409	TLGKCINVL	99	20.145
1689	TLQKFGDFL	71	218.772	175	TLNVLFDSL	100	19.888
1251	KLTDAKKQI	72	149.711	923	KLSNEIETA	101	19.596
638	RLAIFKDLV	10	129.506	1389	KEHENNTDV	102	19.407
1467	QLTEKDSDL	73	87.586	987	DLLGNDYLV	103	19.301
1195	NLQDMKHLL	74	87.586	920	KIMKLSNEI	104	18.577
270	SVWVSFFEI	75	83.497	1703	ILQSKAKKI	105	17.736
129	FQGCIMQPV	76	74.608	512	ILNVKRATI	106	17.736
839	VLQENNEGL	77	72.959	1124	KELETILET	107	17.695
1094	TLDVQIQHV	78	63.988	453	IVNISQCYL	108	17.477
1019	AIWEECKEI	79	48.816	771	UCNETVEV	109	16.258
1696	FLQHSPSIL	80	40.289	623	TLLQEREIL	110	15.879
528	DLMEDEDLV	81	38.775	560	TLEENKAFI	111	15.057
406	SLLTLGKCI	82	38.601	1415	YNADRKKWL	112	14.465
1400	KLTNLQDEL	44	36.637	307	KGYSFIKDL	113	13.65
170	GILPRTLNV	83	35.385	133	IMQPVKDLL	45	12.852
171	ILPRTLNVL	84	34.246	1594	KMAVKHPGC	114	12.558
786	KICSERKRV	85	33.472	365	SEMSRVIRV	115	11.509
880	SLSEKKNLT	86	30.553	1191	QLTNNLQDM	116	11.426
944	LMHTKIDEL	87	29.559	871	QIVHFQQEL	117	11.162
1422	WLEEKMMU	88	28.963	245	NISEFEESI	118	10.951
466	TLNVLKFSA	89	28.814	484	TLNSSQEKL	119	10.468
1539	KLQTEPLST	90	26.082	764	SLIINNKLI	120	10.433
132	CIMQPVKDL	91	24.997	587	UNEKKEKL	121	10.032
1260	KQVQKEVSV	92	24.681				

Start position indicates the number of amino acid from N-terminal of MPHOSPH1. Binding score is derived from "BIMAS" described in Materials and Methods.

[0086]

[Table 3B]

HLA-A*0201 binding 10-mer peptides derived from *MPHOSPH1*

Start Position	Amino Acid Sequence	SEQID NO.	Binding Score	Start Position	Amino Acid Sequence	SEQID NO.	Binding
1274	KLLRIKINEL	56	626.279	1318	QQYERACKDL	140	28.417
551	KLLDEDLDKT	122	445.913	452	MIVNISQCYL	141	27.464
460	YLAYDETLNV	123	319.939	923	KLSNEIETAT	142	26.082
943	KLMHTKIDEL	62	311.777	1257	KQIKQVQKEV	143	24.681
262	NMANSIKFSV	124	291.346	980	NLPNTQLDLL	144	24.075
178	VLFDSLQERL	125	269.948	985	QLDLLGNDYL	145	23.029
770	KLICNETVEV	126	243.432	1427	MMLITQAKEA	146	22.569
34	KLDLSHEFSL	127	173.463	1523	QIMDIKPKRI	147	21.762
407	LLTLGKCINV	128	118.238	1484	QLVAALEIQL	148	21.362
1714	TMSSSKLSNV	11	115.534	466	TLNVLKFSAI	149	19.822
1353	QVLEAKLEEV	129	104.046	511	KILNVKRATI	150	18.577
880	SLSEKKNLTL	130	87.586	1340	TLEEQEQTQV	151	18.25
235	TLYGSLTNSL	131	68.36	372	RVSELSLCDL	152	17.627
1019	AIWEECKEIV	132	65.381	1561	VVLDSCEVST	153	16.816
552	LLDEDLDKTL	133	59.558	309	YSFIKDLQWI	154	14.663
1093	VTLDVQIQHV	134	57.298	353	SIFTVKILQI	155	12.208
559	KTLEENKAFI	135	42.314	1094	TLDVQIQHVV	156	11.407
1332	KIIEDMRMTL	57	42.151	1688	GTLQKFGDFL	157	11.242
152	GLTNSGKTYT	136	40.986	311	FIKDLQWIQV	158	10.732
830	NIAEIEDIRV	137	39.21	1079	TLIQQLKEEL	159	10.468
586	KLINEKKEKL	61	36.637	1128	TILETQKVEC	160	10.363
182	SLQERLYTKM	138	30.553	1487	AALEIQLKAL	161	10.352
1043	QQIEKLQAEV	139	28.912	170	GILPRTLNVL	162	10.249
870	KQIVHFQQEL	55	28.807				

Start position indicates the number of amino acid from N-terminal of MPHOSPH 1. Binding score is derived from "BIMAS" described in Materials and Methods.

[0087]

[Table 4A]

HLA-A*2402 binding 9-mer peptides derived from *DEPDC1*

Start Position	Amino Acid Sequence	SEQ ID NO.	Birding Score	Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score
295	YYELFVNIL	163	360	505	KQLCRSQSL	167	14.4
294	EYYELFVNI	12	86.4	275	VFRTIADYF	168	14
282	YFLDLPEPL	164	43.2	36	HFKKYGNCF	169	12
118	RYPELRKNN	165	21.8	307	GYITVSDRS	170	10.5
338	SFKSTECLL	166	20	298	LFVNILGLL	171	42

Start position indicates the number of amino acid from N-terminal of DEPDC1. Binding score is derived from "BIMAS" described in Materials and Methods.

[0088]

[Table 4B]

HLA-A*2402 binding 10-mer peptidesp derived from *DEPDCI*

Start Position	Amino Acid Sequence	SRQ ID NO.	Binding Score		Start Position	Amino Acid Sequence	SRQ ID NO.	Binding Score
294	EYYELFVNIL	172	288		275	VFRTIADYFL	182	20
281	DYFLDLPEPL	173	240		113	KTLPRRYPEL	183	15.84
118	RYPELRKNNI	174	216		277	RTIADYFLDL	184	14.4
770	EYPLIYQKRF	175	150		270	GFERDVFRTI	185	12.6
267	TYVGFERDVF	176	150		146	RTPKRHGLHL	186	12
523	SYINTPVAEI	177	82.5		505	KQLCRSQSLL	187	12
282	YFLDLPEPLL	178	36		340	KSTECLLLSL	188	11.52
191	RYVILIYLQT	179	21		295	YYELFVNILV	189	10.5
338	SFKSTECLLL	180	20		129	NFSKDKDSIF	190	10
103	LFRFPATSPL	181	20					

Start position indicates the number of amino acid from N-terminal of DEPDCI. Binding score is derived from "BIMAS" described in Materials and Methods.

[0089]

[Table 5A]

HLA-A*0201 binding 9-mer peptides derived from *DEPDCI*

Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score	Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score
674	FLMDHHOEI	191	728.022	563	RLCKSTIEL	209	21.382
589	LLQPHLERV	192	133.255	506	QLCRSQSLL	210	21.362
575	SLLPASSML	193	79.041	193	VILIYLQTI	211	20.753
246	WVLSAMKCL	194	73.172	297	ELFVNILVV	212	18.201
619	LLMRMISRM	195	71.872	235	ILQNKSDDL	213	17.795
581	SMLTGTOSL	196	57.085	616	KLQLLMRMI	214	16.797
290	LLTFEYYEL	197	54.474	623	MISRMSQNV	215	16.258
220	YIMYNMANT	198	40.111	72	TIQLLRKFL	216	16.155
283	FLDLPEPLL	199	39.307	421	CSLEGIVDV	217	15.841
787	ALFGDKPTI	200	38.601	303	LVVCGYITV	218	15.519
582	MLTGTQSLL	201	36.316	524	YINTPVAEI	219	15.177
773	LIYQKRFPT	202	32.33	194	ILIYLQTIL	220	14.89
114	TLPRRYPEL	203	32.044	239	KSDDLPHWV	221	14.333
505	KQLCRSQSL	167	28.049	576	LLPASSMLT	222	12.668
765	KQFQKEYPL	204	28.049	646	MIHTFSRCV	223	12.356
395	IMGGSCHNL	205	26.228	645	LMIHTFSRC	224	11.589
296	YELFVNILV	206	23.018	653	CVLCCAEEV	225	11.034
278	TIADYFLDL	207	22.882	297	ELFVNILGL	226	13.635
601	ALQLCCLLL	208	21.362				

Start position indicates the number of amino acid from N-terminal of DEPDCI. Binding score is derived from "BIMAS" described in Materials and Methods.

[0090]

[Table 5B]

hLA-A*0201 binding 10-mer peptides derived from *DEPDCI*

Start Position	Amino Acid Sequence	SEQ ID NO.	Binding Score	Start Position	Amino Acid Sequence	SEQ ID NO.	Binding
666	LLAGRLVSFL	227	459. 398	575	SLLPASSMLT	241	27. 572
674	FLMDHHQEIL	228	299. 484	296	YELFVNILVV	242	21. 706
588	SLLQPHLERV	229	290. 025	506	QLCRSQSLLL	243	21. 362
302	ILVVCGYITV	230	177. 358	765	KQFQKEYPLI	244	20. 547
291	LTFEYYELFV	231	137. 017	682	ILQVPSYLQT	245	19. 003
201	ILGVPSLEEV	232	133. 255	269	VGFERDVFRT	246	16. 735
195	LIYLQTILGV	233	119. 657	381	QLVNLRNRRV	247	13. 91
688	YLQTAVEKHL	234	98. 267	283	FLDLPEPLLT	248	13. 712
645	LMIHTFSRCV	235	64. 9	395	IMGGSCHNLI	249	12. 809
581	SMLTGTQSLL	236	57. 085	403	LIGLSNMHDL	250	11. 485
622	RMISRMSQNV	237	50. 232	773	LIYQKRFPTT	251	10. 591
618	QLLMRMISRM	238	42. 278	488	TLTVQDQEEL	252	10. 468
654	VLCCAEEVDL	239	36. 316	224	NMANTSKRGV	253	10. 046
644	SLMIHTFSRC	240	34. 925	296	YELFVNILGL	254	16. 26
505	KQLCRSQSLL	187	28. 049	301	NILGLLQPHL	255	10. 868

Start position indicates the number of amino acid from N-terminal of DEPDCI. Binding score is derived from "BIMAS" described in Materials and Methods.

Stimulation of the T cells using the predicted peptides from MPHOSPH 1 restricted with HLA-A*2402

[0091] CTLs for those peptides derived from MPHOSHP1 (SEQ ID No: 2) were generated according to the protocols set forth in "Materials and Methods" section above. Resulting CTLs having detectable specific CTL activity, as assessed by IFN- gamma ELISPOT assay, are shown in Figure 1A and Figure 2A. In Figure 1A, the cells in the well number #4 stimulated with MPHOSPH 1- A24- 9- 278 (SEQ ID NO: 7) demonstrated potent IFN- gamma production as compared with the control. In Figure 2A, the cells in the well number #8 stimulated with MPHOSPH 1- A24- 10- 278 (SEQ ID NO: 8) demonstrated potent IFN- gamma production as compared with the control. Next, these cells in the positive well were expanded and limiting dilution was performed. As shown in Figure 1B (MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7)) and Figure 2B (MPHOSPH1- A24- 10- 278 (SEQ ID NO: 8)), CTL clones having higher specific CTL activities against the peptide- pulsed target as compared to the activities against target without peptide pulse were established

[0092] The CTL clones stimulated by the MPHOSPH1- A24- 9- 278 (IYNEYIYDL (SEQ ID NO: 7)) (Figure 3A) and MPHOSPH1- A24- 10- 278 (IYNEYIYDLF (SEQ ID NO: 8)) (Figure 3B) demonstrated potent specific CTL activity against the peptide- pulsed target without showing any significant specific CTL activity against targets not pulsed with any peptide. This suggests that the CTL clone has the peptide- specific cytotoxicity.

Specific CTL activity against the target cells expressing MPHOSPH1

[0093] The established CTL clones raised against these peptides were examined for their ability to recognize the target cells endogenously expressing MPHOSPH1 and HLA- A*2402. Specific CTL activity against COS7 transfected with both the full length MPHOSPH1 gene and the HLA- A*2402 molecule, which is a specific model for the target cells endogenously express MPHOSPH1 and HLA- A*2402, was tested using as effector cells the CTL clone raised by MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7) . COS7 transfected with full length MPHOSPH1 but not HLA- A*2402 and COS7 transfected HLA- A*2402 but not full length MPHOSPH1 were prepared as controls. The CTL Clone having the highest specific CTL activity against COS7 was that transfected with both MPHOSPH1 and HLA- A24. However, it did not show significant specific CTL activity against COS7 transfected with neither MPHOSPH1 nor HLA- A24 (Figure 4) .

[0094] These results clearly demonstrate that MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7) was naturally expressed to the target cell surface with HLA- A24 molecule and recognized CTL.

CTL activity against bladder cancer cell lines endogenously expressing MPHOSPH1

[0095] The established CTL clone raised against MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7) peptide was examined

for their ability to recognize the tumor cells endogenously expressing MPHOSPH1. CTL activity against HT1376 cells, which endogenously express MPHOSPH1 and HLA- A24, was tested using the CTL clone raised by MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7) as effector cells. J82 cells and RT- 4 cells were used as the target cells which endogenously express MPHOSPH 1 but do not express HLA- A24. The established CTL clone showed high IFN- gamma production against HT1376 cells that express both MPHOSPH1 and HLA- A24. On the other hand, The CTL did not show significant CTL activity against J82 and RT- 4 cells which express MPHOSPH1 but not HLA- A24 (Figure 5) . It clearly demonstrated that MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7) peptide was naturally processed to the tumor cell surface with HLA- A24 molecule and recognized by CTL.

In vivo CTL induction with MPHOSPH1-A24-9-278 peptide in BALB/c mice

[0096] It has been known that H- 2Kd molecule, one of the mouse MHC class I, has resemble peptide anchor motif for HLA- A24 molecule and partially cross- react HLA- A24 restricted peptide. The present inventors then examined whether MPHOSPH1- A24- 9- 278 peptide induce the CTL in vivo by vaccination with this peptide using BALB/c mice (H- 2Kd) . IFA- conjugated peptide was subcutaneously injected into BALB/c mice on the day 0 and 7. On day 14, splenocytes were harvested and used as the responder cells for ELISPOT assay. Splenocytes of all mice injected peptide (Anil~5) showed potent IFN- gamma production compared with control mice, which were injected IFA alone (negal~3) (Figure 6) . This data indicated that MPHOSPH1- A24- 9- 278 peptide could elicit CTL response even in vivo.

Stimulation of the T cells using the predicted peptides from MPHOSPH1 restricted with HLA-A*0201

[0097] Resulting CTLs having detectable specific CTL activity, as assessed by IFN- gamma ELISPOT assay, are shown in Figure 7. As shown in Figure 7A, the cells in the well number #1 and #5, stimulated with MPHOSPH1- A2- 9- 282 (YIYDLFVPV (SEQ ID NO: 9)) demonstrated potent IFN- gamma production as compared with the control. As shown in Figure 7B, the cells in the well number #8 stimulated with MPHOSPH1- A2- 9- 638 (RLAIFKDLV (SEQ ID NO: 10)) demonstrated potent IFN- gamma production as compared with the control. As shown in Figure 7C, the cells in the well number #4 stimulated with MPHOSPH1- A2- 10- 1714 (TMSSSKLSNV (SEQ ID NO: 11)) demonstrated potent IFN- gamma production as compared with the control.

[0098] As shown in figure 8A (MPHOSPH1- A2- 9- 282 (SEQ ID NO: 9)), figure 8B (MPHOSPH1- A2- 9- 638 (SEQ ID NO: 10)), and figure 8C (MPHOSPH1- A2- 10- 1714 (SEQ ID NO: 9)) ., these cells in the positive well were expanded, and CTL lines having higher specific CTL activities against the peptide- pulsed target as compared to the activities against target without peptide pulse were established.

[0099] The CTL clones stimulated by the MPHOSPH1- A2- 9- 282 (YIYDLFVPV (SEQ ID NO: 9)) (Figure 9A, and 9B) demonstrated potent specific CTL activity against the peptide- pulsed target without any significant specific CTL activity against targets not pulsed with any peptide.

Stimulation of the T cells using the predicted peptides from DEPDC1 restricted with HLA-A*2402

[0100] CTLs for those peptides derived from DEPDC1 were generated according to the protocol described in "Materials and Methods" section above. Resulting CTLs having detectable specific CTL activity, as assessed by IFN- gamma ELISPOT assay, are shown in Figure 10. As shown in Figure 10A, the cells in the well number #10 stimulated with DEPDC1- A24- 9- 294 (EYYELFVNI (SEQ ID NO: 12)) demonstrated potent IFN- gamma production as compared with the control. Accordingly, these cells in the positive well were expanded and limiting dilution was performed. As shown in Figure 10B (DEPDC1- A24- 9- 294 (SEQ ID NO: 12)), CTL clones having higher specific CTL activities against the peptide- pulsed target compared to the activities against target without peptide pulse were establishedThe CTL clones stimulated by the DEPDC1- A24- 9- 294 (EYYELFVNI (SEQ ID NO: 12)) (Figure 11) demonstrated potent specific CTL activity against the peptide- pulsed target without showing any significant specific CTL activity against targets not pulsed with any peptide. The results suggest that the CTL clone has the peptide- specific cytotoxicity.

Specific CTL activity against the target cells expressing DEPDC 1 and HLA-A*2402

[0101] The established CTL clones raised against these peptides were examined for their ability to recognize the target cells endogenously expressing DEPDC1 and HLA- A*2402. Specific CTL activity against COS7 transfected both with the full length DEPDC1 gene and the HLA- A*2402 molecule, which serves as a specific model for the target cells endogenously express DEPDC I and HLA- A*2402, was tested using as effector cells the CTL clone raised by DEPDC1- A24- 9- 294 (EYYELFVNI (SEQ ID NO: 12)) . COS7 transfected with full length DEPDC1 but not HLA- A*2402 and COS7 transfected with HLA- A*2402 but not full length DEPDC1 were prepared as controls. The CTL Clone demonstrated high specific CTL activity against COS7 transfected both DEPDC 1 and HLA- A24. However, it did not demonstrate

significant specific CTL activity against COS7 transfected neither DEPDC1 nor HLA- A24 (Figure 12) .

[0102] These results clearly demonstrate that DEPDC1- A24- 9- 294 (EYYELFVNI (SEQ ID NO: 12)) is naturally expressed to the target cell surface with HLA- A24 molecule and recognized CTL.

CTL activity against bladder cancer cell lines endogenously expressing DEPDC1

[0103] The established CTL clone raised against DEPDC1- A24- 9- 294 peptide was examined for their ability to recognize the tumor cells endogenously expressing DEPDC1. CTL activity against HT1376 cells, which endogenously express DEPDC1 and HLA- A24, was tested using the CTL clone raised by DEPDC 1- A24- 9- 294 as effector cells. J82 cells and RT- 4 cells were used as the target cells which endogenously express DEPDC1 but do not express HLA-A24. The established CTL clone showed high IFN- gamma production against HT1376 cells that express both DEPDC1 and HLA- A24. On the other hand, it did not show significant CTL activity against J82 and RT- 4 cells which express DEPDC1 but not HLA- A24 (Figure 13) . It clearly demonstrated that DEPDC1- A24- 9- 294 was naturally processed to the tumor cell surface with HLA- A24 molecule and recognized by CTL.

In vivo CTL induction with DEPDC1-A24-9-294 peptide in BALB/c mice

[0104] It has been known that H- 2Kd molecule, one of the mouse MHC class I, has resemble peptide anchor motif for HLA- A24 molecule and partially cross- react HLA- A24 restricted peptide. The present inventors then examined whether DEPDC 1- A24- 9- 294 peptide induce the CTL in vivo by vaccination of this peptide using BALB/c mice (H-2Kd) . IFA- conjugated peptide was subcutaneously injected into BALB/c mice on the day 0 and 7. On day 14, splenocytes were harvested and used as the responder cells for ELISPOT assay. Splenocytes of all mice injected peptide (Ani 1~5) showed potent IFN- gamma production compared with control mice, which were injected IFA alone (negal, 2) (Figure 14) . This data indicated that DEPDC1- A24- 9- 294 peptide could elicit CTL response even in vivo.

Stimulation of the T cells using the predicted peptides from DEPDC1 restricted with HLA-A*0201

[0105] Resulting CTLs having detectable specific CTL activity when screened by IFN- gamma ELISPOT assay are shown in Figure 15 and Table 6. The cells in the well number #4 and #7 stimulated with DEPDC1- A02- 10- 644 ((SLMIHTFSRC SEQ ID NO: 240)) showed potent IFN- gamma production compared with the control. The cells in the well number #2 stimulated with DEPDC1- A02- 10- 575 (SLLPASSMLT (SEQ ID NO: 241)) showed potent IFN- gamma production compared with the control. The cells in the well number #7 stimulated with DEPDC1- A02- 10- 506 (QLCR-SQSLLL (SEQ ID NO: 243)) showed potent IFN- gamma production compared with the control. The cells in the well number #1 stimulated with DEPDC1- A02- 10- 765 (KQFQKEYPLI (SEQ ID NO: 244)) showed potent IFN- gamma production compared with the control. The cells in the well number #1 stimulated with DEPDC1- A02- 10- 395 (IM-GGSCHNLI (SEQ ID NO: 249)) showed potent IFN- gamma production compared with the control. The cells in the well number #1 and #2 stimulated with DEPDC1- A02- 10- 224 (NMANTSKRGV (SEQ ID NO: 253)) showed potent IFN-gamma production compared with the control. The cells in the well number #4 stimulated with DEPDC1- A02- 9- 297 (ELFVNILGL (SEQ ID NO: 226)) showed potent IFN- gamma production compared with the control. The cells in the well number #3 and #4 stimulated with DEPDC1- A02- 10- 296 (YELFVNILGL (SEQ ID NO: 254)) showed potent IFN-gamma production compared with the control. The cells in the well number #2, #3, #5 and #7 stimulated with DEPDC1-A02- 10- 301 (NILGLLQPHL (SEQ ID NO: 255)) showed potent IFN- gamma production compared with the control. The cells in the well number #6 stimulated with DEPDC1- A02- 9- 598 (LLQPHLERV (SEQ ID NO: 192)) demonstrated potent IFN- gamma production as compared with the control. The cells in the well number #6 stimulated with DEPDC1-A02- 9- 619 (LLMRMISRM (SEQ ID NO: 195)) demonstrated potent IFN- gamma production as compared with the control. The cells in the well number #2 stimulated with DEPDC1- A02- 9- 290 (LLTFEYYEL (SEQ ID NO: 197)) demonstrated potent IFN gamma production as compared with the control. The cells in the well number #5 stimulated with DEPDC1- A02- 9- 563 (RLCKSTIEL (SEQ ID NO: 209)) demonstrated potent IFN- gamma production as compared with the control. The cells in the well number #1 and #3, stimulated with DEPDC1- A02- 9- 653 (CVLCCAEEV (SEQ ID NO: 225)), demonstrated potent IFN- gamma production as compared with the control. The cells in the well number #1 stimulated with DEPDC1- A02- 10- 674 (FLMDHHQEIL (SEQ ID NO: 228)) demonstrated potent IFN- gamma production as compared with the control. Finally, the cells in the well number #2 and #6, stimulated with DEPDC1- A02- 10- 302 (ILVVCGYITV (SEQ ID NO: 230)), demonstrated potent IFN- gamma production as compared with the control.

[0106] The CTL lines stimulated by the DEPDC1- A02- 10- 296 (YELFVNILGL (SEQ ID NO: 254)) and DEPDC1-A02- 9- 653 (CVLCCAEEV (SEQ ID NO: 225)) (Figure 16) showed potent specific CTL activity against the peptide-pulsed target without showing any significant specific CTL activity against targets not pulsed with any peptide. It demonstrates that the CTL clone has the peptide- specific cytotoxicity.

[0107]

[Table 6]
The candidate peptides from DEPDC1 restricted with HLA-A*0201

peptide name	SEQ ID No.	Well No.
DEPDC1-A02-9-589	192	#6
DEPDC1-A02-9-619	195	#6
DEPDC1-A02-9-290	197	#2
DEPDC1-A02-9-563	209	#5
DEPDC1-A02-9-653	225	#1
DEPDC1-A02-9-653	225	#3
DEPDC1-A02-10-674	228	#1
DEPDC1-A02-10-302	230	#2
DEPDC1-A02-10-302	230	#6

Specific CTL activity against the target cells expressing DEPDC1 and HLA-A*0201

[0108] The established CTL lines raised against DEPDC1- A02- 10- 296 peptide (YELFVNILGL (SEQ ID NO: 254)) and DEPDC1- A02- 9- 653 (CVLCCAEEV (SEQ ID NO: 225)) were examined for their ability to recognize the target cells endogenously expressing DEPDC1 and HLA- A2. At first, we established HEK293 cell line constitutively expressed HLA- A*0201 (HEK- A2) to efficiently determine specific CTL response. Specific CTL activity against HEK- A2 cells transfected full length of DEPDC1 gene, which is specific model for the target cells expressed DEPDC1 and HLA- A2, was tested using the established CTL lines raised by DEPDC1- A02- 10- 296 (YELFVNILGL (SEQ ID NO: 254)) or DEPDC1- A02- 9- 653 (CVLCCAEEV (SEQ ID NO: 225)) as effector cells. HEK- A2 transfected Mock expressed vector and HEK- A2 pulsed with no corresponding peptide derived from DEPDC1 were prepared for the negative control. The established CTL lines showed specific CTL activity against HEK- A2 transfected DEPDC1. On the other hand, the CTL lines did not show significant specific CTL activity against HEK- A2 transfected Mock expressed vector and which pulsed DEPDC1- A02- 9- 674 peptide or DEPDC 1- A02- 9- 462 peptide (Figure 17) . It clearly demonstrated that DEPDC1- A02- 10- 296 and DEPDC1- A02- 9- 653 peptide was naturally processed to the target cell surface with HLA- A2 molecule and recognized by CTL.

Homology analysis of the antigen peptides

[0109] The CTLs established against peptides of this disclosure demonstrated potent specific CTL activity. This suggests that the sequences of MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7), MPHOSPH1- A24- 10- 278 (SEQ ID NO: 8), MPHOSPH1- A2- 9- 282 (SEQ ID NO: 9), MPHOSPH1- A2- 9- 638 (SEQ ID NO: 10), MPHOSPH1- A2- 10- 1714 (SEQ ID NO: 11), DEPDC1- A24- 9- 294 (SEQ ID NO: 12), DEPDC1- A2- 9- 589 (SEQ ID NO: 192), DEPDC1- A2- 9- 619 (SEQ ID NO: 195), DEPDC1- A2- 9- 290 (SEQ ID NO: 197), DEPDC1- A2- 9- 563 (SEQ ID NO: 209), DEPDC1- A2- 9- 653 (SEQ ID NO: 225), DEPDC1- A2- 10- 674 (SEQ ID NO: 228), DEPDC1- A2- 10- 302 (SEQ ID NO: 230) DEPDC1- A02- 10- 644 (SEQ ID NO: 240), DEPDC1- A02- 10- 575 (SEQ ID NO: 241), DEPDC1- A02- 10- 506 (SEQ ID NO: 243), DEPDC1- A02- 10- 765 (SEQ ID NO: 244), DEPDC1- A02- 10- 395 (SEQ ID NO: 249), DEPDC1- A02- 10- 224 (SEQ ID NO: 253), DEPDC1- A02- 9- 297 (SEQ ID NO: 226), DEPDC1- A02- 10- 296 (SEQ ID NO: 254) and DEPDC1- A02- 10- 301 (SEQ ID NO: 255) are homologous to the peptides derived from other molecules, which are known to sensitize human immune system. To exclude this possibility, homology analysis was performed with the peptide sequences as queries using BLAST algorithm (http: //www.ncbi.nlm.nih.gov/ blast/ blast.cgi) No significant sequence homology was revealed.

[0110] These results suggest that the sequences of MPHOSPH1- A24- 9- 278 (SEQ ID NO: 7), MPHOSPH1- A24- 10- 278 (SEQ ID NO: 8), MPHOSPH1- A2- 9- 282 (SEQ ID NO: 9), MPHOSPH1- A2- 9- 638 (SEQ ID NO: 10), MPHOSPH1- A2- 10- 1714 (SEQ ID NO: 11), DEPDC1- A24- 9- 294 (SEQ ID NO: 12), DEPDC1- A2- 9- 598 (SEQ ID NO: 192), DEPDC1- A2- 9- 619 (SEQ ID NO: 195), DEPDC1- A2- 9- 290 (SEQ ID NO: 197), DEPDC1- A2- 9- 563 (SEQ ID NO: 209), DEPDC1- A2- 9- 653 (SEQ ID NO: 225), DEPDC1- A2- 10- 674 (SEQ ID NO: 228), DEPDC1- A2- 10- 302 (SEQ ID NO: 230) DEPDC1- A02- 10- 644 (SEQ ID NO: 240), DEPDC1- A02- 10- 575 (SEQ ID NO: 241), DEPDC1- A02- 10- 506 (SEQ ID NO: 243), DEPDC1- A02- 10- 765 (SEQ ID NO: 244), DEPDC1- A02- 10- 395 (SEQ ID NO: 249), DEPDC1- A02- 10- 224 (SEQ ID NO: 253), DEPDC1- A02- 9- 297 (SEQ ID NO: 226), DEPDC1- A02- 10- 296 (SEQ ID NO: 254) and DEPDC1- A02- 10- 301 (SEQ ID NO: 255) are unique and thus possess a low risk of raising unintended immunologic response to any unrelated molecule.

DISCUSSION

[0111] Identification of new TAAs, particularly those that induce potent and specific anti-tumor immune responses, warrants further development of the clinical application of peptide vaccination strategies in various types of cancer (Boon T. et al., (1996) J Exp Med 183: 725-9.; van der Bruggen P et al., (1991) Science 254: 1643-7.; Brichard V et al., (1993) J Exp Med 178: 489-95.; Kawakami Y et al., (1994) J Exp Med 180: 347-52.; Shichijo S et al., (1998) J Exp Med 187: 277-88.; Chen YT et al., (1997) Proc.Natl.Acd. Sci. USA, 94: 1914-8.; Harris CC., (1996) J Natl Cancer Inst 88:1442-5.; Butterfield LH et al., (1999) Cancer Res 59:3134-42.; Vissers JL et al., (1999) Cancer Res 59: 5554-9.; van der Burg SH et al., (1996) J. Immunol 156:3308-14.; Tanaka F et al., (1997) Cancer Res 57:4465-8.; Fujie T et al., (1999) Int J Cancer 80:169-72.; Kikuchi M et al., (1999) Int J Cancer 81 : 459-66.; Oiso M et al., (1999) Int J Cancer 81:387-94.).

[0112] cDNA microarray technologies can disclose comprehensive profiles of gene expression of malignant cells (Lin YM, et al., Oncogene. 2002 Jun 13; 21: 4120- 8.; Kitahara O, et al., Cancer Res. 2001 May 1; 61: 3544- 9.; Suzuki C, et al., Cancer Res. 2003 Nov 1; 63: 7038- 41.; Ashida S, Cancer Res. 2004 Sep 1; 64: 5963- 72.; Ochi K, et al., Int J Oncol. 2004 Mar; 24 (3) : 647- 55.; Kaneta Y, et al., Int J Oncol. 2003 Sep; 23: 681- 91.; Obama K, Hepatology. 2005 Jun; 41: 1339- 48.; Kato T, et al., Cancer Res. 2005 Jul 1; 65: 5638- 46.; Kitahara O, et al., Neoplasia. 2002 Jul- Aug; 4: 295- 303.; Saito- Hisaminato A et al., DNA Res 2002, 9: 35- 45.) and, find utility in the identification of potential TAAs. Among the transcripts that are up- regulated in various cancers, two novel human genes, termed MPHOSPH1 and DEPDC1, respectively, were identified using these technologies.

[0113] As demonstrated above, MPHOSPH1 and DEPDC1, are over-expressed in various cancers but show minimal expression in normal tissues. In addition, these genes have been shown to have a significant function related to cell proliferation (See PCT/JP2006/302684). Thus, peptides derived from MPHOSPH1 and DEPDC1 can serve as TAA epitopes, which, in turn, can be used to induce significant and specific immune responses against cancer cells.

[0114] Thus, as MPHOSPH1 and DEPDC1 are novel TAAs, vaccines using these epitope peptides find utility as immunotherapeutics against various carcinomas or other disease expressing these molecules.

EXAMPLE 2

MATERIALS AND METHODS

Peptides and adjuvant

[0115] The synthesized GMP grade peptides were purchased from Neo Multi Peptide System (MPS) (San Diego, CA). As an adjuvant, incomplete Freund's adjuvant (IFA) (MONTANIDE *ISA51) were used. 1mg of the appropriate peptide was emulsioned with 1mg of IFA.

Antigen Expression

[0116] The present inventors performed immunohistochemical analysis. Tumor cells or tumor tissues from bladder cancers which was obtained from surgery or biopsy was stained by each MPHOSPH1 and DEPDC1- specitic polyclonal antibody. Protocol of staining was established in Human Genome Center, Institute for Medical Science, the University of Tokyo as described previously (Kanehira M et al. Cancer Res.; 67 (7) : 3276- 3285, 2007., Kanehira M et al. Oncogene. 2007 Apr 23; [Epub ahead of print]) . HLA- A*2402 expression was tested to performed at SRL (Tachikawa, Japan)

Enrolled patients

[0117] Enrolled criteria were as follows;

1. Patients with inoperable recurrent bladder cancer with previously treated with standard chemotherapy and turned to be failure.
2. Patients with performance status 0 or 1 in Japanese Criteria.
3. Patients from 20 years old to 80 years old
4. Patients with primary tumor or metastasis which can be recognized by image inspection (CT/MRI) before treatment, regardless of RECIST guideline
5. Patients with more than 4 weeks after prior treatment (surgery, chemotherapy, radiotherapy, thermotherapy, other immunotherapy etc.)
6. Patients expected more than 3 months prognosis
7. Patients with bone marrow function (WBC more than 2000, 15000 less than, plate more than 50000), liver function (GOT less than 150, GPT less than150, T-bil less than 3.0), renal function (Cr less than3.0)

8. Patients with HLA-A*2402
9. Tumor of the patients with expression of MPHOSPH I and/or DEPDC 1

[0118] Exclusion criteria were as follows;

1. Patients with pregnant
2. Patients with breast-feeding
3. Patients willing to be made pregnant
4. Patients with uncontrollable infection
5. Patients with necessity of following medicine in the period of clinical trial systemic administration of steroid systemic administration of immunosuppressant
6. Patients who are not thought to be enrolled this trial by doctor or principal investigator

Protocol

[0119] Enrolled bladder cancer patients with HLA-A*2402, whose tumors express M phase phosphoprotein 1 (MPHOSPH1) and/or DEP domain containing 1 (DEPDC1) were immunized with HLA-A*2402-restricted epitope peptides, MPHOSPH1-9-278 (IYNEYIYDL (SEQ ID NO: 7)) and/or DEPDC1-9-294 (EYYELFVNI (SEQ ID NO: 12)). Each peptide was combined with 1mL of incomplete Freund's adjuvant (IFA, MONTANIDE *ISA51) and was subcutaneously injected into axillary or inguinal lesion once a week. Four times injection is defined as one course, then after 1 course for immunological and clinical evaluation, blood was drawn and CT/MRI was performed.

Evaluation of Safety

[0120] Evaluation of adverse effect was performed along with National Cancer Institute-Common Toxicity Criteria version 3, (NCI-CTC ver.3).

Immunological evaluation

[0121] This is one of secondary endpoint in this study and we confirm whether peptide-specific CTL response occurred or not. Specific CTL response was measure as follows; Peripheral blood mononuclear cells were collected, and re-stimulated by the appropriate peptides. CTL response was tested on the 14th day by IFN-g ELISPOT assay.

Evaluation of anti-tumor effects

[0122] Evaluation of clinical response was performed in accordance with RECIST criteria.

RESULTS

[0123] Table 7 showed the summary of this clinical trial. There were no severe adverse effects, except Grade 2 of exanthema of Case 3. One minor response (Case 3) and one mixed response (Case 4) were obtained. The expression of MPHOSPH1 was 4 of 5 cases, whereas that of DEPDC1 was 5 of 5 cases, respectively.

[0124]

[Table 7]

The summary of this clinical trial

Case	Age/ Gender	Vaccination	Adv. Effect	DTH	Eva Lesion	Eva.	Present Status	Ag expression		CTL
								MPHOSPH1	DEPDC1	
1	79/M	1 course	No	No	LNs, Brain	PD	1.8mo, dead	○	○	No
2	72/F	in 3 course	No	No	Local Rec	SD (4.5mo)	5.0mo, alive	○	○	NT
3	49/M	in 4 course	exanthema	No	Lung Mets	Minor Response	3.7mo, alive	x	○	Yes
4	74/M	in 2 course	No	No	Local Rec	Minor Response	1.4mo, alive	○	○	NT
5	78/M	in 2 course	No	No	Local Rec	SD	1.4mo, alive	○	○	NT

NT: not tested

Case 2

[0125] In case 2, 72 years old female with far advanced bladder cancer in standard chemotherapy failure was enrolled this clinical trial. In figure 18, the antigen expression of her tumor revealed both MPHOSPH1 and DEPDC1 were expressed strongly. Therefore, we have vaccinated two kinds of epitope peptides derived from MPHOSPH1 and DEPDC1. Case 2 had local recurrence of the bladder cancer. It was evaluated stable disease (SD) in accordance with RECIST criteria (Figure 19).

Cace 3

[0126] In case 3, 49 years old male with far advanced bladder cancer in standard chemotherapy failure was enrolled this clinical trial. Only DEPDC1 was expressed strongly (Figure 20). Therefore, we have vaccinated the epitope peptide derived from DEPDC1 alone. Case 3 had multiple lung metastases of the bladder cancer. In right (Figure 21) and left (Figure 22) lobes of lung metastases, the progression rate was decreased after vaccination. Especially, the size of the tumor was decreased after 3rd courses. Figure 23 showed theanti-tumor effect in accordance with RECIST criteria. It was clarified that the progression rate of metastatic tumor was decreased after vaccination. It indicated that minor response was obtained by vaccination using epitope peptide derived from DEPDC 1. In terms of immunological evaluation in case 3, specific CTL response was measured before and after vaccination. Specific CTL response was strongly shown after vaccination (Figure 24). It clearly indicated that CTL induced by epitope peptide derived from DEPDC1 may show the anti-tumor effect.

Cace 4

[0127] In case 4, 74 years old male with far advanced bladder cancer in standard chemotherapy failure was enrolled this clinical trial. MPHOSPH1 and DEPDC1 were expressed from his tumor (Figure 25). Therefore, we have vaccinated two kinds of epitope peptides derived from MPHOSPH1 and DEPDC1. Case 4 had local recurrence of the bladder cancer. After 1 course vaccination, the size of the tumor was reduced 20% in accordance with RECIST criteria (Figure 26). However, new metastatic lesions in the lung were appeared. It indicated that mixed response was obtained by vaccination using two kinds of epitope peptides derived from MPHOSPH1 and DEPDC1.

DISCUSSION

[0128] Rationale of this clinical trial is described blow;

1. Since MPHOSPH1 and DEPDC1 are not expressed in normal tissues except testis, both antigens are highly tumor-specific.
2. These peptides are considered to have strong immunogenicity, since potent and specific CTLs were established by these epitope peptides.
3. There is 60% of Japanese population with HLA-A*2402.
4. These peptides are chemically stable enough to apply to the clinical trial.

The purpose of this study is to obtain clinical information of its toxicity, immunological response and anti-tumor activity.

[0129] Previously reported adverse effects of vaccine clinical trial using peptides are fur-like symptom, such as fever, headache and discomfort. In rare cases, radical skin reaction with blisters, considered as transient cross reactivity at injected site, was reported. In this study, there were no severe adverse effects, except Grade 2 of exanthema of Case 3. This patient had clinical history to show exanthema during chemotherapy. It indicated that this adverse effect did not come from this vaccination, and therefore this protocol may be safe.

[0130] Immunological analysis was performed by specific CTL induction after vaccination. In case 1, specific CTL response was not obtained after vaccination (data not shown). In case 3, specific CTL response against DEPDC1 derived peptide was clearly shown after 1st and 2nd course of vaccination. In case 3, anti-tumor effect was obtained by vaccination. It clearly demonstrated that this DEPDC1 derived peptide showed anti-tumor effect against bladder cancer by induction of the specific CTL.

[0131] In case 4, after only 1st course of vaccination, anti-tumor effect was clearly obtained against the local recurrence of the bladder cancer. This evidence strongly supports that these epitope peptides show anti-tumor effect against bladder cancer.

[0132] In conclusion, it was clarified that this epitope therapy was safe, and furthermore showed strong anti-tumor effect without severe adverse effects.

Industrial Applicability

[0133] The present disclosure identifies new TAAs, particularly those which induce potent and specific anti-tumor immune responses. Such TAAs warrant further development aspeptide vaccines against diseases associated with MPHOSPH1 and/or DEPDC1, e.g. cancers.

SEQUENCE LISTING

[0134]

<110> CNOOTHERAPY SCIENCE, INC. THE UNIVERSITY OF TOKYO FUJICKA, Tomoaki

<120> PEPTIDE VACCINES FOR CANCERS EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES

<130> ONC-A0618P

<150> US 60/852, 575<151> 2006-10-17

<160> 255

<170> Patent In ver si on 3.1

<210> 1
<211> 6319
<212> DNA
<213> Homo sapi ens

<220>
<221> CDS
<222> (73) .. (5415)

<400> 1

```
attgtttgaa tttgaaaacg gtaacatcgc agtgctgctc gcgggtctgg ctagtcaggc      60

gaagtttgca ga atg gaa tct aat ttt aat caa gag gga gta cct cga cca      111
           Met Glu Ser Asn Phe Asn Gln Glu Gly Val Pro Arg Pro
           1               5                  10

tct tat gtt ttt agt gct gac cca att gca agg cct tca gaa ata aat      159
Ser Tyr Val Phe Ser Ala Asp Pro Ile Ala Arg Pro Ser Glu Ile Asn
    15                  20                  25

ttc gat ggc att aag ctt gat ctg tct cat gaa ttt tcc tta gtt gct      207
Phe Asp Gly Ile Lys Leu Asp Leu Ser His Glu Phe Ser Leu Val Ala
30                  35                  40                  45

cca aat act gag gca aac agt ttc gaa tct aaa gat tat ctc cag gtt      255
Pro Asn Thr Glu Ala Asn Ser Phe Glu Ser Lys Asp Tyr Leu Gln Val
                50                  55                  60

tgt ctt cga ata aga cca ttt aca cag tca gaa aaa gaa ctt gag tct      303
Cys Leu Arg Ile Arg Pro Phe Thr Gln Ser Glu Lys Glu Leu Glu Ser
            65                  70                  75

gag ggc tgt gtg cat att ctg gat tca cag act gtt gtg ctg aaa gag      351
Glu Gly Cys Val His Ile Leu Asp Ser Gln Thr Val Val Leu Lys Glu
        80                  85                  90

cct caa tgc atc ctt ggt cgg tta agt gaa aaa agc tca ggg cag atg      399
Pro Gln Cys Ile Leu Gly Arg Leu Ser Glu Lys Ser Ser Gly Gln Met
    95                  100                 105

gca cag aaa ttc agt ttt tcc aag gtt ttt ggc cca gca act aca cag      447
Ala Gln Lys Phe Ser Phe Ser Lys Val Phe Gly Pro Ala Thr Thr Gln
110                 115                 120                 125

aag gaa ttc ttt cag ggt tgc att atg caa cca gta aaa gac ctc ttg      495
Lys Glu Phe Phe Gln Gly Cys Ile Met Gln Pro Val Lys Asp Leu Leu
                130                 135                 140

aaa gga cag agt cgt ctg att ttt act tac ggg cta acc aat tca gga      543
Lys Gly Gln Ser Arg Leu Ile Phe Thr Tyr Gly Leu Thr Asn Ser Gly
            145                 150                 155
```

```
aaa aca tat aca ttt caa ggg aca gaa gaa aat att ggc att ctg cct      591
Lys Thr Tyr Thr Phe Gln Gly Thr Glu Glu Asn Ile Gly Ile Leu Pro
        160                 165                 170

cga act ttg aat gta tta ttt gat agt ctt caa gaa aga ctg tat aca      639
Arg Thr Leu Asn Val Leu Phe Asp Ser Leu Gln Glu Arg Leu Tyr Thr
    175                 180                 185

aag atg aac ctt aaa cca cat aga tcc aga gaa tac tta agg tta tca      687
Lys Met Asn Leu Lys Pro His Arg Ser Arg Glu Tyr Leu Arg Leu Ser
190                 195                 200                 205

tca gaa caa gag aaa gaa gaa att gct agc aaa agt gca ttg ctt cgg      735
Ser Glu Gln Glu Lys Glu Glu Ile Ala Ser Lys Ser Ala Leu Leu Arg
                210                 215                 220

caa att aaa gag gtt act gtg cat aat gat agt gat gat act ctt tat      783
Gln Ile Lys Glu Val Thr Val His Asn Asp Ser Asp Asp Thr Leu Tyr
            225                 230                 235

gga agt tta act aac tct ttg aat atc tca gag ttt gaa gaa tcc ata      831
Gly Ser Leu Thr Asn Ser Leu Asn Ile Ser Glu Phe Glu Glu Ser Ile
        240                 245                 250

aaa gat tat gaa caa gcc aac ttg aat atg gct aat agt ata aaa ttt      879
Lys Asp Tyr Glu Gln Ala Asn Leu Asn Met Ala Asn Ser Ile Lys Phe
    255                 260                 265

tct gtg tgg gtt tct ttc ttt gaa att tac aat gaa tat att tat gac      927
Ser Val Trp Val Ser Phe Phe Glu Ile Tyr Asn Glu Tyr Ile Tyr Asp
270                 275                 280                 285

tta ttt gtt cct gta tca tct aaa ttc caa aag aga aag atg ctg cgc      975
Leu Phe Val Pro Val Ser Ser Lys Phe Gln Lys Arg Lys Met Leu Arg
                290                 295                 300

ctt tcc caa gac gta aag ggc tat tct ttt ata aaa gat cta caa tgg     1023
Leu Ser Gln Asp Val Lys Gly Tyr Ser Phe Ile Lys Asp Leu Gln Trp
            305                 310                 315

att caa gta tct gat tcc aaa gaa gcc tat aga ctt tta aaa cta gga     1071
Ile Gln Val Ser Asp Ser Lys Glu Ala Tyr Arg Leu Leu Lys Leu Gly
        320                 325                 330

ata aag cac cag agt gtt gcc ttc aca aaa ttg aat aat gct tcc agt     1119
Ile Lys His Gln Ser Val Ala Phe Thr Lys Leu Asn Asn Ala Ser Ser
    335                 340                 345

aga agt cac agc ata ttc act gtt aaa ata tta cag att gaa gat tct     1167
Arg Ser His Ser Ile Phe Thr Val Lys Ile Leu Gln Ile Glu Asp Ser
350                 355                 360                 365

gaa atg tct cgt gta att cga gtc agt gaa tta tct tta tgt gat ctt     1215
Glu Met Ser Arg Val Ile Arg Val Ser Glu Leu Ser Leu Cys Asp Leu
                370                 375                 380

gct ggt tca gaa cga act atg aag aca cag aat gaa ggt gaa agg tta     1263
Ala Gly Ser Glu Arg Thr Met Lys Thr Gln Asn Glu Gly Glu Arg Leu
            385                 390                 395

aga gag act ggg aat atc aac act tct tta ttg act ctg gga aag tgt     1311
Arg Glu Thr Gly Asn Ile Asn Thr Ser Leu Leu Thr Leu Gly Lys Cys
        400                 405                 410

att aac gtc ttg aag aat agt gaa aag tca aag ttt caa cag cat gtg     1359
Ile Asn Val Leu Lys Asn Ser Glu Lys Ser Lys Phe Gln Gln His Val
    415                 420                 425
```

```
cct ttc cgg gaa agt aaa ctg act cac tat ttt caa agt ttt ttt aat 1407
Pro Phe Arg Glu Ser Lys Leu Thr His Tyr Phe Gln Ser Phe Phe Asn
430                 435                 440                 445

ggt aaa ggg aaa att tgt atg att gtc aat atc agc caa tgt tat tta 1455
Gly Lys Gly Lys Ile Cys Met Ile Val Asn Ile Ser Gln Cys Tyr Leu
                450                 455                 460

gcc tat gat gaa aca ctc aat gta ttg aag ttc tcc gcc att gca caa 1503
Ala Tyr Asp Glu Thr Leu Asn Val Leu Lys Phe Ser Ala Ile Ala Gln
            465                 470                 475

aaa gtt tgt gtc cca gac act tta aat tcc tct caa gag aaa tta ttt 1551
Lys Val Cys Val Pro Asp Thr Leu Asn Ser Ser Gln Glu Lys Leu Phe
        480                 485                 490

gga cct gtc aaa tct tct caa gat gta tca cta gac agt aat tca aac 1599
Gly Pro Val Lys Ser Ser Gln Asp Val Ser Leu Asp Ser Asn Ser Asn
    495                 500                 505

agt aaa ata tta aat gta aaa aga gcc acc att tca tgg gaa aat agt 1647
Ser Lys Ile Leu Asn Val Lys Arg Ala Thr Ile Ser Trp Glu Asn Ser
510                 515                 520                 525

cta gaa gat ttg atg gaa gac gag gat ttg gtt gag gag cta gaa aac 1695
Leu Glu Asp Leu Met Glu Asp Glu Asp Leu Val Glu Glu Leu Glu Asn
                530                 535                 540

gct gaa gaa act caa aat gtg gaa act aaa ctt ctt gat gaa gat cta 1743
Ala Glu Glu Thr Gln Asn Val Glu Thr Lys Leu Leu Asp Glu Asp Leu
            545                 550                 555

gat aaa aca tta gag gaa aat aag gct ttc att agc cac gag gag aaa 1791
Asp Lys Thr Leu Glu Glu Asn Lys Ala Phe Ile Ser His Glu Glu Lys
        560                 565                 570

aga aaa ctg ttg gac tta ata gaa gac ttg aaa aaa aaa ctg ata aat 1839
Arg Lys Leu Leu Asp Leu Ile Glu Asp Leu Lys Lys Lys Leu Ile Asn
    575                 580                 585

gaa aaa aag gaa aaa tta acc ttg gaa ttt aaa att cga gaa gaa gtt 1887
Glu Lys Lys Glu Lys Leu Thr Leu Glu Phe Lys Ile Arg Glu Glu Val
590                 595                 600                 605

aca cag gag ttt act cag tat tgg gct caa cgg gaa gct gac ttt aag 1935
Thr Gln Glu Phe Thr Gln Tyr Trp Ala Gln Arg Glu Ala Asp Phe Lys
                610                 615                 620

gag act ctg ctt caa gaa cga gag ata tta gaa gaa aat gct gaa cgt 1983
Glu Thr Leu Leu Gln Glu Arg Glu Ile Leu Glu Glu Asn Ala Glu Arg
            625                 630                 635

cgt ttg gct atc ttc aag gat ttg gtt ggt aaa tgt gac act cga gaa 2031
Arg Leu Ala Ile Phe Lys Asp Leu Val Gly Lys Cys Asp Thr Arg Glu
        640                 645                 650

gaa gca gcg aaa gac att tgt gcc aca aaa gtt gaa act gaa gaa gct 2079
Glu Ala Ala Lys Asp Ile Cys Ala Thr Lys Val Glu Thr Glu Glu Ala
    655                 660                 665

act gct tgt tta gaa cta aag ttt aat caa att aaa gct gaa tta gct 2127
Thr Ala Cys Leu Glu Leu Lys Phe Asn Gln Ile Lys Ala Glu Leu Ala
670                 675                 680                 685

aaa acc aaa gga gaa tta atc aaa acc aaa gaa gag tta aaa aag aga 2175
Lys Thr Lys Gly Glu Leu Ile Lys Thr Lys Glu Glu Leu Lys Lys Arg
                690                 695                 700

gaa aat gaa tca gat tca ttg att caa gag ctt gag aca tct aat aag 2223
```

```
Glu Asn Glu Ser Asp Ser Leu Ile Gln Glu Leu Glu Thr Ser Asn Lys
                705                 710                 715

aaa ata att aca cag aat caa aga att aaa gaa ttg ata aat ata att  2271
Lys Ile Ile Thr Gln Asn Gln Arg Ile Lys Glu Leu Ile Asn Ile Ile
        720                 725                 730

gat caa aaa gaa gat act atc aac gaa ttt cag aac cta aag tct cat  2319
Asp Gln Lys Glu Asp Thr Ile Asn Glu Phe Gln Asn Leu Lys Ser His
    735                 740                 745

atg gaa aac aca ttt aaa tgc aat gac aag gct gat aca tct tct tta  2367
Met Glu Asn Thr Phe Lys Cys Asn Asp Lys Ala Asp Thr Ser Ser Leu
750                 755                 760                 765

ata ata aac aat aaa ttg att tgt aat gaa aca gtt gaa gta cct aag  2415
Ile Ile Asn Asn Lys Leu Ile Cys Asn Glu Thr Val Glu Val Pro Lys
                770                 775                 780

gac agc aaa tct aaa atc tgt tca gaa aga aaa aga gta aat gaa aat  2463
Asp Ser Lys Ser Lys Ile Cys Ser Glu Arg Lys Arg Val Asn Glu Asn
            785                 790                 795

gaa ctt cag caa gat gaa cca cca gca aag aaa ggg tct atc cat gtt  2511
Glu Leu Gln Gln Asp Glu Pro Pro Ala Lys Lys Gly Ser Ile His Val
        800                 805                 810

agt tca gct atc act gaa gac caa aag aaa agt gaa gaa gtg cga ccg  2559
Ser Ser Ala Ile Thr Glu Asp Gln Lys Lys Ser Glu Glu Val Arg Pro
    815                 820                 825

aac att gca gaa att gaa gac atc aga gtt tta caa gaa aat aat gaa  2607
Asn Ile Ala Glu Ile Glu Asp Ile Arg Val Leu Gln Glu Asn Asn Glu
830                 835                 840                 845

gga ctg aga gca ttt tta ctc act att gag aat gaa ctt aaa aat gaa  2655
Gly Leu Arg Ala Phe Leu Leu Thr Ile Glu Asn Glu Leu Lys Asn Glu
                850                 855                 860

aag gaa gaa aaa gca gaa tta aat aaa cag att gtt cat ttt cag cag  2703
Lys Glu Glu Lys Ala Glu Leu Asn Lys Gln Ile Val His Phe Gln Gln
            865                 870                 875

gaa ctt tct ctt tct gaa aaa aag aat tta act tta agt aaa gag gtc  2751
Glu Leu Ser Leu Ser Glu Lys Lys Asn Leu Thr Leu Ser Lys Glu Val
        880                 885                 890

caa caa att cag tca aat tat gat att gca att gct gaa tta cat gtg  2799
Gln Gln Ile Gln Ser Asn Tyr Asp Ile Ala Ile Ala Glu Leu His Val
    895                 900                 905

cag aaa agt aaa aat caa gaa cag gag gaa aag atc atg aaa ttg tca  2847
Gln Lys Ser Lys Asn Gln Glu Gln Glu Glu Lys Ile Met Lys Leu Ser
910                 915                 920                 925

aat gag ata gaa act gct aca aga agc att aca aat aat gtt tca caa  2895
Asn Glu Ile Glu Thr Ala Thr Arg Ser Ile Thr Asn Asn Val Ser Gln
                930                 935                 940

ata aaa tta atg cac acg aaa ata gac gaa cta cgt act ctt gat tca  2943
Ile Lys Leu Met His Thr Lys Ile Asp Glu Leu Arg Thr Leu Asp Ser
            945                 950                 955

gtt tct cag att tca aac ata gat ttg ctc aat ctc agg gat ctg tca  2991
Val Ser Gln Ile Ser Asn Ile Asp Leu Leu Asn Leu Arg Asp Leu Ser
        960                 965                 970

aat ggt tct gag gag gat aat ttg cca aat aca cag tta gac ctt tta  3039
Asn Gly Ser Glu Glu Asp Asn Leu Pro Asn Thr Gln Leu Asp Leu Leu
```

```
     975                 980                 985
ggt aat gat tat ttg gta agt aag caa gtt aaa gaa tat cga att caa   3087
Gly Asn Asp Tyr Leu Val Ser Lys Gln Val Lys Glu Tyr Arg Ile Gln
990                 995                 1000                1005

gaa ccc aat agg gaa aat tct ttc cac tct agt att gaa gct att      3132
Glu Pro Asn Arg Glu Asn Ser Phe His Ser Ser Ile Glu Ala Ile
                1010                1015                1020

tgg gaa gaa tgt aaa gag att gtg aag gcc tct tcc aaa aaa agt      3177
Trp Glu Glu Cys Lys Glu Ile Val Lys Ala Ser Ser Lys Lys Ser
            1025                1030                1035

cat cag att gag gaa ctg gaa caa caa att gaa aaa ttg cag gca      3222
His Gln Ile Glu Glu Leu Glu Gln Gln Ile Glu Lys Leu Gln Ala
        1040                1045                1050

gaa gta aaa ggc tat aag gat gaa aac aat aga cta aag gag aag      3267
Glu Val Lys Gly Tyr Lys Asp Glu Asn Asn Arg Leu Lys Glu Lys
    1055                1060                1065

gag cat aaa aac caa gat gac cta cta aaa gaa aaa gaa act ctt      3312
Glu His Lys Asn Gln Asp Asp Leu Leu Lys Glu Lys Glu Thr Leu
1070                1075                1080

ata cag cag ctg aaa gaa gaa ttg caa gaa aaa aat gtt act ctt      3357
Ile Gln Gln Leu Lys Glu Glu Leu Gln Glu Lys Asn Val Thr Leu
            1085                1090                1095

gat gtt caa ata cag cat gta gtt gaa gga aag aga gcg ctt tca      3402
Asp Val Gln Ile Gln His Val Val Glu Gly Lys Arg Ala Leu Ser
        1100                1105                1110

gaa ctt aca caa ggt gtt act tgc tat aag gca aaa ata aag gaa      3447
Glu Leu Thr Gln Gly Val Thr Cys Tyr Lys Ala Lys Ile Lys Glu
    1115                1120                1125

ctt gaa aca att tta gag act cag aaa gtt gaa tgt agt cat tca      3492
Leu Glu Thr Ile Leu Glu Thr Gln Lys Val Glu Cys Ser His Ser
1130                1135                1140

gcc aag tta gaa caa gac att ttg gaa aag gaa tct atc atc tta      3537
Ala Lys Leu Glu Gln Asp Ile Leu Glu Lys Glu Ser Ile Ile Leu
            1145                1150                1155

aag cta gaa aga aat ttg aag gaa ttt caa gaa cat ctt cag gat      3582
Lys Leu Glu Arg Asn Leu Lys Glu Phe Gln Glu His Leu Gln Asp
        1160                1165                1170

tct gtc aaa aac acc aaa gat tta aat gta aag gaa ctc aag ctg      3627
Ser Val Lys Asn Thr Lys Asp Leu Asn Val Lys Glu Leu Lys Leu
    1175                1180                1185

aaa gaa gaa atc aca cag tta aca aat aat ttg caa gat atg aaa      3672
Lys Glu Glu Ile Thr Gln Leu Thr Asn Asn Leu Gln Asp Met Lys
1190                1195                1200

cat tta ctt caa tta aaa gaa gaa gaa gaa gaa gaa acc aac agg caa  3717
His Leu Leu Gln Leu Lys Glu Glu Glu Glu Glu Glu Thr Asn Arg Gln
            1205                1210                1215

gaa aca gaa aaa ttg aaa gag gaa ctc tct gca agc tct gct cgt      3762
Glu Thr Glu Lys Leu Lys Glu Glu Leu Ser Ala Ser Ser Ala Arg
        1220                1225                1230

acc cag aat ctg aaa gca gat ctt cag agg aag gaa gaa gat tat      3807
Thr Gln Asn Leu Lys Ala Asp Leu Gln Arg Lys Glu Glu Asp Tyr
    1235                1240                1245
```

```
gct gac ctg aaa gag  aaa ctg act gat gcc  aaa aag cag att aag      3852
Ala Asp Leu Lys Glu  Lys Leu Thr Asp Ala  Lys Lys Gln Ile Lys
                1250                1255                1260

caa gta cag aaa gag  gta tct gta atg cgt  gat gag gat aaa tta      3897
Gln Val Gln Lys Glu  Val Ser Val Met Arg  Asp Glu Asp Lys Leu
                1265                1270                1275

ctg agg att aaa att  aat gaa ctg gag aaa  aag aaa aac cag tgt      3942
Leu Arg Ile Lys Ile  Asn Glu Leu Glu Lys  Lys Lys Asn Gln Cys
                1280                1285                1290

tct cag gaa tta gat  atg aaa cag cga acc  att cag caa ctc aag      3987
Ser Gln Glu Leu Asp  Met Lys Gln Arg Thr  Ile Gln Gln Leu Lys
                1295                1300                1305

gag cag tta aat aat  cag aaa gtg gaa gaa  gct ata caa cag tat      4032
Glu Gln Leu Asn Asn  Gln Lys Val Glu Glu  Ala Ile Gln Gln Tyr
                1310                1315                1320

gag aga gca tgc aaa  gat cta aat gtt aaa  gag aaa ata att gaa      4077
Glu Arg Ala Cys Lys  Asp Leu Asn Val Lys  Glu Lys Ile Ile Glu
                1325                1330                1335

gac atg cga atg aca  cta gaa gaa cag gaa  caa act cag gta gaa      4122
Asp Met Arg Met Thr  Leu Glu Glu Gln Glu  Gln Thr Gln Val Glu
                1340                1345                1350

cag gat caa gtg ctt  gag gct aaa tta gag  gaa gtt gaa agg ctg      4167
Gln Asp Gln Val Leu  Glu Ala Lys Leu Glu  Glu Val Glu Arg Leu
                1355                1360                1365

gcc aca gaa ttg gaa  aaa tgg aag gaa aaa  tgc aat gat ttg gaa      4212
Ala Thr Glu Leu Glu  Lys Trp Lys Glu Lys  Cys Asn Asp Leu Glu
                1370                1375                1380

acc aaa aac aat caa  agg tca aat aaa gaa  cat gag aac aac aca      4257
Thr Lys Asn Asn Gln  Arg Ser Asn Lys Glu  His Glu Asn Asn Thr
                1385                1390                1395

gat gtg ctt gga aag  ctc act aat ctt caa  gat gag tta cag gag      4302
Asp Val Leu Gly Lys  Leu Thr Asn Leu Gln  Asp Glu Leu Gln Glu
                1400                1405                1410

tct gaa cag aaa tat  aat gct gat aga aag  aaa tgg tta gaa gaa      4347
Ser Glu Gln Lys Tyr  Asn Ala Asp Arg Lys  Lys Trp Leu Glu Glu
                1415                1420                1425

aaa atg atg ctt atc  act caa gcg aaa gaa  gca gag aat ata cga      4392
Lys Met Met Leu Ile  Thr Gln Ala Lys Glu  Ala Glu Asn Ile Arg
                1430                1435                1440

aat aaa gag atg aaa  aaa tat gct gag gac  agg gag cgt ttt ttt      4437
Asn Lys Glu Met Lys  Lys Tyr Ala Glu Asp  Arg Glu Arg Phe Phe
                1445                1450                1455

aag caa cag aat gaa  atg gaa ata ctg aca  gcc cag ctg aca gag      4482
Lys Gln Gln Asn Glu  Met Glu Ile Leu Thr  Ala Gln Leu Thr Glu
                1460                1465                1470

aaa gat agt gac ctt  caa aag tgg cga gaa  gaa cga gat caa ctg      4527
Lys Asp Ser Asp Leu  Gln Lys Trp Arg Glu  Glu Arg Asp Gln Leu
                1475                1480                1485

gtt gca gct tta gaa  ata cag cta aaa gca  ctg ata tcc agt aat      4572
Val Ala Ala Leu Glu  Ile Gln Leu Lys Ala  Leu Ile Ser Ser Asn
                1490                1495                1500
```

gta cag aaa gat aat gaa att gaa caa cta aaa agg atc ata tca 4617
Val Gln Lys Asp Asn Glu Ile Glu Gln Leu Lys Arg Ile Ile Ser
1505 1510 1515

gag act tct aaa ata gaa aca caa atc atg gat atc aag ccc aaa 4662
Glu Thr Ser Lys Ile Glu Thr Gln Ile Met Asp Ile Lys Pro Lys
1520 1525 1530

cgt att agt tca gca gat cct gac aaa ctt caa act gaa cct cta 4707
Arg Ile Ser Ser Ala Asp Pro Asp Lys Leu Gln Thr Glu Pro Leu
1535 1540 1545

tcg aca agt ttt gaa att tcc aga aat aaa ata gag gat gga tct 4752
Ser Thr Ser Phe Glu Ile Ser Arg Asn Lys Ile Glu Asp Gly Ser
1550 1555 1560

gta gtc ctt gac tct tgt gaa gtg tca aca gaa aat gat caa agc 4797
Val Val Leu Asp Ser Cys Glu Val Ser Thr Glu Asn Asp Gln Ser
1565 1570 1575

act cga ttt cca aaa cct gag tta gag att caa ttt aca cct tta 4842
Thr Arg Phe Pro Lys Pro Glu Leu Glu Ile Gln Phe Thr Pro Leu
1580 1585 1590

cag cca aac aaa atg gca gtg aaa cac cct ggt tgt acc aca cca 4887
Gln Pro Asn Lys Met Ala Val Lys His Pro Gly Cys Thr Thr Pro
1595 1600 1605

gtg aca gtt aag att ccc aag gct cgg aag agg aag agt aat gaa 4932
Val Thr Val Lys Ile Pro Lys Ala Arg Lys Arg Lys Ser Asn Glu
1610 1615 1620

atg gag gag gac ttg gtg aaa tgt gaa aat aag aag aat gct aca 4977
Met Glu Glu Asp Leu Val Lys Cys Glu Asn Lys Lys Asn Ala Thr
1625 1630 1635

ccc aga act aat ttg aaa ttt cct att tca gat gat aga aat tct 5022
Pro Arg Thr Asn Leu Lys Phe Pro Ile Ser Asp Asp Arg Asn Ser
1640 1645 1650

tct gtc aaa aag gaa caa aag gtt gcc ata cgt cca tca tct aag 5067
Ser Val Lys Lys Glu Gln Lys Val Ala Ile Arg Pro Ser Ser Lys
1655 1660 1665

aaa aca tat tct tta cgg agt cag gca tcc ata att ggt gta aac 5112
Lys Thr Tyr Ser Leu Arg Ser Gln Ala Ser Ile Ile Gly Val Asn
1670 1675 1680

ctg gcc act aag aaa aaa gaa gga aca cta cag aaa ttt gga gac 5157
Leu Ala Thr Lys Lys Lys Glu Gly Thr Leu Gln Lys Phe Gly Asp
1685 1690 1695

ttc tta caa cat tct ccc tca att ctt caa tca aaa gca aag aag 5202
Phe Leu Gln His Ser Pro Ser Ile Leu Gln Ser Lys Ala Lys Lys
1700 1705 1710

ata att gaa aca atg agc tct tca aag ctc tca aat gta gaa gca 5247
Ile Ile Glu Thr Met Ser Ser Ser Lys Leu Ser Asn Val Glu Ala
1715 1720 1725

agt aaa gaa aat gtg tct caa cca aaa cga gcc aaa cgg aaa tta 5292
Ser Lys Glu Asn Val Ser Gln Pro Lys Arg Ala Lys Arg Lys Leu
1730 1735 1740

tac aca agt gaa att tca tct cct att gat ata tca ggc caa gtg 5337
Tyr Thr Ser Glu Ile Ser Ser Pro Ile Asp Ile Ser Gly Gln Val
1745 1750 1755

att tta atg gac cag aaa atg aag gag agt gat cac cag att atc 5382

```
Ile Leu Met Asp Gln Lys Met Lys Glu Ser Asp His Gln Ile Ile
                1760                1765                1770

aaa cga cga ctt cga aca aaa aca gcc aaa taa atcacttatg                5425
Lys Arg Arg Leu Arg Thr Lys Thr Ala Lys
                1775                1780

gaaatgtttа atataaattt tatagtcata gtcattggaa cttgcatcct gtattgtaaa    5485

tataaatgta tatattatgc atttaaatcac tctgcatata gattgctgtt ttatacatag   5545

tataatttta attcaataaa tgagtcaaaa tttgtatatt tttataaggc ttttttataa    5605

tagcttcttt caaactgtat ttccctatta tctcagacat tggatcagtg aagatcctag    5665

gaaagaggct gttattctca tttatttttgc tatacaggat gtaataggtc aggtatttgg   5725

tttacttata tttaacaatg tcttatgaat ttttttttact ttatctgtta tacaactgat   5785

tttacatatc tgttttggatt atagctagga tttggagaat aagtgtgtac agatcacaaa   5845

acatgtatat acattattta gaaaagatct caagtctttа attagaatgt ctcacttatt    5905

ttgtaaacat tttgtgggta catagtacat gtatatattt acggggtatg tgagatgttt    5965

tgacacaggc atgcaatgtg aaatacgtgt atcatggaga atgaggtatc catcccctca    6025

agcatttttc ctttgaatta cagataatcc aattacattc tttagatcat ttaaaaatat    6085

acaagtaagt tattattgat tatagtcact ctattgtgct atcagatagt agatcatttct   6145

ttttatctta tttgtttttg tacccattaa ccatccccac ctccccctgc aaccgtcagt    6205

acccttacca gccactggta accattcttc tactctgtat gcccatgagg tcaattgatt    6265

ttatttttag atcccataaa taaatgagaa catgcagtct ttgtcaaaaa aaaa          6319
```

<210> 2
<211> 1780
<212> PRT
<213> Homo sapi ens

<400> 2

```
Met Glu Ser Asn Phe Asn Gln Glu Gly Val Pro Arg Pro Ser Tyr Val
1               5                  10                  15

Phe Ser Ala Asp Pro Ile Ala Arg Pro Ser Glu Ile Asn Phe Asp Gly
            20                  25                  30

Ile Lys Leu Asp Leu Ser His Glu Phe Ser Leu Val Ala Pro Asn Thr
        35                  40                  45

Glu Ala Asn Ser Phe Glu Ser Lys Asp Tyr Leu Gln Val Cys Leu Arg
    50                  55                  60

Ile Arg Pro Phe Thr Gln Ser Glu Lys Glu Leu Glu Ser Glu Gly Cys
65                  70                  75                  80

Val His Ile Leu Asp Ser Gln Thr Val Val Leu Lys Glu Pro Gln Cys
                85                  90                  95
```

Ile Leu Gly Arg Leu Ser Glu Lys Ser Ser Gly Gln Met Ala Gln Lys
100 105 110

Phe Ser Phe Ser Lys Val Phe Gly Pro Ala Thr Thr Gln Lys Glu Phe
115 120 125

Phe Gln Gly Cys Ile Met Gln Pro Val Lys Asp Leu Leu Lys Gly Gln
130 135 140

Ser Arg Leu Ile Phe Thr Tyr Gly Leu Thr Asn Ser Gly Lys Thr Tyr
145 150 155 160

Thr Phe Gln Gly Thr Glu Glu Asn Ile Gly Ile Leu Pro Arg Thr Leu
165 170 175

Asn Val Leu Phe Asp Ser Leu Gln Glu Arg Leu Tyr Thr Lys Met Asn
180 185 190

Leu Lys Pro His Arg Ser Arg Glu Tyr Leu Arg Leu Ser Ser Glu Gln
195 200 205

Glu Lys Glu Glu Ile Ala Ser Lys Ser Ala Leu Leu Arg Gln Ile Lys
210 215 220

Glu Val Thr Val His Asn Asp Ser Asp Asp Thr Leu Tyr Gly Ser Leu
225 230 235 240

Thr Asn Ser Leu Asn Ile Ser Glu Phe Glu Glu Ser Ile Lys Asp Tyr
245 250 255

Glu Gln Ala Asn Leu Asn Met Ala Asn Ser Ile Lys Phe Ser Val Trp
260 265 270

Val Ser Phe Phe Glu Ile Tyr Asn Glu Tyr Ile Tyr Asp Leu Phe Val
275 280 285

Pro Val Ser Ser Lys Phe Gln Lys Arg Lys Met Leu Arg Leu Ser Gln
290 295 300

Asp Val Lys Gly Tyr Ser Phe Ile Lys Asp Leu Gln Trp Ile Gln Val
305 310 315 320

Ser Asp Ser Lys Glu Ala Tyr Arg Leu Leu Lys Leu Gly Ile Lys His
325 330 335

Gln Ser Val Ala Phe Thr Lys Leu Asn Asn Ala Ser Ser Arg Ser His
340 345 350

Ser Ile Phe Thr Val Lys Ile Leu Gln Ile Glu Asp Ser Glu Met Ser
355 360 365

Arg Val Ile Arg Val Ser Glu Leu Ser Leu Cys Asp Leu Ala Gly Ser

370 375 380

Glu Arg Thr Met Lys Thr Gln Asn Glu Gly Glu Arg Leu Arg Glu Thr
385 390 395 400

Gly Asn Ile Asn Thr Ser Leu Leu Thr Leu Gly Lys Cys Ile Asn Val
405 410 415

Leu Lys Asn Ser Glu Lys Ser Lys Phe Gln Gln His Val Pro Phe Arg
420 425 430

Glu Ser Lys Leu Thr His Tyr Phe Gln Ser Phe Phe Asn Gly Lys Gly
435 440 445

Lys Ile Cys Met Ile Val Asn Ile Ser Gln Cys Tyr Leu Ala Tyr Asp
450 455 460

Glu Thr Leu Asn Val Leu Lys Phe Ser Ala Ile Ala Gln Lys Val Cys
465 470 475 480

Val Pro Asp Thr Leu Asn Ser Ser Gln Glu Lys Leu Phe Gly Pro Val
485 490 495

Lys Ser Ser Gln Asp Val Ser Leu Asp Ser Asn Ser Asn Ser Lys Ile
500 505 510

Leu Asn Val Lys Arg Ala Thr Ile Ser Trp Glu Asn Ser Leu Glu Asp
515 520 525

Leu Met Glu Asp Glu Asp Leu Val Glu Glu Leu Glu Asn Ala Glu Glu
530 535 540

Thr Gln Asn Val Glu Thr Lys Leu Leu Asp Glu Asp Leu Asp Lys Thr
545 550 555 560

Leu Glu Glu Asn Lys Ala Phe Ile Ser His Glu Glu Lys Arg Lys Leu
565 570 575

Leu Asp Leu Ile Glu Asp Leu Lys Lys Lys Leu Ile Asn Glu Lys Lys
580 585 590

Glu Lys Leu Thr Leu Glu Phe Lys Ile Arg Glu Glu Val Thr Gln Glu
595 600 605

Phe Thr Gln Tyr Trp Ala Gln Arg Glu Ala Asp Phe Lys Glu Thr Leu
610 615 620

Leu Gln Glu Arg Glu Ile Leu Glu Glu Asn Ala Glu Arg Arg Leu Ala
625 630 635 640

Ile Phe Lys Asp Leu Val Gly Lys Cys Asp Thr Arg Glu Glu Ala Ala
645 650 655

Lys Asp Ile Cys Ala Thr Lys Val Glu Thr Glu Glu Ala Thr Ala Cys
660 665 670

Leu Glu Leu Lys Phe Asn Gln Ile Lys Ala Glu Leu Ala Lys Thr Lys
675 680 685

Gly Glu Leu Ile Lys Thr Lys Glu Glu Leu Lys Lys Arg Glu Asn Glu
690 695 700

Ser Asp Ser Leu Ile Gln Glu Leu Glu Thr Ser Asn Lys Lys Ile Ile
705 710 715 720

Thr Gln Asn Gln Arg Ile Lys Glu Leu Ile Asn Ile Ile Asp Gln Lys
725 730 735

Glu Asp Thr Ile Asn Glu Phe Gln Asn Leu Lys Ser His Met Glu Asn
740 745 750

Thr Phe Lys Cys Asn Asp Lys Ala Asp Thr Ser Ser Leu Ile Ile Asn
755 760 765

Asn Lys Leu Ile Cys Asn Glu Thr Val Glu Val Pro Lys Asp Ser Lys
770 775 780

Ser Lys Ile Cys Ser Glu Arg Lys Arg Val Asn Glu Asn Glu Leu Gln
785 790 795 800

Gln Asp Glu Pro Pro Ala Lys Lys Gly Ser Ile His Val Ser Ser Ala
805 810 815

Ile Thr Glu Asp Gln Lys Lys Ser Glu Glu Val Arg Pro Asn Ile Ala
820 825 830

Glu Ile Glu Asp Ile Arg Val Leu Gln Glu Asn Asn Glu Gly Leu Arg
835 840 845

Ala Phe Leu Leu Thr Ile Glu Asn Glu Leu Lys Asn Glu Lys Glu Glu
850 855 860

Lys Ala Glu Leu Asn Lys Gln Ile Val His Phe Gln Gln Glu Leu Ser
865 870 875 880

Leu Ser Glu Lys Lys Asn Leu Thr Leu Ser Lys Glu Val Gln Gln Ile
885 890 895

Gln Ser Asn Tyr Asp Ile Ala Ile Ala Glu Leu His Val Gln Lys Ser
900 905 910

Lys Asn Gln Glu Gln Glu Glu Lys Ile Met Lys Leu Ser Asn Glu Ile
915 920 925

Glu Thr Ala Thr Arg Ser Ile Thr Asn Asn Val Ser Gln Ile Lys Leu
930 935 940

Met His Thr Lys Ile Asp Glu Leu Arg Thr Leu Asp Ser Val Ser Gln
945 950 955 960

Ile Ser Asn Ile Asp Leu Leu Asn Leu Arg Asp Leu Ser Asn Gly Ser
965 970 975

Glu Glu Asp Asn Leu Pro Asn Thr Gln Leu Asp Leu Leu Gly Asn Asp
980 985 990

Tyr Leu Val Ser Lys Gln Val Lys Glu Tyr Arg Ile Gln Glu Pro Asn
995 1000 1005

Arg Glu Asn Ser Phe His Ser Ser Ile Glu Ala Ile Trp Glu Glu
1010 1015 1020

Cys Lys Glu Ile Val Lys Ala Ser Ser Lys Lys Ser His Gln Ile
1025 1030 1035

Glu Glu Leu Glu Gln Gln Ile Glu Lys Leu Gln Ala Glu Val Lys
1040 1045 1050

Gly Tyr Lys Asp Glu Asn Asn Arg Leu Lys Glu Lys Glu His Lys
1055 1060 1065

Asn Gln Asp Asp Leu Leu Lys Glu Lys Glu Thr Leu Ile Gln Gln
1070 1075 1080

Leu Lys Glu Glu Leu Gln Glu Lys Asn Val Thr Leu Asp Val Gln
1085 1090 1095

Ile Gln His Val Val Glu Gly Lys Arg Ala Leu Ser Glu Leu Thr
1100 1105 1110

Gln Gly Val Thr Cys Tyr Lys Ala Lys Ile Lys Glu Leu Glu Thr
1115 1120 1125

Ile Leu Glu Thr Gln Lys Val Glu Cys Ser His Ser Ala Lys Leu
1130 1135 1140

Glu Gln Asp Ile Leu Glu Lys Glu Ser Ile Ile Leu Lys Leu Glu
1145 1150 1155

Arg Asn Leu Lys Glu Phe Gln Glu His Leu Gln Asp Ser Val Lys
1160 1165 1170

Asn Thr Lys Asp Leu Asn Val Lys Glu Leu Lys Leu Lys Glu Glu
1175 1180 1185

Ile Thr Gln Leu Thr Asn Asn Leu Gln Asp Met Lys His Leu Leu
1190 1195 1200

Gln Leu Lys Glu Glu Glu Glu Glu Thr Asn Arg Gln Glu Thr Glu
1205 1210 1215

Lys Leu Lys Glu Glu Leu Ser Ala Ser Ser Ala Arg Thr Gln Asn
1220 1225 1230

Leu Lys Ala Asp Leu Gln Arg Lys Glu Glu Asp Tyr Ala Asp Leu
1235 1240 1245

Lys Glu Lys Leu Thr Asp Ala Lys Lys Gln Ile Lys Gln Val Gln
1250 1255 1260

Lys Glu Val Ser Val Met Arg Asp Glu Asp Lys Leu Leu Arg Ile
1265 1270 1275

Lys Ile Asn Glu Leu Glu Lys Lys Lys Asn Gln Cys Ser Gln Glu
1280 1285 1290

Leu Asp Met Lys Gln Arg Thr Ile Gln Gln Leu Lys Glu Gln Leu
1295 1300 1305

Asn Asn Gln Lys Val Glu Glu Ala Ile Gln Gln Tyr Glu Arg Ala
1310 1315 1320

Cys Lys Asp Leu Asn Val Lys Glu Lys Ile Ile Glu Asp Met Arg
1325 1330 1335

Met Thr Leu Glu Glu Gln Glu Gln Thr Gln Val Glu Gln Asp Gln
1340 1345 1350

Val Leu Glu Ala Lys Leu Glu Glu Val Glu Arg Leu Ala Thr Glu
1355 1360 1365

Leu Glu Lys Trp Lys Glu Lys Cys Asn Asp Leu Glu Thr Lys Asn
1370 1375 1380

Asn Gln Arg Ser Asn Lys Glu His Glu Asn Asn Thr Asp Val Leu
1385 1390 1395

Gly Lys Leu Thr Asn Leu Gln Asp Glu Leu Gln Glu Ser Glu Gln
1400 1405 1410

Lys Tyr Asn Ala Asp Arg Lys Lys Trp Leu Glu Glu Lys Met Met
1415 1420 1425

Leu Ile Thr Gln Ala Lys Glu Ala Glu Asn Ile Arg Asn Lys Glu
1430 1435 1440

Met Lys Lys Tyr Ala Glu Asp Arg Glu Arg Phe Phe Lys Gln Gln

1445 1450 1455

Asn Glu Met Glu Ile Leu Thr Ala Gln Leu Thr Glu Lys Asp Ser
1460 1465 1470

Asp Leu Gln Lys Trp Arg Glu Glu Arg Asp Gln Leu Val Ala Ala
1475 1480 1485

Leu Glu Ile Gln Leu Lys Ala Leu Ile Ser Ser Asn Val Gln Lys
1490 1495 1500

Asp Asn Glu Ile Glu Gln Leu Lys Arg Ile Ile Ser Glu Thr Ser
1505 1510 1515

Lys Ile Glu Thr Gln Ile Met Asp Ile Lys Pro Lys Arg Ile Ser
1520 1525 1530

Ser Ala Asp Pro Asp Lys Leu Gln Thr Glu Pro Leu Ser Thr Ser
1535 1540 1545

Phe Glu Ile Ser Arg Asn Lys Ile Glu Asp Gly Ser Val Val Leu
1550 1555 1560

Asp Ser Cys Glu Val Ser Thr Glu Asn Asp Gln Ser Thr Arg Phe
1565 1570 1575

Pro Lys Pro Glu Leu Glu Ile Gln Phe Thr Pro Leu Gln Pro Asn
1580 1585 1590

Lys Met Ala Val Lys His Pro Gly Cys Thr Thr Pro Val Thr Val
1595 1600 1605

Lys Ile Pro Lys Ala Arg Lys Arg Lys Ser Asn Glu Met Glu Glu
1610 1615 1620

Asp Leu Val Lys Cys Glu Asn Lys Lys Asn Ala Thr Pro Arg Thr
1625 1630 1635

Asn Leu Lys Phe Pro Ile Ser Asp Asp Arg Asn Ser Ser Val Lys
1640 1645 1650

Lys Glu Gln Lys Val Ala Ile Arg Pro Ser Ser Lys Lys Thr Tyr
1655 1660 1665

Ser Leu Arg Ser Gln Ala Ser Ile Ile Gly Val Asn Leu Ala Thr
1670 1675 1680

Lys Lys Lys Glu Gly Thr Leu Gln Lys Phe Gly Asp Phe Leu Gln
1685 1690 1695

His Ser Pro Ser Ile Leu Gln Ser Lys Ala Lys Lys Ile Ile Glu
1700 1705 1710

Thr Met Ser Ser Ser Lys Leu Ser Asn Val Glu Ala Ser Lys Glu
1715 1720 1725

Asn Val Ser Gln Pro Lys Arg Ala Lys Arg Lys Leu Tyr Thr Ser
1730 1735 1740

Glu Ile Ser Ser Pro Ile Asp Ile Ser Gly Gln Val Ile Leu Met
1745 1750 1755

Asp Gln Lys Met Lys Glu Ser Asp His Gln Ile Ile Lys Arg Arg
1760 1765 1770

Leu Arg Thr Lys Thr Ala Lys
1775 1780

<210> 3
<211> 5318
<212> DNA
<213> Homo sapi ens

<220>
<221> CDS
<222> (79) .. (2511)

<400> 3

gagactcgcc actgccgcgg ccgctgggcc tgagtgtcgc cttcgccgcc atggacgcca 60

ccgggcgctg acagacct atg gag agt cag ggt gtg cct ccc ggg cct tat 111
Met Glu Ser Gln Gly Val Pro Pro Gly Pro Tyr
1 5 10

cgg gcc acc aag ctg tgg aat gaa gtt acc aca tct ttt cga gca gga 159
Arg Ala Thr Lys Leu Trp Asn Glu Val Thr Thr Ser Phe Arg Ala Gly
15 20 25

atg cct cta aga aaa cac aga caa cac ttt aaa aaa tat ggc aat tgt 207
Met Pro Leu Arg Lys His Arg Gln His Phe Lys Lys Tyr Gly Asn Cys
30 35 40

ttc aca gca gga gaa gca gtg gat tgg ctt tat gac cta tta aga aat 255
Phe Thr Ala Gly Glu Ala Val Asp Trp Leu Tyr Asp Leu Leu Arg Asn
45 50 55

aat agc aat ttt ggt cct gaa gtt aca agg caa cag act atc caa ctg 303
Asn Ser Asn Phe Gly Pro Glu Val Thr Arg Gln Gln Thr Ile Gln Leu
60 65 70 75

ttg agg aaa ttt ctt aag aat cat gta att gaa gat atc aaa ggg agg 351
Leu Arg Lys Phe Leu Lys Asn His Val Ile Glu Asp Ile Lys Gly Arg
80 85 90

tgg gga tca gaa aat gtt gat gat aac aac cag ctc ttc aga ttt cct 399
Trp Gly Ser Glu Asn Val Asp Asp Asn Asn Gln Leu Phe Arg Phe Pro
95 100 105

gca act tcg cca ctt aaa act cta cca cga agg tat cca gaa ttg aga 447
Ala Thr Ser Pro Leu Lys Thr Leu Pro Arg Arg Tyr Pro Glu Leu Arg
110 115 120

aaa aac aac ata gag aac ttt tcc aaa gat aaa gat agc att ttt aaa 495
Lys Asn Asn Ile Glu Asn Phe Ser Lys Asp Lys Asp Ser Ile Phe Lys
125 130 135

```
tta cga aac tta tct cgt aga act cct aaa agg cat gga tta cat tta      543
Leu Arg Asn Leu Ser Arg Arg Thr Pro Lys Arg His Gly Leu His Leu
140                 145                 150                 155

tct cag gaa aat ggc gag aaa ata aag cat gaa ata atc aat gaa gat      591
Ser Gln Glu Asn Gly Glu Lys Ile Lys His Glu Ile Ile Asn Glu Asp
                160                 165                 170

caa gaa aat gca att gat aat aga gaa cta agc cag gaa gat gtt gaa      639
Gln Glu Asn Ala Ile Asp Asn Arg Glu Leu Ser Gln Glu Asp Val Glu
            175                 180                 185

gaa gtt tgg aga tat gtt att ctg atc tac ctg caa acc att tta ggt      687
Glu Val Trp Arg Tyr Val Ile Leu Ile Tyr Leu Gln Thr Ile Leu Gly
        190                 195                 200

gtg cca tcc cta gaa gaa gtc ata aat cca aaa caa gta att ccc caa      735
Val Pro Ser Leu Glu Glu Val Ile Asn Pro Lys Gln Val Ile Pro Gln
    205                 210                 215

tat ata atg tac aac atg gcc aat aca agt aaa cgt gga gta gtt ata      783
Tyr Ile Met Tyr Asn Met Ala Asn Thr Ser Lys Arg Gly Val Val Ile
220                 225                 230                 235

cta caa aac aaa tca gat gac ctc cct cac tgg gta tta tct gcc atg      831
Leu Gln Asn Lys Ser Asp Asp Leu Pro His Trp Val Leu Ser Ala Met
                240                 245                 250

aag tgc cta gca aat tgg cca aga agc aat gat atg aat aat cca act      879
Lys Cys Leu Ala Asn Trp Pro Arg Ser Asn Asp Met Asn Asn Pro Thr
            255                 260                 265

tat gtt gga ttt gaa cga gat gta ttc aga aca atc gca gat tat ttt      927
Tyr Val Gly Phe Glu Arg Asp Val Phe Arg Thr Ile Ala Asp Tyr Phe
        270                 275                 280

cta gat ctc cct gaa cct cta ctt act ttt gaa tat tac gaa tta ttt      975
Leu Asp Leu Pro Glu Pro Leu Leu Thr Phe Glu Tyr Tyr Glu Leu Phe
    285                 290                 295

gta aac att ttg gtt gtt tgt ggc tac atc aca gtt tca gat aga tcc     1023
Val Asn Ile Leu Val Val Cys Gly Tyr Ile Thr Val Ser Asp Arg Ser
300                 305                 310                 315

agt ggg ata cat aaa att caa gat gat cca cag tct tca aaa ttc ctt     1071
Ser Gly Ile His Lys Ile Gln Asp Asp Pro Gln Ser Ser Lys Phe Leu
                320                 325                 330

cac tta aac aat ttg aat tcc ttc aaa tca act gag tgc ctt ctt ctc     1119
His Leu Asn Asn Leu Asn Ser Phe Lys Ser Thr Glu Cys Leu Leu Leu
            335                 340                 345

agt ctg ctt cat aga gaa aaa aac aaa gaa gaa tca gat tct act gag     1167
Ser Leu Leu His Arg Glu Lys Asn Lys Glu Glu Ser Asp Ser Thr Glu
        350                 355                 360

aga cta cag ata agc aat cca gga ttt caa gaa aga tgt gct aag aaa     1215
Arg Leu Gln Ile Ser Asn Pro Gly Phe Gln Glu Arg Cys Ala Lys Lys
    365                 370                 375

atg cag cta gtt aat tta aga aac aga aga gtg agt gct aat gac ata     1263
Met Gln Leu Val Asn Leu Arg Asn Arg Arg Val Ser Ala Asn Asp Ile
380                 385                 390                 395

atg gga gga agt tgt cat aat tta ata ggg tta agt aat atg cat gat     1311
Met Gly Gly Ser Cys His Asn Leu Ile Gly Leu Ser Asn Met His Asp
                400                 405                 410
```

```
cta tcc tct aac agc aaa cca agg tgc tgt tct ttg gaa gga att gta 1359
Leu Ser Ser Asn Ser Lys Pro Arg Cys Cys Ser Leu Glu Gly Ile Val
                415                 420                 425

gat gtg cca ggg aat tca agt aaa gag gca tcc agt gtc ttt cat caa 1407
Asp Val Pro Gly Asn Ser Ser Lys Glu Ala Ser Ser Val Phe His Gln
            430                 435                 440

tct ttt ccg aac ata gaa gga caa aat aat aaa ctg ttt tta gag tct 1455
Ser Phe Pro Asn Ile Glu Gly Gln Asn Asn Lys Leu Phe Leu Glu Ser
        445                 450                 455

aag ccc aaa cag gaa ttc ctg ttg aat ctt cat tca gag gaa aat att 1503
Lys Pro Lys Gln Glu Phe Leu Leu Asn Leu His Ser Glu Glu Asn Ile
460                 465                 470                 475

caa aag cca ttc agt gct ggt ttt aag aga acc tct act ttg act gtt 1551
Gln Lys Pro Phe Ser Ala Gly Phe Lys Arg Thr Ser Thr Leu Thr Val
                480                 485                 490

caa gac caa gag gag ttg tgt aat ggg aaa tgc aag tca aaa cag ctt 1599
Gln Asp Gln Glu Glu Leu Cys Asn Gly Lys Cys Lys Ser Lys Gln Leu
            495                 500                 505

tgt agg tct cag agt ttg ctt tta aga agt agt aca aga agg aat agt 1647
Cys Arg Ser Gln Ser Leu Leu Leu Arg Ser Ser Thr Arg Arg Asn Ser
        510                 515                 520

tat atc aat aca cca gtg gct gaa att atc atg aaa cca aat gtt gga 1695
Tyr Ile Asn Thr Pro Val Ala Glu Ile Ile Met Lys Pro Asn Val Gly
    525                 530                 535

caa ggc agc aca agt gtg caa aca gct atg gaa agt gaa ctc gga gag 1743
Gln Gly Ser Thr Ser Val Gln Thr Ala Met Glu Ser Glu Leu Gly Glu
540                 545                 550                 555

tct agt gcc aca atc aat aaa aga ctc tgc aaa agt aca ata gaa ctt 1791
Ser Ser Ala Thr Ile Asn Lys Arg Leu Cys Lys Ser Thr Ile Glu Leu
                560                 565                 570

tca gaa aat tct tta ctt cca gct tct tct atg ttg act ggc aca caa 1839
Ser Glu Asn Ser Leu Leu Pro Ala Ser Ser Met Leu Thr Gly Thr Gln
            575                 580                 585

agc ttg ctg caa cct cat tta gag agg gtt gcc atc gat gct cta cag 1887
Ser Leu Leu Gln Pro His Leu Glu Arg Val Ala Ile Asp Ala Leu Gln
        590                 595                 600

tta tgt tgt ttg tta ctt ccc cca cca aat cgt aga aag ctt caa ctt 1935
Leu Cys Cys Leu Leu Leu Pro Pro Pro Asn Arg Arg Lys Leu Gln Leu
    605                 610                 615

tta atg cgt atg att tcc cga atg agt caa aat gtt gat atg ccc aaa 1983
Leu Met Arg Met Ile Ser Arg Met Ser Gln Asn Val Asp Met Pro Lys
620                 625                 630                 635

ctt cat gat gca atg ggt acg agg tca ctg atg ata cat acc ttt tct 2031
Leu His Asp Ala Met Gly Thr Arg Ser Leu Met Ile His Thr Phe Ser
                640                 645                 650

cga tgt gtg tta tgc tgt gct gaa gaa gtg gat ctt gat gag ctt ctt 2079
Arg Cys Val Leu Cys Cys Ala Glu Glu Val Asp Leu Asp Glu Leu Leu
            655                 660                 665

gct gga aga tta gtt tct ttc tta atg gat cat cat cag gaa att ctt 2127
Ala Gly Arg Leu Val Ser Phe Leu Met Asp His His Gln Glu Ile Leu
        670                 675                 680

caa gta ccc tct tac tta cag act gca gtg gaa aaa cat ctt gac tac 2175
```

```
Gln Val Pro Ser Tyr Leu Gln Thr Ala Val Glu Lys His Leu Asp Tyr
    685                 690                 695

tta aaa aag gga cat att gaa aat cct gga gat gga cta ttt gct cct  2223
Leu Lys Lys Gly His Ile Glu Asn Pro Gly Asp Gly Leu Phe Ala Pro
700                 705                 710                 715

ttg cca act tac tca tac tgt aag cag att agt gct cag gag ttt gat  2271
Leu Pro Thr Tyr Ser Tyr Cys Lys Gln Ile Ser Ala Gln Glu Phe Asp
                720                 725                 730

gag caa aaa gtt tct acc tct caa gct gca att gca gaa ctt tta gaa  2319
Glu Gln Lys Val Ser Thr Ser Gln Ala Ala Ile Ala Glu Leu Leu Glu
            735                 740                 745

aat att att aaa aac agg agt tta cct cta aag gag aaa aga aaa aaa  2367
Asn Ile Ile Lys Asn Arg Ser Leu Pro Leu Lys Glu Lys Arg Lys Lys
        750                 755                 760

cta aaa cag ttt cag aag gaa tat cct ttg ata tat cag aaa aga ttt  2415
Leu Lys Gln Phe Gln Lys Glu Tyr Pro Leu Ile Tyr Gln Lys Arg Phe
    765                 770                 775

cca acc acg gag agt gaa gca gca ctt ttt ggt gac aaa cct aca atc  2463
Pro Thr Thr Glu Ser Glu Ala Ala Leu Phe Gly Asp Lys Pro Thr Ile
780                 785                 790                 795

aag caa cca atg ctg att tta aga aaa cca aag ttc cgt agt cta aga  2511
Lys Gln Pro Met Leu Ile Leu Arg Lys Pro Lys Phe Arg Ser Leu Arg
                800                 805                 810

taactaactg aatttaaaaat tatgtaatac ttgtggaact ttgataaatg aagccatatc  2571

tgagaatgta gctactcaaa aggaagtctg tcatttaataa ggtatttcta aataaacaca  2631

ttatgtaagg aagtgccaaa atagttatca atgtgagact cttaggaaac taactagatc  2691

tcaattgaga gcacataaca atagatgata ccaaatactt tttgttttta acacagctat  2751

ccagtaaggc tatcatgatg tgtgctaaaa ttttatttac ttgaatttg aaaactgagc  2811

tgtgttaggg attaaactat aatttctgttc ttaaaagaaa atttatctgc aaatgtgcaa  2871

gttctgagat attagctaat gaattagttg tttggggtta cttctttgtt tctaagtata  2931

agaatgtgaa gaatatttga aaactcaatg aaataatttct cagctgccaa atgttgcact  2991

cttttatata ttcttttttcc acttttgatc tatttatata tatgtatgtg ttttttaaaat  3051

atgtgtatat tttatcagat ttggttttgc cttaaatatt atccccaatt gcttcagtca  3111

ttcatttgtt cagtatatat attttgaatt ctagttttca taatctatta gaagatgggg  3171

atataaaaga agtataaggc aatcatatat tcattcaaaa gatatttatt tagcaactgc  3231

tatgtgcctt tcgttgttcc agatatgcag agacaatgat aaataaaaca tataatctct  3291

tccataaggt atttatttttt taatcaaggg agatacacct atcagatgtt taaaataaca  3351

acactaccca ctgaaatcag ggcatatata atcattcagc taaagagtga cttctatgat  3411

gatggaacag gtctctaagc tagtggtttt caaactggta cacattagac tcacccgagg  3471

aattttaaaa cagcctatat gcccagggcc taacttacac taatttaaatc tgaatttgg  3531

ggatgttgta tagggattag tatttttttt aatctaggtg attccaatat tcagccaact  3591

gtgagaatca atggcctaaa tgcttttttat aaacatttttt ataagtgtca agataatggc  3651
```

acatt gactt tatttttt ca ttggaagaaa atgcctgcca agtat aaatg actctcatct 3711
taaaacaagg ttcttcaggt ttctgcttga ttgacttggt acaaacttga agcaagttgc 3771
cttctaattt ttactccaag attgtttcat atctatt cct taagtgtaaa gaaatatata 3831
atgcatggtt tgtaataaaa tcttaatgtt taatgactgt tctcatttct caatgtaatt 3891
tcatactgtt tctctataaa atgatagtat tccatttaac attactgatt tttattaaaa 3951
acctggacag aaaattataa attatаaata tgactttatc ctggctataa aattattgaa 4011
ccaaaatgaa ttctttctaa ggcatttgaa tactaaaacg tttattgttt atagatatgt 4071
aaaatgtgga ttatgttgca aattgagatt aaaattattt ggggttttgt aacaatataa 4131
ttttgctttt gtattataga caaatatata aataataaag gcaggcaact ttcatttgca 4191
ctaatgtaca tgcaattgag attacaaaat acatggtaca atgctttaat aacaaactct 4251
gccagtcagg tttgaatcct actgtgctat taactagcta gtaaactcag acaagttact 4311
taacttctct aagccccagt tttgttatct ataaaatgaa tattataata gtacctcttt 4371
ttaggattgc gaggattaag caggataatg catgtaaagt gttagcacag tgtctcacat 4431
agaataagca ctctataaat attttactag aatcacctag gattatagca ctagaagaga 4491
tcttagcaaa aatgtggtcc tttctgttgc tttggacaga catgaaccaa aacaaaatta 4551
cggacaattg atgagccttа ttaactatct tttcattatg agacaaaggt tctgattatg 4611
cctactggtt gaaatttttt aatctagtca agaaggaaaa tttgatgagg aaggaaggaa 4671
tggatatctt cagaagggct tcgcctaagc tggaacatgg atagatttcca ttctaacata 4731
aagatctttа agttcaaata tagatgagtt gactggtaga tttggtggta gttgctttct 4791
cgggatataa gaagcaaaat caactgctac aagtaaagag gggatgggga aggtgttgca 4851
catttaaaga gagaaagtgt gaaaaagcct aattgtggga atgcacaggt ttcaccagat 4911
cagatgatgt ctggttattc tgtaaattat agttcttatc ccagaaatta ctgcctccac 4971
catccctaat atcttctaat tggtatcata taatgaccca ctcttcttat gttatccaaa 5031
cagttatgtg gcatttagta atggaatgta catggaattt cccactgact tacctttctg 5091
tccttgggaa gcttaaactc tgaatcttct catctgtaaa atgtgaatta aagtatctac 5151
ctaactgagt tgtgattgta gtgaaagaaa ggcaatatat ttaaatcttg aatttagcaa 5211
gcccacgctc gatttttatg tcctttcctc ttgccttgta ttgagtttaa gatctctact 5271
gattaaaact cttttgctat caaaaaaaaa aaaaaaaaaa aaaaaaa 5318

<210> 4
<211> 811
<212> PRT
<213> Homo sapiens

<400> 4

Met Glu Ser Gln Gly Val Pro Pro Gly Pro Tyr Arg Ala Thr Lys Leu
1 5 10 15

Trp Asn Glu Val Thr Thr Ser Phe Arg Ala Gly Met Pro Leu Arg Lys

20 25 30

His Arg Gln His Phe Lys Lys Tyr Gly Asn Cys Phe Thr Ala Gly Glu
35 40 45

Ala Val Asp Trp Leu Tyr Asp Leu Leu Arg Asn Asn Ser Asn Phe Gly
50 55 60

Pro Glu Val Thr Arg Gln Gln Thr Ile Gln Leu Leu Arg Lys Phe Leu
65 70 75 80

Lys Asn His Val Ile Glu Asp Ile Lys Gly Arg Trp Gly Ser Glu Asn
85 90 95

Val Asp Asp Asn Asn Gln Leu Phe Arg Phe Pro Ala Thr Ser Pro Leu
100 105 110

Lys Thr Leu Pro Arg Arg Tyr Pro Glu Leu Arg Lys Asn Asn Ile Glu
115 120 125

Asn Phe Ser Lys Asp Lys Asp Ser Ile Phe Lys Leu Arg Asn Leu Ser
130 135 140

Arg Arg Thr Pro Lys Arg His Gly Leu His Leu Ser Gln Glu Asn Gly
145 150 155 160

Glu Lys Ile Lys His Glu Ile Ile Asn Glu Asp Gln Glu Asn Ala Ile
165 170 175

Asp Asn Arg Glu Leu Ser Gln Glu Asp Val Glu Glu Val Trp Arg Tyr
180 185 190

Val Ile Leu Ile Tyr Leu Gln Thr Ile Leu Gly Val Pro Ser Leu Glu
195 200 205

Glu Val Ile Asn Pro Lys Gln Val Ile Pro Gln Tyr Ile Met Tyr Asn
210 215 220

Met Ala Asn Thr Ser Lys Arg Gly Val Val Ile Leu Gln Asn Lys Ser
225 230 235 240

Asp Asp Leu Pro His Trp Val Leu Ser Ala Met Lys Cys Leu Ala Asn
245 250 255

Trp Pro Arg Ser Asn Asp Met Asn Asn Pro Thr Tyr Val Gly Phe Glu
260 265 270

Arg Asp Val Phe Arg Thr Ile Ala Asp Tyr Phe Leu Asp Leu Pro Glu
275 280 285

Pro Leu Leu Thr Phe Glu Tyr Tyr Glu Leu Phe Val Asn Ile Leu Val
290 295 300

Val Cys Gly Tyr Ile Thr Val Ser Asp Arg Ser Ser Gly Ile His Lys
305 310 315 320

Ile Gln Asp Asp Pro Gln Ser Ser Lys Phe Leu His Leu Asn Asn Leu
325 330 335

Asn Ser Phe Lys Ser Thr Glu Cys Leu Leu Leu Ser Leu Leu His Arg
340 345 350

Glu Lys Asn Lys Glu Glu Ser Asp Ser Thr Glu Arg Leu Gln Ile Ser
355 360 365

Asn Pro Gly Phe Gln Glu Arg Cys Ala Lys Lys Met Gln Leu Val Asn
370 375 380

Leu Arg Asn Arg Arg Val Ser Ala Asn Asp Ile Met Gly Gly Ser Cys
385 390 395 400

His Asn Leu Ile Gly Leu Ser Asn Met His Asp Leu Ser Ser Asn Ser
405 410 415

Lys Pro Arg Cys Cys Ser Leu Glu Gly Ile Val Asp Val Pro Gly Asn
420 425 430

Ser Ser Lys Glu Ala Ser Ser Val Phe His Gln Ser Phe Pro Asn Ile
435 440 445

Glu Gly Gln Asn Asn Lys Leu Phe Leu Glu Ser Lys Pro Lys Gln Glu
450 455 460

Phe Leu Leu Asn Leu His Ser Glu Glu Asn Ile Gln Lys Pro Phe Ser
465 470 475 480

Ala Gly Phe Lys Arg Thr Ser Thr Leu Thr Val Gln Asp Gln Glu Glu
485 490 495

Leu Cys Asn Gly Lys Cys Lys Ser Lys Gln Leu Cys Arg Ser Gln Ser
500 505 510

Leu Leu Leu Arg Ser Ser Thr Arg Arg Asn Ser Tyr Ile Asn Thr Pro
515 520 525

Val Ala Glu Ile Ile Met Lys Pro Asn Val Gly Gln Gly Ser Thr Ser
530 535 540

Val Gln Thr Ala Met Glu Ser Glu Leu Gly Glu Ser Ser Ala Thr Ile
545 550 555 560

Asn Lys Arg Leu Cys Lys Ser Thr Ile Glu Leu Ser Glu Asn Ser Leu
565 570 575

Leu Pro Ala Ser Ser Met Leu Thr Gly Thr Gln Ser Leu Leu Gln Pro
580 585 590

His Leu Glu Arg Val Ala Ile Asp Ala Leu Gln Leu Cys Cys Leu Leu
595 600 605

Leu Pro Pro Pro Asn Arg Arg Lys Leu Gln Leu Leu Met Arg Met Ile
610 615 620

Ser Arg Met Ser Gln Asn Val Asp Met Pro Lys Leu His Asp Ala Met
625 630 635 640

Gly Thr Arg Ser Leu Met Ile His Thr Phe Ser Arg Cys Val Leu Cys
645 650 655

Cys Ala Glu Glu Val Asp Leu Asp Glu Leu Leu Ala Gly Arg Leu Val
660 665 670

Ser Phe Leu Met Asp His His Gln Glu Ile Leu Gln Val Pro Ser Tyr
675 680 685

Leu Gln Thr Ala Val Glu Lys His Leu Asp Tyr Leu Lys Lys Gly His
690 695 700

Ile Glu Asn Pro Gly Asp Gly Leu Phe Ala Pro Leu Pro Thr Tyr Ser
705 710 715 720

Tyr Cys Lys Gln Ile Ser Ala Gln Glu Phe Asp Glu Gln Lys Val Ser
725 730 735

Thr Ser Gln Ala Ala Ile Ala Glu Leu Leu Glu Asn Ile Ile Lys Asn
740 745 750

Arg Ser Leu Pro Leu Lys Glu Lys Arg Lys Lys Leu Lys Gln Phe Gln
755 760 765

Lys Glu Tyr Pro Leu Ile Tyr Gln Lys Arg Phe Pro Thr Thr Glu Ser
770 775 780

Glu Ala Ala Leu Phe Gly Asp Lys Pro Thr Ile Lys Gln Pro Met Leu
785 790 795 800

Ile Leu Arg Lys Pro Lys Phe Arg Ser Leu Arg
805 810

<210> 5
<211> 8666
<212> DNA
<213> Homo sapi ens

<220>
<221> CDS
<222> (79) .. (1659)

<400> 5

```
gagactcgcc actgccgcgg ccgctgggcc tgagtgtcgc cttcgccgcc atggacgcca      60

ccgggcgctg acagacct atg gag agt cag ggt gtg cct ccc ggg cct tat        111
                      Met Glu Ser Gln Gly Val Pro Pro Gly Pro Tyr
                      1               5                  10

cgg gcc acc aag ctg tgg aat gaa gtt acc aca tct ttt cga gca gga        159
Arg Ala Thr Lys Leu Trp Asn Glu Val Thr Thr Ser Phe Arg Ala Gly
            15                  20                  25

atg cct cta aga aaa cac aga caa cac ttt aaa aaa tat ggc aat tgt        207
Met Pro Leu Arg Lys His Arg Gln His Phe Lys Lys Tyr Gly Asn Cys
        30                  35                  40

ttc aca gca gga gaa gca gtg gat tgg ctt tat gac cta tta aga aat        255
Phe Thr Ala Gly Glu Ala Val Asp Trp Leu Tyr Asp Leu Leu Arg Asn
    45                  50                  55

aat agc aat ttt ggt cct gaa gtt aca agg caa cag act atc caa ctg        303
Asn Ser Asn Phe Gly Pro Glu Val Thr Arg Gln Gln Thr Ile Gln Leu
60                  65                  70                  75

ttg agg aaa ttt ctt aag aat cat gta att gaa gat atc aaa ggg agg        351
Leu Arg Lys Phe Leu Lys Asn His Val Ile Glu Asp Ile Lys Gly Arg
                80                  85                  90

tgg gga tca gaa aat gtt gat gat aac aac cag ctc ttc aga ttt cct        399
Trp Gly Ser Glu Asn Val Asp Asp Asn Asn Gln Leu Phe Arg Phe Pro
            95                  100                 105

gca act tcg cca ctt aaa act cta cca cga agg tat cca gaa ttg aga        447
Ala Thr Ser Pro Leu Lys Thr Leu Pro Arg Arg Tyr Pro Glu Leu Arg
        110                 115                 120

aaa aac aac ata gag aac ttt tcc aaa gat aaa gat agc att ttt aaa        495
Lys Asn Asn Ile Glu Asn Phe Ser Lys Asp Lys Asp Ser Ile Phe Lys
    125                 130                 135

tta cga aac tta tct cgt aga act cct aaa agg cat gga tta cat tta        543
Leu Arg Asn Leu Ser Arg Arg Thr Pro Lys Arg His Gly Leu His Leu
140                 145                 150                 155

tct cag gaa aat ggc gag aaa ata aag cat gaa ata atc aat gaa gat        591
Ser Gln Glu Asn Gly Glu Lys Ile Lys His Glu Ile Ile Asn Glu Asp
                160                 165                 170

caa gaa aat gca att gat aat aga gaa cta agc cag gaa gat gtt gaa        639
Gln Glu Asn Ala Ile Asp Asn Arg Glu Leu Ser Gln Glu Asp Val Glu
            175                 180                 185

gaa gtt tgg aga tat gtt att ctg atc tac ctg caa acc att tta ggt        687
Glu Val Trp Arg Tyr Val Ile Leu Ile Tyr Leu Gln Thr Ile Leu Gly
        190                 195                 200

gtg cca tcc cta gaa gaa gtc ata aat cca aaa caa gta att ccc caa        735
Val Pro Ser Leu Glu Glu Val Ile Asn Pro Lys Gln Val Ile Pro Gln
    205                 210                 215

tat ata atg tac aac atg gcc aat aca agt aaa cgt gga gta gtt ata        783
Tyr Ile Met Tyr Asn Met Ala Asn Thr Ser Lys Arg Gly Val Val Ile
220                 225                 230                 235

cta caa aac aaa tca gat gac ctc cct cac tgg gta tta tct gcc atg        831
Leu Gln Asn Lys Ser Asp Asp Leu Pro His Trp Val Leu Ser Ala Met
                240                 245                 250

aag tgc cta gca aat tgg cca aga agc aat gat atg aat aat cca act        879
```

```
Lys Cys Leu Ala Asn Trp Pro Arg Ser Asn Asp Met Asn Asn Pro Thr
                255                 260                 265

tat gtt gga ttt gaa cga gat gta ttc aga aca atc gca gat tat ttt  927
Tyr Val Gly Phe Glu Arg Asp Val Phe Arg Thr Ile Ala Asp Tyr Phe
    270                 275                 280

cta gat ctc cct gaa cct cta ctt act ttt gaa tat tac gaa tta ttt  975
Leu Asp Leu Pro Glu Pro Leu Leu Thr Phe Glu Tyr Tyr Glu Leu Phe
285                 290                 295

gta aac att ttg gtt gtt tgt ggc tac atc aca gtt tca gat aga tcc 1023
Val Asn Ile Leu Val Val Cys Gly Tyr Ile Thr Val Ser Asp Arg Ser
300                 305                 310                 315

agt ggg ata cat aaa att caa gat gat cca cag tct tca aaa ttc ctt 1071
Ser Gly Ile His Lys Ile Gln Asp Asp Pro Gln Ser Ser Lys Phe Leu
                320                 325                 330

cac tta aac aat ttg aat tcc ttc aaa tca act gag tgc ctt ctt ctc 1119
His Leu Asn Asn Leu Asn Ser Phe Lys Ser Thr Glu Cys Leu Leu Leu
            335                 340                 345

agt ctg ctt cat aga gaa aaa aac aaa gaa gaa tca gat tct act gag 1167
Ser Leu Leu His Arg Glu Lys Asn Lys Glu Glu Ser Asp Ser Thr Glu
        350                 355                 360

aga cta cag ata agc aat cca gga ttt caa gaa aga tgt gct aag aaa 1215
Arg Leu Gln Ile Ser Asn Pro Gly Phe Gln Glu Arg Cys Ala Lys Lys
    365                 370                 375

atg cag cta gtt aat tta aga aac aga aga gtg agt gct aat gac ata 1263
Met Gln Leu Val Asn Leu Arg Asn Arg Arg Val Ser Ala Asn Asp Ile
380                 385                 390                 395

atg gga gga agt tgt cat aat tta ata ggg tta agt aat atg cat gat 1311
Met Gly Gly Ser Cys His Asn Leu Ile Gly Leu Ser Asn Met His Asp
                400                 405                 410

cta tcc tct aac agc aaa cca agg tgc tgt tct ttg gaa gga att gta 1359
Leu Ser Ser Asn Ser Lys Pro Arg Cys Cys Ser Leu Glu Gly Ile Val
            415                 420                 425

gat gtg cca ggg aat tca agt aaa gag gca tcc agt gtc ttt cat caa 1407
Asp Val Pro Gly Asn Ser Ser Lys Glu Ala Ser Ser Val Phe His Gln
        430                 435                 440

tct ttt ccg aac ata gaa gga caa aat aat aaa ctg ttt tta gag tct 1455
Ser Phe Pro Asn Ile Glu Gly Gln Asn Asn Lys Leu Phe Leu Glu Ser
    445                 450                 455

aag ccc aaa cag gaa ttc ctg ttg aat ctt cat tca gag gaa aat att 1503
Lys Pro Lys Gln Glu Phe Leu Leu Asn Leu His Ser Glu Glu Asn Ile
460                 465                 470                 475

caa aag cca ttc agt gct ggt ttt aag aga acc tct act ttg act gtt 1551
Gln Lys Pro Phe Ser Ala Gly Phe Lys Arg Thr Ser Thr Leu Thr Val
                480                 485                 490

caa gac caa gag gag ttg tgt aat ggg aaa tgc aag tca aaa cag ctt 1599
Gln Asp Gln Glu Glu Leu Cys Asn Gly Lys Cys Lys Ser Lys Gln Leu
            495                 500                 505

tgt agg tct cag agt ttg ctt tta aga agt agt aca aga agg aat agt 1647
Cys Arg Ser Gln Ser Leu Leu Leu Arg Ser Ser Thr Arg Arg Asn Ser
        510                 515                 520

tat atc aat aca ccagtggctg aaattatcat gaaaccaaat gttggacaag     1699
Tyr Ile Asn Thr
```

525

gcagcacaag tgtgcaaaca gctatggaaa gtgaactcgg agagtctagt gccacaatca 1759

ataaaagact ctgcaaaagt acaatagaac tttcagaaaa ttctttactt ccagcttctt 1819

ctatgttgac tggcacacaa agcttgctgc aacctcattt agagagggtt gccatcgatg 1879

ctctacagtt atgttgtttg ttacttcccc caccaaatcg tagaaagctt caacttttaa 1939

tgcgtatgat ttcccgaatg agtcaaaatg ttgatatgcc caaacttcat gatgcaatgg 1999

gtacgaggtc actgatgata catacctttt ctcgatgtgt gttatgctgt gctgaagaag 2059

tggatcttga tgagcttctt gctggaagat tagtttcttt cttaatggat catcatcagg 2119

aaattcttca agtaccctct tacttacaga ctgcagtgga aaaacatctt gactacttaa 2179

aaaagggaca tattgaaaat cctggagatg gactatttgc tcctttgcca acttactcat 2239

actgtaagca gattagtgct caggagtttg atgagcaaaa agtttctacc tctcaagctg 2299

caattgcaga acttttagaa aatattatta aaaacaggag tttacctcta aaggagaaaa 2359

gaaaaaaact aaaacagttt cagaaggaat atcctttgat atatcagaaa agatttccaa 2419

ccacggagag tgaagcagca cttttggtg acaaacctac aatcaagcaa ccaatgctga 2479

ttttaagaaa accaaagttc cgtagtctaa gataactaac tgaattaaaa attatgtaat 2539

acttgtggaa ctttgataaa tgaagccata tctgagaatg tagctactca aaaggaagtc 2599

tgtcatttaat aaggtatttc taaataaaca cattatgtaa ggaagtgcca aaatagttat 2659

caatgtgaga ctcttaggaa actaactaga tctcaatttga gagcacataa caatagatga 2719

taccaaatac ttttttgtttt taacacagct atccagtaag gctatcatga tgtgtgctaa 2779

aatttttattt acttgaatttt tgaaaactga gctgtgttag ggattaaact ataatttctgt 2839

tcttaaaaga aaatttatct gcaaatgtgc aagttctgag atattagcta atgaatttagt 2899

tgttttggggt tacttctttg tttctaagta taagaatgtg aagaatattt gaaaactcaa 2959

tgaaataatt ctcagctgcc aaatgttgca ctctttttata tattctttttt ccacttttga 3019

tctatttata tatatgtatg tgtttttaaa atatgtgtat atttttatcag atttggttttt 3079

gccttaaata ttatccccaa ttgcttcagt cattcatttg ttcagtatat atattttgaa 3139

ttctagtttt cataatctat tagaagatgg ggatataaaa gaagtataag gcaatcatat 3199

attcattcaa aagatatttа tttagcaact gctatgtgcc tttcgttgtt ccagatatgc 3259

agagacaatg ataaataaaa catataatct cttccataag gtatttattt tttaatcaag 3319

ggagatacac ctatcagatg tttaaaataa caacactacc cactgaaatc agggcatata 3379

gaatcattca gctaaagagt gacttctatg atgatggaac aggtctctaa gctagtggtt 3439

ttcaaactgg tacacattag actcacccga ggaatttttaa aacagcctat atgcccaggg 3499

cctaacttac actaatttaaa tctgaatttt ggggatgttg tatagggatt agtatttttt 3559

ttaatctagg tgattccaat attcagccaa ctgtgagaat caatggccta aatgctttttt 3619

ataaacattt ttatаagtgt caagataatg gcacattgac tttatttttt cattggaaga 3679

aaatgcctgc caagtataaa tgactctcat cttaaaacaa ggttcttcag gttttctgctt 3739

gattgacttg gtacaaactt gaagcaagtt gccttctaat ttttactcca agattgtttc 3799
atatctattc cttaagtgta aagaaatata taatgcatgg tttgtaataa aatcttaatg 3859
tttaatgact gttctcattt ctcaatgtaa tttcatactg tttctctata aaatgatagt 3919
attccattta acattactga ttttttattaa aaacctggac agaaaattat aaatttataaa 3979
tatgacttta tcctggctat aaaattattg aaccaaaatg aattctttct aaggcatttg 4039
aatactaaaa cgtttattgt ttatagatat gtaaaatgtg gattatgttg caaattgaga 4099
ttaaaatttat ttggggtttt gtaacaatat aatttttgctt ttgtatttata gacaaatata 4159
taaataataa aggcaggcaa ctttcatttg cactaatgta cgagactcgc cactgccgcg 4219
gccgctgggc ctgagtgtcg ccttcgccgc catggacgcc accgggcgct gacagacctta 4279
tggagagtca gggtgtgcct cccgggcctt atcgggccac caagctgtgg aatgaagttta 4339
ccacatcttt tcgagcagga atgcctctaa gaaaacacag acaacacttt aaaaaatatg 4399
gcaattgttt cacagcagga gaagcagtgg attggcttta tgacctatta agaaataata 4459
gcaattttgg tcctgaagtt acaaggcaac agactatcca actgttgagg aaatttcttta 4519
agaatcatgt aattgaagat atcaaaggga ggtggggatc agaaaatgtt gatgataaca 4579
accagctctt cagatttcct gcaacttcgc cacttaaaac tctaccacga aggtatccag 4639
aattgagaaa aaacaacata gagaacttt ccaaagataa agatagcatt tttaaatttac 4699
gaaacttatc tcgtagaact cctaaaaggc atggattaca tttatctcag gaaaatggcg 4759
agaaaataaa gcatgaaata atcaatgaag atcaagaaaa tgcaattgat aatagagaac 4819
taagccagga agatgttgaa gaagttggga gatatgttat tctgatctac ctgcaaacca 4879
ttttaggtgt gccatccctta gaagaagtca taaatccaaa acaagtaatt ccccaatata 4939
taatgtacaa catggccaat acaagtaaac gtggagtagt tatactacaa aacaaatcag 4999
atgacctccc tcactgggta ttatctgcca tgaagtgcct agcaaattgg ccaagaagca 5059
atgatatgaa taatccaact tatgttggat ttgaacgaga tgtattcaga acaatcgcag 5119
attatttttct agatctccct gaacctctac ttacttttga atattacgaa ttatttgtaa 5179
acatttttggg cttgctgcaa cctcatttag agagggttgc catcgatgct ctacagttat 5239
gttgttttgtt acttccccca ccaaatcgta gaaagcttca acttttaatg cgtatgattt 5299
cccgaatgag tcaaaatgtt gatatgccca aacttcatga tgcaatgggt acgaggtcac 5359
tgatgataca tacctttttct cgatgtgtgt tatgctgtgc tgaagaagtg gatcttgatg 5419
agcttcttgc tggaagatta gtttctttct taatggatca tcatcaggaa attcttcaag 5479
taccctctta cttacagact gcagtggaaa aacatcttga ctacttaaaa aagggacata 5539
ttgaaaatcc tggagatgga ctatttgctc ctttgccaac ttactcatac tgtaagcaga 5599
ttagtgctca ggagttttgat gagcaaaaag tttctacctc tcaagctgca attgcagaac 5659
ttttagaaaa tattattaaa aacaggagtt tacctctaaa ggagaaaaga aaaaaactaa 5719
aacagtttca gaaggaatat cctttgatat atcagaaaag atttccaacc acggagagtg 5779

aagcagcact ttttggtgac aaacctacaa tcaagcaacc aatgctgatt ttaagaaaac 5839
caaagttccg tagtctaaga taactaactg aattaaaaat tatgtaatac ttgtggaact 5899
ttgataaatg aagccatatc tgagaatgta gctactcaaa aggaagtctg tcatttaataa 5959
ggtatttcta aataaacaca ttatgtaagg aagtgccaaa atagttatca atgtgagact 6019
cttaggaaac taactagatc tcaattgaga gcacataaca atagatgata ccaaatactt 6079
tttgttttta acacagctat ccagtaaggc tatcatgatg tgtgctaaaa ttttatttac 6139
ttgaatttg aaaactgagc tgtgttaggg attaaactat aatctgttc ttaaaagaaa 6199
atttatctgc aaatgtgcaa gttctgagat attagctaat gaattagttg tttggggtta 6259
cttctttgtt tctaagtata agaatgtgaa gaatatttga aaactcaatg aaataatttct 6319
cagctgccaa atgttgcact cttttatata ttctttttcc actttgatc tatttatata 6379
tatgtatgtg ttttaaaat atgtgtatat tttatcagat ttggttttgc cttaaatatt 6439
atccccaatt gcttcagtca ttcatttgtt cagtatatat attttgaatt ctagttttca 6499
taatctatta gaagatgggg atataaaaga agtataaggc aatcatatat tcatttcaaaa 6559
gatatttatt tagcaactgc tatgtgcctt tcgttgttcc agatatgcag agacaatgat 6619
aaataaaaca tataatctct tccataaggt atttatttttt taatcaaggg agatacacct 6679
atcagatgtt taaaataaca acactaccca ctgaaatcag ggcatataga atcatttcagc 6739
taaagagtga cttctatgat gatggaacag gtctcttaagc tagtggtttt caaactggta 6799
cacatttagac tcacccgagg aatttttaaaa cagcctatat gcccagggcc taacttacac 6859
taatttaaatc tgaatttttgg ggatgttgta tagggattag tatttttttt aatctaggtg 6919
attccaatat tcagccaact gtgagaatca atggcctaaa tgctttttat aaacatttttt 6979
ataagtgtca agataatggc acatttgactt tatttttttca ttggaagaaa atgcctgcca 7039
agtataaatg actctcatct taaaacaagg ttcttcaggt ttctgcttga ttgacttggt 7099
acaaacttga agcaagttgc cttctaattt ttactccaag attgtttcat atctatttcct 7159
taagtgtaaa gaaatatata atgcatggtt tgtaataaaa tcttaatgtt taatgactgt 7219
tctcatttct caatgtaatt tcatactgtt tctctataaa atgatagtat tccatttaac 7279
attactgatt tttattaaaa acctggacag aaaatttataa attataaata tgactttatc 7339
ctggctataa aatttattgaa ccaaaatgaa ttctttctaa ggcatttgaa tactaaaacg 7399
tttattgttt atagatatgt aaaatgtgga ttatgttgca aattgagatt aaaatttatt 7459
ggggttttgt aacaatataa ttttgctttt gtattatata caaatatata aataataaag 7519
gcaggcaact ttcatttgca ctaatgtaca tgcaattgag attacaaaat acatggtaca 7579
atgctttaat aacaaactct gccagtcagg tttgaatcct actgtgctat taactagcta 7639
gtaaactcag acaagttact taacttctct aagccccagt tttgttatct atataaatgaa 7699
tattataata gtacctcttt ttaggattgc gaggattaag caggataatg catgtaaagt 7759
gttagcacag tgtctcacat agaataagca ctctataaat attttactag aatcacctag 7819
gattatagca ctagaagaga tcttagcaaa aatgtggtcc tttctgttgc tttggacaga 7879

catgaaccaa aacaaaatta cggacaattg atgagcctta ttaactatct tttcattatg 7939
agacaaaggt tctgattatg cctactggtt gaaatttttt aatctagtca agaaggaaaa 7999
tttgatgagg aaggaaggaa tggatatctt cagaagggct tcgcctaagc tggaacatgg 8059
atagattcca ttctaacata aagatcttta agttcaaata tagatgagtt gactggtaga 8119
tttggtggta gttgctttct cgggatataa gaagcaaaat caactgctac aagtaaagag 8179
gggatgggga aggtgttgca catttaaaga gagaaagtgt gaaaaagcct aattgtggga 8239
atgcacaggt ttcaccagat cagatgatgt ctggttattc tgtaaattat agttcttatc 8299
ccagaaatta ctgcctccac catccctaat atcttctaat tggtatcata taatgaccca 8359
ctcttcttat gttatccaaa cagttatgtg gcatttagta atggaatgta catggaattt 8419
cccactgact tacctttctg tccttgggaa gcttaaactc tgaatcttct catctgtaaa 8479
atgtgaatta aagtatctac ctaactgagt tgtgattgta gtgaaagaaa ggcaatatat 8539
ttaaatcttg aatttagcaa gcccacgctc gatttttatg tcctttcctc ttgccttgta 8599
ttgagtttaa gatctctact gattaaaact cttttgctat caaaaaaaaa aaaaaaaaaa 8659
aaaaaaa 8666

<210> 6
<211> 527
<212> PRT
<213> Homo sapiens

<400> 6

Met Glu Ser Gln Gly Val Pro Pro Gly Pro Tyr Arg Ala Thr Lys Leu
1 5 10 15

Trp Asn Glu Val Thr Thr Ser Phe Arg Ala Gly Met Pro Leu Arg Lys
20 25 30

His Arg Gln His Phe Lys Lys Tyr Gly Asn Cys Phe Thr Ala Gly Glu
35 40 45

Ala Val Asp Trp Leu Tyr Asp Leu Leu Arg Asn Asn Ser Asn Phe Gly
50 55 60

Pro Glu Val Thr Arg Gln Gln Thr Ile Gln Leu Leu Arg Lys Phe Leu
65 70 75 80

Lys Asn His Val Ile Glu Asp Ile Lys Gly Arg Trp Gly Ser Glu Asn
85 90 95

Val Asp Asp Asn Asn Gln Leu Phe Arg Phe Pro Ala Thr Ser Pro Leu
100 105 110

Lys Thr Leu Pro Arg Arg Tyr Pro Glu Leu Arg Lys Asn Asn Ile Glu
115 120 125

Asn Phe Ser Lys Asp Lys Asp Ser Ile Phe Lys Leu Arg Asn Leu Ser
130 135 140

Arg Arg Thr Pro Lys Arg His Gly Leu His Leu Ser Gln Glu Asn Gly
145 150 155 160

Glu Lys Ile Lys His Glu Ile Ile Asn Glu Asp Gln Glu Asn Ala Ile
165 170 175

Asp Asn Arg Glu Leu Ser Gln Glu Asp Val Glu Glu Val Trp Arg Tyr
180 185 190

Val Ile Leu Ile Tyr Leu Gln Thr Ile Leu Gly Val Pro Ser Leu Glu
195 200 205

Glu Val Ile Asn Pro Lys Gln Val Ile Pro Gln Tyr Ile Met Tyr Asn
210 215 220

Met Ala Asn Thr Ser Lys Arg Gly Val Val Ile Leu Gln Asn Lys Ser
225 230 235 240

Asp Asp Leu Pro His Trp Val Leu Ser Ala Met Lys Cys Leu Ala Asn
245 250 255

Trp Pro Arg Ser Asn Asp Met Asn Asn Pro Thr Tyr Val Gly Phe Glu
260 265 270

Arg Asp Val Phe Arg Thr Ile Ala Asp Tyr Phe Leu Asp Leu Pro Glu
275 280 285

Pro Leu Leu Thr Phe Glu Tyr Tyr Glu Leu Phe Val Asn Ile Leu Val
290 295 300

Val Cys Gly Tyr Ile Thr Val Ser Asp Arg Ser Ser Gly Ile His Lys
305 310 315 320

Ile Gln Asp Asp Pro Gln Ser Ser Lys Phe Leu His Leu Asn Asn Leu
325 330 335

Asn Ser Phe Lys Ser Thr Glu Cys Leu Leu Leu Ser Leu Leu His Arg
340 345 350

Glu Lys Asn Lys Glu Glu Ser Asp Ser Thr Glu Arg Leu Gln Ile Ser
355 360 365

Asn Pro Gly Phe Gln Glu Arg Cys Ala Lys Lys Met Gln Leu Val Asn
370 375 380

Leu Arg Asn Arg Arg Val Ser Ala Asn Asp Ile Met Gly Gly Ser Cys
385 390 395 400

His Asn Leu Ile Gly Leu Ser Asn Met His Asp Leu Ser Ser Asn Ser

405 410 415

Lys Pro Arg Cys Cys Ser Leu Glu Gly Ile Val Asp Val Pro Gly Asn
420 425 430

Ser Ser Lys Glu Ala Ser Ser Val Phe His Gln Ser Phe Pro Asn Ile
435 440 445

Glu Gly Gln Asn Asn Lys Leu Phe Leu Glu Ser Lys Pro Lys Gln Glu
450 455 460

Phe Leu Leu Asn Leu His Ser Glu Glu Asn Ile Gln Lys Pro Phe Ser
465 470 475 480

Ala Gly Phe Lys Arg Thr Ser Thr Leu Thr Val Gln Asp Gln Glu Glu
485 490 495

Leu Cys Asn Gly Lys Cys Lys Ser Lys Gln Leu Cys Arg Ser Gln Ser
500 505 510

Leu Leu Leu Arg Ser Ser Thr Arg Arg Asn Ser Tyr Ile Asn Thr
515 520 525

<210> 7
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 7

Ile Tyr Asn Glu Tyr Ile Tyr Asp Leu
1 5

<210> 8
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 8

Ile Tyr Asn Glu Tyr Ile Tyr Asp Leu Phe
1 5 10

<210> 9
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 9

Tyr Ile Tyr Asp Leu Phe Val Pro Val
1 5

<210> 10
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 10

Arg Leu Ala Ile Phe Lys Asp Leu Val
1 5

<210> 11
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 11

Thr Met Ser Ser Ser Lys Leu Ser Asn Val
1 5 10

<210> 12
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 12

Glu Tyr Tyr Glu Leu Phe Val Asn Ile
1 5

<210> 13
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 13

Asp Tyr Ala Asp Leu Lys Glu Lys Leu
1 5

<210> 14
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 14

Gln Tyr Glu Arg Ala Cys Lys Asp Leu
1 5

<210> 15
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 15

Cys Tyr Leu Ala Tyr Asp Glu Thr Leu
1 5

<210> 16
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 16

Ala Tyr Asp Glu Thr Leu Asn Val Leu
1 5

<210> 17
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 17

Gly Tyr Lys Asp Glu Asn Asn Arg Leu
1 5

<210> 18
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 18

Leu Tyr Gly Ser Leu Thr Asn Ser Leu
1 5

<210> 19
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 19

Lys Tyr Ala Glu Asp Arg Glu Arg Phe
1 5

<210> 20
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 20

Asn Tyr Asp Ile Ala Ile Ala Glu Leu
1 5

<210> 21
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 21

Cys Tyr Lys Ala Lys Ile Lys Glu Leu
1 5

<210> 22
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 22

Asp Tyr Leu Gln Val Cys Leu Arg Ile
1 5

<210> 23
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 23

Lys Phe Asn Gln Ile Lys Ala Glu Leu
1 5

<210> 24
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 24

Ser Tyr Val Phe Ser Ala Asp Pro Ile
1 5

<210> 25
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 25

Ala Tyr Arg Leu Leu Lys Leu Gly Ile
1 5

<210> 26
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 26

Asp Tyr Glu Gln Ala Asn Leu Asn Met
1 5

<210> 27
<211> 9

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 27

Asn Phe Asp Gly Ile Lys Leu Asp Leu
1 5

<210> 28
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 28

Leu Phe Val Pro Val Ser Ser Lys Phe
1 5

<210> 29
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 29

Leu Phe Asp Ser Leu Gln Glu Arg Leu
1 5

<210> 30
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 30

Lys Phe Ser Val Trp Val Ser Phe Phe
1 5

<210> 31
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 31

Lys Leu Leu Asp Leu Ile Glu Asp Leu
1 5

<210> 32
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 32

Arg Phe Pro Lys Pro Glu Leu Glu Ile
1 5

<210> 33
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 33

Lys Tyr Asn Ala Asp Arg Lys Lys Trp
1 5

<210> 34
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 34

Arg Thr Gln Asn Leu Lys Ala Asp Leu
1 5

<210> 35
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 35

Lys Trp Leu Glu Glu Lys Met Met Leu
1 5

<210> 36
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 36

Lys Ser Asn Glu Met Glu Glu Asp Leu
1 5

<210> 37
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 37

Lys Ile Glu Asp Gly Ser Val Val Leu
1 5

<210> 38
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 38

Lys Gln Gln Asn Glu Met Glu Ile Leu
1 5

<210> 39
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 39

Lys Thr Gln Asn Glu Gly Glu Arg Leu
1 5

<210> 40
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 40

Lys Trp Lys Glu Lys Cys Asn Asp Leu
1 5

<210> 41
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 41

Lys Ile Lys Glu Leu Glu Thr Ile Leu
1 5

<210> 42
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 42

Phe Leu Leu Thr Ile Glu Asn Glu Leu
1 5

<210> 43
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 43

Ser Ser Leu Ile Ile Asn Asn Lys Leu
1 5

<210> 44
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 44

Lys Leu Thr Asn Leu Gln Asp Glu Leu
1 5

<210> 45
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 45

Ile Met Gln Pro Val Lys Asp Leu Leu
1 5

<210> 46
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 46

Lys Tyr Asn Ala Asp Arg Lys Lys Trp Leu
1 5 10

<210> 47
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 47

Lys Tyr Ala Glu Asp Arg Glu Arg Phe Phe
1 5 10

<210> 48
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 48

Gln Tyr Trp Ala Gln Arg Glu Ala Asp Phe
1 5 10

<210> 49
<211> 10

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 49

Leu Tyr Thr Ser Glu Ile Ser Ser Pro Ile
1 5 10

<210> 50
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 50

Lys Phe Gln Lys Arg Lys Met Leu Arg Leu
1 5 10

<210> 51
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 51

Ala Phe Leu Leu Thr Ile Glu Asn Glu Leu
1 5 10

<210> 52
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 52

Thr Tyr Ser Leu Arg Ser Gln Ala Ser Ile
1 5 10

<210> 53
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 53

Asp Phe Leu Gln His Ser Pro Ser Ile Leu
1 5 10

<210> 54
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 54

Arg Thr Leu Asn Val Leu Phe Asp Ser Leu
1 5 10

<210> 55
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 55

Lys Gln Ile Val His Phe Gln Gln Glu Leu
1 5 10

<210> 56
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 56

Lys Leu Leu Arg Ile Lys Ile Asn Glu Leu
1 5 10

<210> 57
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 57

Lys Ile Ile Glu Asp Met Arg Met Thr Leu
1 5 10

<210> 58

<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed pept i de sequence

<400> 58

Arg Thr Ile Gln Gln Leu Lys Glu Gln Leu
1 5 10

<210> 59
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 59

Lys Val Glu Cys Ser His Ser Ala Lys Leu
1 5 10

<210> 60
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 60

Lys Asn Glu Lys Glu Glu Lys Ala Glu Leu
1 5 10

<210> 61
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 61

Lys Leu Ile Asn Glu Lys Lys Glu Lys Leu
1 5 10

<210> 62
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 62

Lys Leu Met His Thr Lys Ile Asp Glu Leu
1 5 10

<210> 63
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 63

Arg Val Leu Gln Glu Asn Asn Glu Gly Leu
1 5 10

<210> 64
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 64

Arg Val Ile Arg Val Ser Glu Leu Ser Leu
1 5 10

<210> 65
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 65

Arg Asn Leu Lys Glu Phe Gln Glu His Leu
1 5 10

<210> 66
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 66

Glu Tyr Ile Tyr Asp Leu Phe Val Pro Val
1 5 10

<210> 67

<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 67

Lys Met Leu Arg Leu Ser Gln Asp Val
1 5

<210> 68
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 68

Ala Leu Leu Arg Gln Ile Lys Glu Val
1 5

<210> 69
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 69

Ala Leu Ser Glu Leu Thr Gln Gly Val
1 5

<210> 70
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 70

Lys Leu Gly Ile Lys His Gln Ser Val
1 5

<210> 71
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 71

Thr Leu Gln Lys Phe Gly Asp Phe Leu
1 5

<210> 72
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 72

Lys Leu Thr Asp Ala Lys Lys Gln Ile
1 5

<210> 73
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 73

Gln Leu Thr Glu Lys Asp Ser Asp Leu
1 5

<210> 74
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 74

Asn Leu Gln Asp Met Lys His Leu Leu
1 5

<210> 75
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 75

Ser Val Trp Val Ser Phe Phe Glu Ile
1 5

<210> 76
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 76

Phe Gln Gly Cys Ile Met Gln Pro Val
1 5

<210> 77
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 77

Val Leu Gln Glu Asn Asn Glu Gly Leu
1 5

<210> 78
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 78

Thr Leu Asp Val Gln Ile Gln His Val
1 5

<210> 79
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 79

Ala Ile Trp Glu Glu Cys Lys Glu Ile
1 5

<210> 80
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 80

Phe Leu Gln His Ser Pro Ser Ile Leu
1 5

<210> 81
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 81

Asp Leu Met Glu Asp Glu Asp Leu Val
1 5

<210> 82
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 82

Ser Leu Leu Thr Leu Gly Lys Cys Ile
1 5

<210> 83
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 83

Gly Ile Leu Pro Arg Thr Leu Asn Val
1 5

<210> 84
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 84

Ile Leu Pro Arg Thr Leu Asn Val Leu
1 5

<210> 85
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 85

Lys Ile Cys Ser Glu Arg Lys Arg Val
1 5

<210> 86
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 86

Ser Leu Ser Glu Lys Lys Asn Leu Thr
1 5

<210> 87
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 87

Leu Met His Thr Lys Ile Asp Glu Leu
1 5

<210> 88
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 88

Trp Leu Glu Glu Lys Met Met Leu Ile
1 5

<210> 89
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 89

Thr Leu Asn Val Leu Lys Phe Ser Ala
1 5

<210> 90
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 90

Lys Leu Gln Thr Glu Pro Leu Ser Thr
1 5

<210> 91
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 91

Cys Ile Met Gln Pro Val Lys Asp Leu
1 5

<210> 92
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 92

Lys Gln Val Gln Lys Glu Val Ser Val
1 5

<210> 93
<211> 9

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 93

Lys Leu Lys Glu Glu Ile Thr Gln Leu
1 5

<210> 94
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 94

Thr Leu Ser Lys Glu Val Gln Gln Ile
1 5

<210> 95
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 95

Asn Glu Tyr Ile Tyr Asp Leu Phe Val
1 5

<210> 96
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 96

Leu Leu Asp Glu Asp Leu Asp Lys Thr
1 5

<210> 97
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 97

Leu Ala Tyr Asp Glu Thr Leu Asn Val
1 5

<210> 98
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 98

Asn Leu Pro Asn Thr Gln Leu Asp Leu
1 5

<210> 99
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pepti de sequence

<400> 99

Thr Leu Gly Lys Cys Ile Asn Val Leu
1 5

<210> 100
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 100

Thr Leu Asn Val Leu Phe Asp Ser Leu
1 5

<210> 101
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 101

Lys Leu Ser Asn Glu Ile Glu Thr Ala
1 5

<210> 102
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 102

Lys Glu His Glu Asn Asn Thr Asp Val
1 5

<210> 103
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 103

Asp Leu Leu Gly Asn Asp Tyr Leu Val
1 5

<210> 104
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 104

Lys Ile Met Lys Leu Ser Asn Glu Ile
1 5

<210> 105
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 105

Ile Leu Gln Ser Lys Ala Lys Lys Ile
1 5

<210> 106
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 106

Ile Leu Asn Val Lys Arg Ala Thr Ile
1 5

<210> 107
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 107

Lys Glu Leu Glu Thr Ile Leu Glu Thr
1 5

<210> 108
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 108

Ile Val Asn Ile Ser Gln Cys Tyr Leu
1 5

<210> 109
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 109

Leu Ile Cys Asn Glu Thr Val Glu Val
1 5

<210> 110
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 110

Thr Leu Leu Gln Glu Arg Glu Ile Leu
1 5

<210> 111
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 111

Thr Leu Glu Glu Asn Lys Ala Phe Ile
1 5

<210> 112
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 112

Tyr Asn Ala Asp Arg Lys Lys Trp Leu
1 5

<210> 113
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 113

Lys Gly Tyr Ser Phe Ile Lys Asp Leu
1 5

<210> 114
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 114

Lys Met Ala Val Lys His Pro Gly Cys
1 5

<210> 115
<211> 9

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 115

Ser Glu Met Ser Arg Val Ile Arg Val
1 5

<210> 116
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 116

Gln Leu Thr Asn Asn Leu Gln Asp Met
1 5

<210> 117
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 117

Gln Ile Val His Phe Gln Gln Glu Leu
1 5

<210> 118
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 118

Asn Ile Ser Glu Phe Glu Glu Ser Ile
1 5

<210> 119
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 119

Thr Leu Asn Ser Ser Gln Glu Lys Leu
1 5

<210> 120
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 120

Ser Leu Ile Ile Asn Asn Lys Leu Ile
1 5

<210> 121
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 121

Leu Ile Asn Glu Lys Lys Glu Lys Leu
1 5

<210> 122
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 122

Lys Leu Leu Asp Glu Asp Leu Asp Lys Thr
1 5 10

<210> 123
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An Artificially synthesized peptide sequence

<400> 123

Tyr Leu Ala Tyr Asp Glu Thr Leu Asn Val
1 5 10

<210> 124

<211> 10
<212> PRT
<213> Art i f i ci al

<220>
<223> An artificially synthesized peptide sequence

<400> 124

Asn Met Al a Asn Ser I l e Lys Phe Ser Val
1 5 10

<210> 125
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An art i f i ci ally synthesized peptide sequence

<400> 125

Val Leu Phe Asp Ser Leu Gl n Gl u Arg Leu
1 5 10

<210> 126
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 126

Lys Leu I l e Cys Asn Gl u Thr Val Gl u Val
1 5 10

<210> 127
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 127

Lys Leu Asp Leu Ser Hi s Gl u Phe Ser Leu
1 5 10

<210> 128
<211> 10
<212> PRT
<213> Art i f i ci al

<220>

<223> An artificially synthesized pept i de sequence

<400> 128

Leu Leu Thr Leu Gly Lys Cys Ile Asn Val
1 5 10

<210> 129
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 129

Gln Val Leu Glu Ala Lys Leu Glu Glu Val
1 5 10

<210> 130
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 130

Ser Leu Ser Glu Lys Lys Asn Leu Thr Leu
1 5 10

<210> 131
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 131

Thr Leu Tyr Gly Ser Leu Thr Asn Ser Leu
1 5 10

<210> 132
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 132

Ala Ile Trp Glu Glu Cys Lys Glu Ile Val
1 5 10

<210> 133
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 133

Leu Leu Asp Glu Asp Leu Asp Lys Thr Leu
1 5 10

<210> 134
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 134

Val Thr Leu Asp Val Gln Ile Gln His Val
1 5 10

<210> 135
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 135

Lys Thr Leu Glu Glu Asn Lys Ala Phe Ile
1 5 10

<210> 136
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 136

Gly Leu Thr Asn Ser Gly Lys Thr Tyr Thr
1 5 10

<210> 137
<211> 10

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 137

Asn Ile Ala Glu Ile Glu Asp Ile Arg Val
1 5 10

<210> 138
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 138

Ser Leu Gln Glu Arg Leu Tyr Thr Lys Met
1 5 10

<210> 139
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 139

Gln Gln Ile Glu Lys Leu Gln Ala Glu Val
1 5 10

<210> 140
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 140

Gln Gln Tyr Glu Arg Ala Cys Lys Asp Leu
1 5 10

<210> 141
<211> 10
<212> PRT
<213> Artificial

<220>

<223> An artificially synthesized peptide sequence

<400> 141

Met Ile Val Asn Ile Ser Gln Cys Tyr Leu
1 5 10

<210> 142
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 142

Lys Leu Ser Asn Glu Ile Glu Thr Ala Thr
1 5 10

<210> 143
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 143

Lys Gln Ile Lys Gln Val Gln Lys Glu Val
1 5 10

<210> 144
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 144

Asn Leu Pro Asn Thr Gln Leu Asp Leu Leu
1 5 10

<210> 145
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 145

Gln Leu Asp Leu Leu Gly Asn Asp Tyr Leu
1 5 10

<210> 146
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 146

Met Met Leu Ile Thr Gln Ala Lys Glu Ala
1 5 10

<210> 147
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 147

Gln Ile Met Asp Ile Lys Pro Lys Arg Ile
1 5 10

<210> 148
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 148

Gln Leu Val Ala Ala Leu Glu Ile Gln Leu
1 5 10

<210> 149
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 149

Thr Leu Asn Val Leu Lys Phe Ser Ala Ile
1 5 10

<210> 150
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 150

Lys Ile Leu Asn Val Lys Arg Ala Thr Ile
1 5 10

<210> 151
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 151

Thr Leu Glu Glu Gln Glu Gln Thr Gln Val
1 5 10

<210> 152
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 152

Arg Val Ser Glu Leu Ser Leu Cys Asp Leu
1 5 10

<210> 153
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 153

Val Val Leu Asp Ser Cys Glu Val Ser Thr
1 5 10

<210> 154
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 154

Tyr Ser Phe Ile Lys Asp Leu Gln Trp Ile
1 5 10

<210> 155
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 155

Ser Ile Phe Thr Val Lys Ile Leu Gln Ile
1 5 10

<210> 156
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 156

Thr Leu Asp Val Gln Ile Gln His Val Val
1 5 10

<210> 157
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 157

Gly Thr Leu Gln Lys Phe Gly Asp Phe Leu
1 5 10

<210> 158
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 158

Phe Ile Lys Asp Leu Gln Trp Ile Gln Val
1 5 10

<210> 159
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 159

Thr Leu Ile Gln Gln Leu Lys Glu Glu Leu
1 5 10

<210> 160
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 160

Thr Ile Leu Glu Thr Gln Lys Val Glu Cys
1 5 10

<210> 161
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 161

Ala Ala Leu Glu Ile Gln Leu Lys Ala Leu
1 5 10

<210> 162
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 162

Gly Ile Leu Pro Arg Thr Leu Asn Val Leu
1 5 10

<210> 163
<211> 9

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 163

Tyr Tyr Glu Leu Phe Val Asn Ile Leu
1 5

<210> 164
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 164

Tyr Phe Leu Asp Leu Pro Glu Pro Leu
1 5

<210> 165
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 165

Arg Tyr Pro Glu Leu Arg Lys Asn Asn
1 5

<210> 166
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 166

Ser Phe Lys Ser Thr Glu Cys Leu Leu
1 5

<210> 167
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 167

Lys Gln Leu Cys Arg Ser Gln Ser Leu
1 5

<210> 168
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially y synt hesi zed peptide sequence

<400> 168

Val Phe Arg Thr Ile Ala Asp Tyr Phe
1 5

<210> 169
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 169

His Phe Lys Lys Tyr Gly Asn Cys Phe
1 5

<210> 170
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 170

Gly Tyr Ile Thr Val Ser Asp Arg Ser
1 5

<210> 171
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 171

Leu Phe Val Asn Ile Leu Gly Leu Leu
1 5

<210> 172
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 172

Glu Tyr Tyr Glu Leu Phe Val Asn Ile Leu
1 5 10

<210> 173
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 173

Asp Tyr Phe Leu Asp Leu Pro Glu Pro Leu
1 5 10

<210> 174
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 174

Arg Tyr Pro Glu Leu Arg Lys Asn Asn Ile
1 5 10

<210> 175
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 175

Glu Tyr Pro Leu Ile Tyr Gln Lys Arg Phe
1 5 10

<210> 176
<211> 10
<212> PRT
<213> Artificial

<220>

<223> An artificially synt hesi zed pept i de sequence

<400> 176

Thr Tyr Val Gly Phe Glu Arg Asp Val Phe
1 5 10

<210> 177
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 177

Ser Tyr Ile Asn Thr Pro Val Ala Glu Ile
1 5 10

<210> 178
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 178

Tyr Phe Leu Asp Leu Pro Glu Pro Leu Leu
1 5 10

<210> 179
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 179

Arg Tyr Val Ile Leu Ile Tyr Leu Gln Thr
1 5 10

<210> 180
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 180

Ser Phe Lys Ser Thr Glu Cys Leu Leu Leu
1 5 10

<210> 181
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 181

Leu Phe Arg Phe Pro Ala Thr Ser Pro Leu
1 5 10

<210> 182
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 182

Val Phe Arg Thr Ile Ala Asp Tyr Phe Leu
1 5 10

<210> 183
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 183

Lys Thr Leu Pro Arg Arg Tyr Pro Glu Leu
1 5 10

<210> 184
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 184

Arg Thr Ile Ala Asp Tyr Phe Leu Asp Leu
1 5 10

<210> 185
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 185

Gly Phe Glu Arg Asp Val Phe Arg Thr Ile
1 5 10

<210> 186
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 186

Arg Thr Pro Lys Arg His Gly Leu His Leu
1 5 10

<210> 187
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 187

Lys Gln Leu Cys Arg Ser Gln Ser Leu Leu
1 5 10

<210> 188
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 188

Lys Ser Thr Glu Cys Leu Leu Leu Ser Leu
1 5 10

<210> 189
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 189

Tyr Tyr Glu Leu Phe Val Asn Ile Leu Val
1 5 10

<210> 190
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized zed peptide sequence

<400> 190

Asn Phe Ser Lys Asp Lys Asp Ser Ile Phe
1 5 10

<210> 191
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 191

Phe Leu Met Asp His His Gln Glu Ile
1 5

<210> 192
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 192

Leu Leu Gln Pro His Leu Glu Arg Val
1 5

<210> 193
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 193

Ser Leu Leu Pro Ala Ser Ser Met Leu
1 5

<210> 194
<211> 9

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 194

Trp Val Leu Ser Ala Met Lys Cys Leu
1 5

<210> 195
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 195

Leu Leu Met Arg Met Ile Ser Arg Met
1 5

<210> 196
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 196

Ser Met Leu Thr Gly Thr Gln Ser Leu
1 5

<210> 197
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 197

Leu Leu Thr Phe Glu Tyr Tyr Glu Leu
1 5

<210> 198
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 198

Tyr Ile Met Tyr Asn Met Ala Asn Thr
1 5

<210> 199
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 199

Phe Leu Asp Leu Pro Glu Pro Leu Leu
1 5

<210> 200
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 200

Ala Leu Phe Gly Asp Lys Pro Thr Ile
1 5

<210> 201
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 201

Met Leu Thr Gly Thr Gln Ser Leu Leu
1 5

<210> 202
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 202

Leu Ile Tyr Gln Lys Arg Phe Pro Thr
1 5

<210> 203
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 203

Thr Leu Pro Arg Arg Tyr Pro Glu Leu
1 5

<210> 204
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 204

Lys Gln Phe Gln Lys Glu Tyr Pro Leu
1 5

<210> 205
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially y synt hesi zed peptide sequence

<400> 205

Ile Met Gly Gly Ser Cys His Asn Leu
1 5

<210> 206
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed pept i de sequence

<400> 206

Tyr Glu Leu Phe Val Asn Ile Leu Val
1 5

<210> 207
<211> 9
<212> PRT
<213> Artificial

<220>

<223> An artificially synthesized peptide sequence

<400> 207

Thr Ile Ala Asp Tyr Phe Leu Asp Leu
1 5

<210> 208
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 208

Ala Leu Gln Leu Cys Cys Leu Leu Leu
1 5

<210> 209
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 209

Arg Leu Cys Lys Ser Thr Ile Glu Leu
1 5

<210> 210
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 210

Gln Leu Cys Arg Ser Gln Ser Leu Leu
1 5

<210> 211
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 211

Val Ile Leu Ile Tyr Leu Gln Thr Ile

1 5

<210> 212
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 212

Glu Leu Phe Val Asn Ile Leu Val Val
1 5

<210> 213
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized pept i de sequence

<400> 213

Ile Leu Gln Asn Lys Ser Asp Asp Leu
1 5

<210> 214
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 214

Lys Leu Gln Leu Leu Met Arg Met Ile
1 5

<210> 215
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 215

Met Ile Ser Arg Met Ser Gln Asn Val
1 5

<210> 216
<211> 9
<212> PRT

<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 216

Thr Ile Gln Leu Leu Arg Lys Phe Leu
1 5

<210> 217
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 217

Cys Ser Leu Glu Gly Ile Val Asp Val
1 5

<210> 218
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized hesi zed peptide sequence

<400> 218

Leu Val Val Cys Gly Tyr Ile Thr Val
1 5

<210> 219
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 219

Tyr Ile Asn Thr Pro Val Ala Glu Ile
1 5

<210> 220
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 220

Ile Leu Ile Tyr Leu Gln Thr Ile Leu
1 5

<210> 221
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 221

Lys Ser Asp Asp Leu Pro His Trp Val
1 5

<210> 222
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 222

Leu Leu Pro Ala Ser Ser Met Leu Thr
1 5

<210> 223
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 223

Met Ile His Thr Phe Ser Arg Cys Val
1 5

<210> 224
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 224

Leu Met Ile His Thr Phe Ser Arg Cys
1 5

<210> 225
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 225

Cys Val Leu Cys Cys Ala Glu Glu Val
1 5

<210> 226
<211> 9
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 226

Glu Leu Phe Val Asn Ile Leu Gly Leu
1 5

<210> 227
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 227

Leu Leu Ala Gly Arg Leu Val Ser Phe Leu
1 5 10

<210> 228
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed peptide sequence

<400> 228

Phe Leu Met Asp His His Gln Glu Ile Leu
1 5 10

<210> 229
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 229

Ser Leu Leu Gln Pro His Leu Glu Arg Val
1 5 10

<210> 230
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 230

Ile Leu Val Val Cys Gly Tyr Ile Thr Val
1 5 10

<210> 231
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 231

Leu Thr Phe Glu Tyr Tyr Glu Leu Phe Val
1 5 10

<210> 232
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 232

Ile Leu Gly Val Pro Ser Leu Glu Glu Val
1 5 10

<210> 233
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 233

Leu Ile Tyr Leu Gln Thr Ile Leu Gly Val
1 5 10

<210> 234
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 234

Tyr Leu Gln Thr Ala Val Glu Lys His Leu
1 5 10

<210> 235
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 235

Leu Met Ile His Thr Phe Ser Arg Cys Val
1 5 10

<210> 236
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 236

Ser Met Leu Thr Gly Thr Gln Ser Leu Leu
1 5 10

<210> 237
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 237

Arg Met Ile Ser Arg Met Ser Gln Asn Val
1 5 10

<210> 238
<211> 10

<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 238

Gln Leu Leu Met Arg Met Ile Ser Arg Met
1 5 10

<210> 239
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 239

Val Leu Cys Cys Ala Glu Glu Val Asp Leu
1 5 10

<210> 240
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 240

Ser Leu Met Ile His Thr Phe Ser Arg Cys
1 5 10

<210> 241
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 241

Ser Leu Leu Pro Ala Ser Ser Met Leu Thr
1 5 10

<210> 242
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 242

Tyr Glu Leu Phe Val Asn Ile Leu Val Val
1 5 10

<210> 243
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 243

Gln Leu Cys Arg Ser Gln Ser Leu Leu Leu
1 5 10

<210> 244
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 244

Lys Gln Phe Gln Lys Glu Tyr Pro Leu Ile
1 5 10

<210> 245
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 245

Ile Leu Gln Val Pro Ser Tyr Leu Gln Thr
1 5 10

<210> 246
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 246

Val Gly Phe Glu Arg Asp Val Phe Arg Thr
1 5 10

<210> 247
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 247

Gln Leu Val Asn Leu Arg Asn Arg Arg Val
1 5 10

<210> 248
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 248

Phe Leu Asp Leu Pro Glu Pro Leu Leu Thr
1 5 10

<210> 249
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially y synt hesi zed peptide sequence

<400> 249

Ile Met Gly Gly Ser Cys His Asn Leu Ile
1 5 10

<210> 250
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synt hesi zed pept i de sequence

<400> 250

Leu Ile Gly Leu Ser Asn Met His Asp Leu
1 5 10

<210> 251
<211> 10
<212> PRT
<213> Artificial

<220>

<223> An artificially synthesized peptide sequence

<400> 251

Leu Ile Tyr Gln Lys Arg Phe Pro Thr Thr
1 5 10

<210> 252
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially y synthesized peptide sequence

<400> 252

Thr Leu Thr Val Gln Asp Gln Glu Glu Leu
1 5 10

<210> 253
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 253

Asn Met Ala Asn Thr Ser Lys Arg Gly Val
1 5 10

<210> 254
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially y synt hesi zed peptide sequence

<400> 254

Tyr Glu Leu Phe Val Asn Ile Leu Gly Leu
1 5 10

<210> 255
<211> 10
<212> PRT
<213> Artificial

<220>
<223> An artificially synthesized peptide sequence

<400> 255

Asn Ile Leu Gly Leu Leu Gln Pro His Leu
1 5 10

Claims

1. A peptide of the following (a) or (b)

   (a) a peptide having cytotoxic T cell inducibility, wherein said peptide is derived from the amino acid sequence of SEQ ID NO: 2, wherein said peptide is of less than about 15 amino acids and is selected from the group consisting of peptides comprising the amino acid sequences of SEQ ID NO: 7 or 8; or
   (b) the peptide of (a) in which 1 or 2 amino acids are substituted, deleted or added, in the sequence of SEQ ID NO: 7 or 8.

2. The peptide of claim 1(b), wherein the peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 7 and 8 has at least one substitution in the sequence of SEQ ID NO: 7 or 8 selected from the group consisting of:

   (a) the second amino acid from the N-terminus is phenylalanine, tyrosine, methionine, or tryptophan, and
   (b) the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.

3. The peptide of claim I of the following (a) or (b):

   (a) a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or 8; or
   (b) a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or 8 in which 1 or 2 amino acids are substituted, deleted, or added.

4. The peptide of claim 3(b), wherein the peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 7 and 8 has at least one substitution selected from the group consisting of:

   (a) the second amino acid from the N-terminus is phenylalanine, tyrosine, methionine, or tryptophan, and
   (b) the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.

5. A vector comprising DNA encoding the peptide of any one of claims 1 to 4.

6. A pharmaceutical composition for use in treating or preventing a disease associated with over-expression of the gene of SEQ ID NO: 1, said composition comprising one or more of the peptides of any one of claims 1 to 4.

7. The pharmaceutical composition of claim 6 for use in treating or preventing cancer.

8. A vaccine for use in inhibiting proliferation of cells expressing gene of SEQ ID NO: 1 comprising a peptide of any one of claims 1 to 4 as the active ingredient.

9. The vaccine of claim 8, formulated for administration to a subject whose HLA antigen is HLA-A24.

10. The vaccine of claim 8 or 9, wherein the cells are cancer cells.

11. The peptide of any one of claims 1 to 4 for use in treating or preventing cancer in a subject.

12. Use of the peptide of any one of claims 1 to 4 in the preparation of a vaccine for treating or preventing cancer in a subject.

13. The pharmaceutical composition of claim 7, vaccine of claim 10, the peptide for use as defined in claim 11 or the use of claim 12, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal carcinoma, SCLC and soft tissue tumor.

14. The peptide of any one of claims 1 to 4 for use in inducing antigen-presenting cells having a high cytotoxic T cell

inducibility by contacting an antigen-presenting cell with said peptide.

15. The peptide of any one of claims 1 to 4 for use in inducing cytotoxic T cells by contacting a T cell with said peptide.

16. A polynucleotide encoding the peptide of any one of claims 1 to 4 for use in inducing antigen-presenting cells having high cytotoxic T cell inducibility, by transferring the gene comprising a polynucleotide encoding said peptide to an antigen-presenting cell.

17. An in vitro method of inducing antigen-presenting cells having a high cytotoxic T cell inducibility comprising the step of contacting an antigen-presenting cell with the peptide of any one of claims 1 to 4.

18. An in vitro method of inducing antigen-presenting cells having high cytotoxic T cell inducibility, said method comprising the step of transferring a polynucleotide encoding the peptide of any one of claims 1 to 4 to an antigen-presenting cell.

19. A cytotoxic T cell induced by contacting a T cell with a peptide of any one of claims 1 to 4 or transduced with the nucleic acids encoding the T cell receptor subunit polypeptides binding with said peptide.

20. An antigen-presenting cell comprising a complex of an HLA antigen and a peptide of any one of claims 1 to 4.

21. The antigen-presenting cell of claim 20, produced by the peptide of claim 14 or the polynucleotide of claim 16.

22. An exosome that presents on its surface a complex comprising a peptide of any one of the claims 1 to 4 and an HLA antigen.

23. The exosome of claim 22 or the antigen-presenting cell of claim 20 or 21, wherein the HLA antigen is HLA-A24.

24. The exosome or antigen-presenting cell of claim 23, wherein the HLA antigen is HLA-A2402.

Patentansprüche

1. Peptid gemäß den folgenden (a) oder (b)

(a) ein Peptid, das die Fähigkeit cytotoxische T-Zellen zu induzieren hat, wobei das Peptid von der Aminosäuresequenz der SEQ ID NO:2 abgeleitet ist, wobei das Peptid weniger als 15 Aminosäuren aufweist und ausgewählt ist aus der Gruppe bestehend aus Peptiden, die die Aminosäuresequenzen der SEQ ID NO:7 oder 8 umfassen; oder
(b) das Peptid gemäß (a), in dem 1 oder 2 Aminosäuren in der Sequenz der SEQ ID NO:7 oder 8 substituiert, deletiert oder hinzugefügt sind.

2. Peptid nach Anspruch 1 (b), wobei das Peptid, das die Aminosäuresequenz umfasst, die ausgewählt ist aus der Gruppe bestehend aus SEQ ID NO:7 und 8, mindestens eine Substitution in der Sequenz der SEQ ID NO:7 oder 8 aufweist, die ausgewählt ist aus der Gruppe bestehend aus:

(a) die zweite Aminosäuresequenz vom N-Terminus aus ist Phenylalanin, Tyrosin, Methionin oder Tryptophan, und
(b) die C-terminale Aminosäure ist Phenylalanin, Leucin, Isoleucin, Tryptophan oder Methionin.

3. Peptid nach Anspruch 1 gemäß den folgenden (a) oder (b):

(a) ein Peptid, das aus der Aminosäuresequenz der SEQ ID NO:7 oder 8 besteht; oder
(b) ein Peptid, das aus der Aminosäuresequenz der SEQ ID NO:7 oder 8 besteht, in der 1 oder 2 Aminosäuren substituiert, deletiert oder hinzugefügt sind.

4. Peptid nach Anspruch 3(b), wobei das Peptid, das aus der Aminosäuresequenz besteht, die ausgewählt ist aus der Gruppe bestehend aus SEQ ID NO:7 und 8, mindestens eine Substitution aufweist, die ausgewählt ist aus der Gruppe bestehend aus:

(a) die zweite Aminosäuresequenz vom N-Terminus aus ist Phenylalanin, Tyrosin, Methionin oder Tryptophan, und
(b) die C-terminale Aminosäure ist Phenylalanin, Leucin, Isoleucin, Tryptophan oder Methionin.

5. Vektor, umfassend die DNA, die das Peptid nach einem der Ansprüche 1 bis 4 codiert.

6. Arzneimittel zur Verwendung bei der Behandlung oder Prävention einer Erkrankung, die mit Überexpression des Gens der SEQ ID NO:1 in Zusammenhang steht, wobei das Arzneimittel ein oder mehrere der Peptide nach einem der Ansprüche 1 bis 4 umfasst.

7. Arzneimittel nach Anspruch 6 zur Verwendung bei der Behandlung oder Prävention von Krebs.

8. Impfstoff zur Verwendung bei der Inhibierung der Proliferation von Zellen, die das Gen der SEQ ID NO:1 exprimieren, umfassend ein Peptid nach einem der Ansprüche 1 bis 4 als Wirkstoff.

9. Impfstoff nach Anspruch 8, der für die Verabreichung an ein Individuum formuliert ist, dessen HLA-Antigen HLA-A24 ist.

10. Impfstoff nach Anspruch 8 oder 9, wobei die Zellen Krebszellen sind.

11. Peptid nach einem der Ansprüche 1 bis 4 zur Verwendung bei der Behandlung oder Prävention von Krebs bei einem Individuum.

12. Verwendung des Peptids nach einem der Ansprüche 1 bis 4 bei der Herstellung eines Impfstoffs zur Behandlung oder Prävention von Krebs bei einem Individuum.

13. Arzneimittel nach Anspruch 7, Impfstoff nach Anspruch 10, Peptid zur Verwendung wie in Anspruch 11 definiert oder Verwendung nach Anspruch 12, wobei die Krebserkrankung ausgewählt ist aus der Gruppe bestehend aus Blasenkrebs, Brustkrebs, Gebärmutterhalskrebs, cholangiozellulärem Karzinom, CML, kolorektalem Krebs, Magenkrebs, NSCLC, Lymphom, Osteosarkom, Prostatakrebs, Nierenkarzinom, SCLC und Weichteiltumor.

14. Peptid nach einem der Ansprüche 1 bis 4 zur Verwendung bei der Induzierung von Antigen-präsentierenden Zellen, die in hohem Maße fähig sind, cytotoxische T-Zellen zu induzieren, durch Inkontaktbringen einer Antigen-präsentierenden Zelle mit dem Peptid.

15. Peptid nach einem der Ansprüche 1 bis 4 zur Verwendung bei der Induzierung cytotoxischer T-Zellen durch Inkontaktbringen einer T-Zelle mit dem Peptid.

16. Polynucleotid, das das Peptid nach einem der Ansprüche 1 bis 4 codiert, zur Verwendung bei der Induzierung Antigen-präsentierender Zellen, die in hohem Maße fähig sind, cytotoxische T-Zellen zu induzieren, durch Transfer des Gens, das das Peptid codierende Polynucleotid umfasst, zu einer Antigen-präsentierenden Zelle.

17. In vitro-Verfahren zum Induzieren Antigen-präsentierender Zellen, die in hohem Maße fähig sind, cytotoxische T-Zellen zu induzieren, umfassend den Schritt des Inkontaktbringens einer Antigen-präsentierenden Zelle mit dem Peptid nach einem der Ansprüche 1 bis 4.

18. In vitro-Verfahren zum Induzieren Antigen-präsentierender Zellen, die in hohem Maße fähig sind, cytotoxische T-Zellen zu induzieren, wobei das Verfahren den Schritt des Transfers eines Polynucleotids, das das Peptid nach einem der Ansprüche 1 bis 4 codiert, zu einer Antigen-präsentierenden Zelle umfasst.

19. Cytotoxische T- Zelle, die durch Inkontaktbringen einer T- Zelle mit einem Peptid nach einem der Ansprüche 1 bis 4 induziert wird oder mit den Nucleinsäuren transduziert wird, die die Polypeptide der T- Zellrezeptor- Untereinheit, die an das Peptid binden, codieren.

20. Antigen-präsentierende Zelle, die einen Komplex aus einem HLA-Antigen und einem Peptid nach einem der Ansprüche 1 bis 4 umfasst.

21. Antigen-präsentierende Zelle nach Anspruch 20, die durch das Peptid nach Anspruch 14 oder das Polynucleotid

nach Anspruch 16 erzeugt wird.

22. Exosom, das auf seiner Oberfläche einen Komplex präsentiert, der ein Peptid nach einem der Ansprüche 1 bis 4 und ein HLA-Antigen umfasst.

23. Exosom nach Anspruch 22 oder Antigen-päsentierende Zelle nach Anspruch 20 oder 21, wobei das HLA-Antigen HLA-A24 ist.

24. Exosom oder Antigen-präsentierende Zelle nach Anspruch 23, wobei das HLA-Antigen HLA-A2402 ist.

Revendications

1. Peptide de (a) ou (b) ci- après

(a) un peptide ayant une inductibilité de lymphocytes T cytotoxiques, ledit peptide étant dérivé de la séquence d'acides aminés de SEQ ID NO: 2, ledit peptide étant de moins d'environ 15 acides aminés et choisi dans le groupe constitué de peptides comprenant les séquences d'acides aminés de SEQ ID NO: 7 ou 8 ; ou
(b) le peptide de (a), dans lequel 1 ou 2 acides aminés sont substitués, délétés ou ajoutés dans la séquence de SEQ ID NO: 7 ou 8.

2. Peptide de la revendication 1(b), le peptide comprenant la séquence d'acides aminés choisie dans le groupe constitué de SEQ ID NO: 7 et 8 ayant au moins une substitution dans la séquence de SEQ ID NO: 7 ou 8 choisie dans le groupe constitué de :

(a) le deuxième acide aminé de l'extrémité-N est phénylalanine, tyrosine, méthionine, ou tryptophane, et
(b) l'acide aminé C-terminal est phénylalanine, leucine, isoleucine, tryptophane, ou méthionine.

3. Peptide de la revendication 1 de (a) ou (b) ci- après :

(a) un peptide constitué de la séquence d'acides aminés SEQ ID NO: 7 ou 8 ; ou
(b) un peptide constitué de la séquence d'acides aminés SEQ ID NO: 7 ou 8, dans lequel 1 ou 2 acides aminés sont substitués, délétés ou ajoutés.

4. Peptide de la revendication 3(b), le peptide constitué de la séquence d'acides aminés choisie dans le groupe constitué de SEQ ID NO: 7 et 8 ayant au moins une substitution choisie dans le groupe constitué de :

(a) le deuxième acide aminé de l'extrémité-N est phénylalanine, tyrosine, méthionine, ou tryptophane, et
(b) l'acide aminé C-terminal est phénylalanine, leucine, isoleucine, tryptophane, ou méthionine.

5. Vecteur comprenant de l'ADN codant pour le peptide de l'une quelconque des revendications 1 à 4.

6. Composition pharmaceutique destinée à être utilisée dans le traitement ou la prévention d'une maladie associée à la surexpression du gène de SEQ ID NO: 1, ladite composition comprenant un ou plusieurs des peptides de l'une quelconque des revendications 1 à 4.

7. Composition pharmaceutique de la revendication 6, destinée à être utilisée dans le traitement ou la prévention du cancer.

8. Vaccin destiné à être utilisé dans l'inhibition de la prolifération de cellules exprimant le gène de SEQ ID NO: 1 comprenant un peptide de l'une quelconque des revendications 1 à 4 en tant qu'ingrédient actif.

9. Vaccin de la revendication 8, formulé pour être administré à un sujet dont l'antigène HLA est HLA-A24.

10. Vaccin de la revendication 8 ou 9, dans lequel les cellules sont des cellules cancéreuses.

11. Peptide de l'une quelconque des revendications 1 à 4, destiné à être utilisé dans le traitement ou la prévention du cancer chez un sujet.

12. Utilisation du peptide de l'une quelconque des revendications 1 à 4, dans la préparation d'un vaccin destiné à traiter ou prévenir le cancer chez un sujet.

13. Composition pharmaceutique de la revendication 7, vaccin de la revendication 10, peptide pour utilisation tel que défini dans la revendication 11 ou l'utilisation de la revendication 12, le cancer étant choisi dans le groupe constitué d'un cancer de la vessie, un cancer du sein, un cancer du col de l'utérus, un carcinome cholangiocellulaire, une LMC, un cancer colorectal, un cancer de l'estomac, un cancer du poumon non à petites cellules, un lymphome, un ostéosarcome, un cancer de la prostate, un carcinome rénal, un cancer du poumon à petites cellules et une tumeur des tissus mous.

14. Peptide de l'une quelconque des revendications 1 à 4, destiné à être utilisé dans l'induction de cellules présentatrices d'antigène ayant une haute inductibilité de lymphocytes T cytotoxiques par mise en contact d'une cellule présentatrice d'antigène avec ledit peptide.

15. Peptide de l'une quelconque des revendications 1 à 4, destiné à être utilisé dans l'induction de lymphocytes T cytotoxiques par mise en contact d'un lymphocyte T avec ledit peptide.

16. Polynucléotide codant pour le peptide de l'une quelconque des revendications 1 à 4, destiné à être utilisé dans l'induction de cellules présentatrices d'antigène ayant une haute inductibilité de lymphocytes T cytotoxiques, par transfert du gène comprenant un polynucléotide codant pour ledit peptide vers une cellule présentatrice d'antigène.

17. Procédé *in vitro* d'induction de cellules présentatrices d'antigène ayant une haute inductibilité de lymphocytes T cytotoxiques, comprenant l'étape de mise en contact d'une cellule présentatrice d'antigène avec le peptide de l'une quelconque des revendications 1 à 4.

18. Procédé *in vitro* d'induction de cellules présentatrices d'antigène ayant une haute inductibilité de lymphocytes T cytotoxiques, ledit procédé comprenant l'étape de transfert d'un polynucléotide codant pour le peptide de l'une quelconque des revendications 1 à 4 vers une cellule présentatrice d'antigène.

19. Lymphocyte T cytotoxique induit par mise en contact d'un lymphocyte T avec un peptide de l'une quelconque des revendications 1 à 4 ou transduit avec les acides nucléiques codant pour les polypeptides de sous-unité de récepteur de lymphocyte T se liant audit peptide.

20. Cellule présentatrice d'antigène comprenant un complexe d'un antigène HLA et un peptide de l'une quelconque des revendications 1 à 4.

21. Cellule présentatrice d'antigène de la revendication 20, produite par le peptide de la revendication 14 ou le polynucléotide de la revendication 16.

22. Exosome qui présente sur sa surface un complexe comprenant un peptide de l'une quelconque des revendications 1 à 4 et un antigène HLA.

23. Exosome de la revendication 22 ou cellule présentatrice d'antigène de la revendication 20 ou 21, l'antigène HLA étant HLA-A24.

24. Exosome ou cellule présentatrice d'antigène de la revendication 23, l'antigène HLA étant HLA-A2402.

[Fig. 1]


A
MPH-9-278
C.T.L. Cellular Technology Ltd
B
Peptide
C.T.L.
Counted by: ImmunoSpot 4.0.15

[Fig. 2]


A
MPH-10-278
C.T.L. Cellular Technology Ltd.
060712 PH003-A8-1
1 2 3 4 5 6 7 8 9 10 11 12
E
F
+
−
B
Peptide
Peptide
A B C D E F G H
CTL

[Fig. 3]


MPH-10-278 #15
IFN γ (pg/ml)
R/S ratio
B
MPH-A24-9-278 #22
MPH-A24-9-278 #51
A
MPH-A24-9-278 #5-2
MPH-A24-9-278 #49

[Fig. 4]


MPH
HLA+MPH
HLA
MPH-A24-9-278 clone#49, #5-2 endo
300
250
200
150
100
50
0
IFN-γ (pg/ml)
×5
×2.5
×1.2
×0.6
R/S ratio

[Fig. 5]


MPH-A24-9-278
HT1376
J82
RT-4
IFN-γ (pg/ml)
80
70
60
50
40
30
20
10
0
R/S ratio
0.6
1.2
2.5

[Fig. 6]


R/S=20
R/S=5
R/S=1
SFC
80
60
40
20
0
Ani 1
Ani 2
Ani 3
Ani 4
Ani 5
nega 1
nega 2
nega 3

[Fig. 7]



[Fig. 8]


A
MPH-A02-9-282 #5
IFN-g (pg/ml)
5000
4000
3000
2000
1000
0
-1000
R/S ratio
40
20
10
5
2.5
1.25
0.63
0.32
B
MPH-A02-9-638 #8
IFN-g (pg/ml)
800
600
400
200
0
-200
R/S ratio
40
20
10
5
2.5
1.25
0.63
0.32
C
MPH-A02-10-1714 #4
IFN-g (pg/ml)
1000
800
600
400
200
0
R/S ratio
40
20
10
5
2.5
1.2
0.6
0.3

[Fig. 9]


A
Peptide
A
B
C
D
E
F
G
H
B
C.T.L
MPH-A02-9-282 clone #81
MPH-A02-9-282 clone #50
IFN-γ (pg/ml)
3000
2000
1000
0
-1000
R/S ratio
10
5
2.5
1.3
0.6
0.3
0.15
0.075

[Fig. 10]


A
DEPDC1-A24-9-294
C.T.L. Cellular Technology Ltd.
060712 PH003-48-5
1 2 3 4 5 6 7 8 9 10 11 12
A
B
Peptide
+ − + − + − + − + − + −
B
A B C D E F G H
C.T.L.
Counted by: ImmunoSpot 4.0.15

[Fig. 11]


DEPDC1-A24-9-294 #10
DEPDC1-A24-9-294 #48
DEPDC1-A24-9-294 #8
DEPDC1-A24-9-294 #42
IFNγ (pg/ml)
R/S ratio
+
-
4000
3000
2000
1000
0
-1000
5000
40
20
10
5
2.5
1.3
0.6
0.3

[Fig. 12]


DEPDC1-A24-9-294 clone #8 endo
DEP
HLA+DEP
HLA
DEP:DEPDC1
IFN-γ (pg/ml)
120
100
80
60
40
20
0
×5
×2.5
×1.2
×0.6
R/S ratio

[Fig. 13]


DEPDC1-A24-9-294
HT1376
J82
RT-4
IFN-γ (pg/ml)
50
40
30
20
10
0
2.5
1.2
0.6
R/S ratio

[Fig. 14]


R/S=40
R/S=10
R/S=2
SFC
200
180
160
140
120
100
80
60
40
20
0
Ani 1
Ani 2
Ani 3
Ani 4
Ani 5
nega 1
nega 2

[Fig. 15]


DEPDC1-A02
-10-301
DEPDC1-A02
-10-296
DEPDC1-A02
-9-297
DEPDC1-A02
-10-224
DEPDC1-A02
-10-395
DEPDC1-A02
-10-765
DEPDC1-A02
-10-506
DEPDC1-A02
-10-575
DEPDC1-A02
-10-644
Peptide
1
2
3
4
5
6
7
8
-
+

[Fig. 16]


DEPDC1-A02-10-296 #4
IFN-γ (pg/ml)
3000
2500
2000
1500
1000
500
0
R/S ratio
5
2.5
1.25
0.63
0.31
0.16
0.08
0.04
DEPDC1-A02-9-653 #1
IFN γ (pg/ml)
7500
6000
4500
3000
1500
0
R/S ratio
+20
+10
+5
+2.5
+1.25
+0.6

[Fig. 17]


Hek-A02 DEPDC1V1-9-674 pep
Hek-A02 DEPDC1V2
Hek-Mock DEPDC1V2
IFN γ (pg/ml)
R/S ratio
16
14
12
10
8
6
4
2
0
9
4.5
2.2
1.1
0.6
0.3
Hek293 DEP-A02-9-653
A02/DEP
A02/DEP-9-462 pep
DEP
IFN γ (pg/ml)
R/S ratio
35
30
25
20
15
10
5
0
1.5
0.7
0.3
0.15
0.07
0.03

[Fig. 18]



[Fig. 19]


Bladder
23 mm
After Vaccination
Bladder
24 mm
Before Vaccination

[Fig. 20]



[Fig. 21]


2006.12.12
2007.02.06
2007.05.08
Before
2007.06.04
After 1 co.
2007.07.06
After 2 co.
2007.08.04
After 3 co.
2006.12.12
2007.02.06
2007.05.08
Before
2007.06.04
After 1 co.
2007.07.06
After 2 co.
2007.08.04
After 3 co.

[Fig. 22]


2006.12.12
2007.02.06
2007.05.08
Before
2007.06.04
After 1 co.
2007.07.06
After 2 co.
2007.08.04
After 3 co.
2006.12.12
2007.02.06
2007.05.08
Before
2007.06.04
After 1 co.
2007.07.06
After 2 co.
2007.08.04
After 3 co.

[Fig. 23]


Vaccination
250
200
150
100
RECIST Sum
06.12.12
07.02.06
07.05.08
07.06.04
07.07.06
07.08.10

[Fig. 24]


Specific spots = Spots(DEPDC1 pep) – Spots(HIV pep)
Before
After 1course
After 2 course
0
10
20
30
Specific spots

[Fig. 25]



[Fig. 26]



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2004031413 A **[0005]**
- WO 2006085684 A **[0005]**
- WO 2007013665 A **[0005]**
- JP 2006302684 W **[0005] [0008] [0019] [0020] [0113]**
- JP HEI11510507 B **[0040]**
- JP 2000512161 A **[0040]**
- US 5580859 A **[0043]**
- US 5589466 A **[0043]**
- US 5804566 A **[0043]**
- US 5739118 A **[0043]**
- US 5736524 A **[0043]**
- US 5679647 A **[0043]**
- WO 9804720 A **[0043]**
- US 5922687 A **[0043]**
- US 4722848 A **[0044]**
- JP 2000509281 A **[0047]**
- WO 2007032255 A **[0053]**
- WO 2006031221 A **[0055]**
- US 60852575 A **[0134]**

Non-patent literature cited in the description

- **BOON T.** *Int J Cancer,* 1993, vol. 54, 177-80 **[0002]**
- **BOON T. et al.** *J Exp Med,* 1996, vol. 183, 725-9 **[0002] [0111]**
- **VAN DER BRUGGEN P et al.** *Science,* 1991, vol. 254, 1643-7 **[0002] [0018] [0111]**
- **BRICHARD V et al.** *J Exp Med,* vol. 178, 489-95 **[0002]**
- **KAWAKAMI Y et al.** *J Exp Med,* 1994, vol. 180, 347-52 **[0002] [0018] [0111]**
- **SHICHIJO S et al.** *J Exp Med,* 1998, vol. 187, 277-88 **[0002] [0018] [0111]**
- **CHEN Y.T. et al.** *Proc. Natl. Acd. Sci. USA,* 1997, vol. 94, 1914-8 **[0002]**
- **UMANO Y et al.** *Br J Cancer,* 2001, vol. 84, 1052-7 **[0002]**
- **TANAKA H et al.** *Br J Cancer,* 2001, vol. 84, 94-9 **[0002]**
- **NUKAYA I et al.** *Int. J. Cancer,* 1999, vol. 80, 92-7 **[0002] [0074]**
- **ROSENBERG SA et al.** *Nature Med,* 1998, vol. 4, 321-7 **[0003]**
- **MUKHERJI B. et al.** *Proc Natl Acad Sci USA,* 1995, vol. 92, 8078-82 **[0003]**
- **HU X et al.** *Cancer Res,* 1996, vol. 56, 2479-83 **[0003]**
- **DATE Y et al.** *Tissue Antigens,* 1996, vol. 47, 93-101 **[0004]**
- **KONDO A et al.** *J Immunol,* 1995, vol. 155, 4307-12 **[0004]**
- **KUBO RT et al.** *J Immunol,* 1994, vol. 152, 3913-24 **[0004]**
- **IMANISHI et al.** Proceeding of the eleventh International Histocompatibility Workshop and Conference. Oxford University Press, 1992, 1065 **[0004]**
- **WILLIAMS F et al.** *Tissue Antigen,* 1997, vol. 49, 129-33 **[0004]**
- **ALEXANDER-MILLER et al.** *Proc Natl Acad Sci USA,* 1996, vol. 93, 4102-7 **[0004]**
- **OKABE, H. et al.** *Cancer Res.,* 2001, vol. 61, 2129-37 **[0005]**
- **LIN YM. et al.** *Oncogene,* 2002, vol. 21, 4120-8 **[0005]**
- **HASEGAWA S. et al.** *Cancer Res,* 2002, vol. 62, 7012-7 **[0005]**
- **BIENZ M. et al.** *Cell,* 2000, vol. 103, 311-20 **[0005]**
- **LIN YM et al.** *Oncogene,* 13 June 2002, vol. 21, 4120-8 **[0006] [0112]**
- **KITAHARA O et al.** *Cancer Res.,* 01 May 2001, vol. 61, 3544-9 **[0006] [0112]**
- **SUZUKI C et al.** *Cancer Res.,* 01 November 2003, vol. 63, 7038-41 **[0006] [0112]**
- **ASHIDA S.** *Cancer Res.,* 01 September 2004, vol. 64, 5963-72 **[0006] [0112]**
- **OCHI K et al.** *Int J Oncol.,* March 2004, vol. 24 (3), 647-55 **[0006] [0112]**
- **KANETA Y et al.** *Int J Oncol.,* September 2003, vol. 23, 681-91 **[0006] [0112]**
- **OBAMA K.** *Hepatology,* June 2005, vol. 41, 1339-48 **[0006] [0112]**
- **KATO T et al.** *Cancer Res.,* 01 July 2005, vol. 65, 5638-46 **[0006] [0112]**
- **KITAHARA O et al.** *Neoplasia,* July 2002, vol. 4, 295-303 **[0006] [0112]**
- **SAITO-HISAMINATO A et al.** *DNA Res,* 2002, vol. 9, 35-45 **[0006] [0112]**
- **ABAZA A et al.** *J Biol Chem,* 2003, vol. 278, 27844-52 **[0007] [0018]**
- **KAMIMOTO T et al.** *J Biol Chem,* 2001, vol. 276, 37520-8 **[0007] [0018]**
- **BOON T et al.** *J Exp Med,* 1996, vol. 183, 725-9 **[0018]**

- **BRICHARD V et al.** *J Exp Med,* 1993, vol. 178, 489-95 **[0018] [0111]**
- **CHEN YT et al.** *Proc.Natl.Acd. Sci.USA,* 1997, vol. 94, 1914-8 **[0018]**
- **HARRIS CC.** *J Natl Cancer Inst,* 1996, vol. 88, 1442-55 **[0018]**
- **BUTTERFIELD LH et al.** *Cancer Res,* 1999, vol. 59, 3134-42 **[0018] [0111]**
- **VISSERS JL et al.** *Cancer Res,* 1999, vol. 59, 5554-9 **[0018] [0111]**
- **VAN DER BURG SH et al.** *J. Immunol,* 1996, vol. 156, 3308-14 **[0018] [0111]**
- **TANAKA F et al.** *Cancer Res,* 1997, vol. 57, 4465-8 **[0018] [0111]**
- **FUJIE T et al.** *Int J Cancer,* 1999, vol. 80, 169-72 **[0018] [0111]**
- **KIKUCHI M et al.** *Int J Cancer,* 1999, vol. 81, 459-66 **[0018] [0111]**
- **OISO M et al.** *Int J Cancer,* 1999, vol. 81, 387-94 **[0018] [0111]**
- **MARK DF et al.** *Proc Natl Acad Sci USA,* 1984, vol. 81, 5662-6 **[0023]**
- **ZOLLER MJ ; SMITH M.** *Nucleic Acids Res,* 1982, vol. 10, 6487-500 **[0023]**
- **DALBADIE-MCFARLAND G et al.** *Proc Natl Acad Sci USA,* 1982, vol. 79, 6409-13 **[0023]**
- **KUBO RT et al.** *J. Immunol.,* 1994, vol. 152, 3913-24 **[0029]**
- **RAMMENSEE HG et al.** *Immunogenetics,* 1995, vol. 41, 178-228 **[0029]**
- **KONDO A et al.** *J. Immunol.,* 1995, vol. 155, 4307-12 **[0029]**
- **BENMOHAMED L et al.** *Hum. Immunol.,* 2000, vol. 61 (8), 764-79 **[0031]**
- **JOHNSON AG.** *Clin. Microbiol. Rev.,* 1994, vol. 7, 277-89 **[0039]**
- **DERES K et al.** *Nature,* 1989, vol. 342, 561-4 **[0042]**
- **WOLFF JA et al.** *Science,* 1990, vol. 247, 1465-8 **[0043]**
- **STOVER CK et al.** *Nature,* 1991, vol. 351, 456-60 **[0044]**
- **SHATA MT et al.** *Mol. Med. Today,* 2000, vol. 6, 66-71 **[0044]**
- **SHEDLOCK DJ ; WEINER DB. et al.** *J. Leukoc. Biol.,* 2000, vol. 68, 793-806 **[0044]**
- **HIPP JD et al.** *In Vivo,* 2000, vol. 14, 571-85 **[0044]**
- **REEVES ME et al.** *Cancer Res.,* 1996, vol. 56, 5672-7 **[0047]**
- **BUTTERFIELD LH et al.** *J. Immunol.,* 1998, vol. 161, 5607-13 **[0047]**
- **BOCZKOWSKI D et al.** *J. Exp. Med.,* 1996, vol. 184, 465-72 **[0047]**
- **MORGAN et al.** *J Immunol,* 2003, vol. 171, 3288 **[0053]**
- **KAWAKAMI et al.** *J Immunol.,* 1989, vol. 142, 3452-3461 **[0055]**
- **PARKER KC et al.** *J Immunol.,* 1994, vol. 152 (1), 163-75 **[0073]**
- **KUZUSHIMA K et al.** *Blood,* 2001, vol. 98 (6), 1872-81 **[0073]**
- **TSAI V et al.** *J. Immunol,* 1997, vol. 158, 1796-802 **[0074]**
- **WALTER EA et al.** *N Engl J Med,* 1995, vol. 333, 1038-44 **[0075]**
- **RIDDEL SR et al.** *Nature Med.,* 1996, vol. 2, 216-23 **[0075]**
- **CHEN YT et al.** *Proc.Natl.Acd. Sci. USA,* 1997, vol. 94, 1914-8 **[0111]**
- **HARRIS CC.** *J Natl Cancer Inst,* 1996, vol. 88, 1442-5 **[0111]**
- **KANEHIRA M et al.** *Cancer Res.,* 2007, vol. 67 (7), 3276-3285 **[0116]**
- **KANEHIRA M et al.** *Oncogene,* 23 April 2007 **[0116]**